Home Stock Cipla Ltd

Wed 30/04/2025,16:1:0

NSE

BSE

Cipla Ltd

Wed 30/04/2025,16:1:0 | BSE : CIPLA

₹ 1551.0010.00 (0.65%)

Cipla Ltd

Wed 30/04/2025,15:59:7 | NSE : CIPLA

₹ 1550.108.60 (0.56%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 1530.05

Previous Close

₹ 1541.00

Volume

23268

Mkt Cap ( Rs. Cr)

₹125192.34

High

₹ 1570.10

Low

₹ 1530.05

52 Week High

₹ 1702.00

52 Week Low

₹ 1310.05

Book Value Per Share

₹ 351.17

Dividend Yield

0.83

Face Value

₹ 2.00

TTM EPS

61.78

TTM PE

25.08

P/B

4.41

Open

₹ 1542.00

Previous Close

₹ 1541.50

Volume

2315010

Mkt Cap ( Rs. Cr)

₹125192.34

High

₹ 1570.80

Low

₹ 1538.00

52 Week High

₹ 1702.05

52 Week Low

₹ 1317.25

Book Value Per Share

₹ 351.17

Dividend Yield

0.83

Face Value

₹ 2.00

TTM EPS

61.78

TTM PE

25.08

P/B

4.41

What’s Your Call?

Collective community sentiment on Cipla Ltd

Your Vote -

Buy Hold Sell

Buy

71.88%

Hold

13.18%

Sell

14.94%

71.88%

17647 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

1550.10

1025

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

1025

Option Chain

Analyzes market sentiment, predicts Cipla Ltd' movement.

2025-05-29 2025-06-26 2025-07-31

Call Price	Open interest	Strike Price	Put Price	Open interest

News

Media spotlight triggers stock stock attention, sentiment.

• Cipla - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

  30 Apr 2025, 3:08PM Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that

• Cipla - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

  30 Apr 2025, 1:05PM Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herein

• Cipla - Updates

  29 Apr 2025, 4:30PM Cipla Limited has informed the Exchange regarding 'Cipla Limited is not a Large Corporate as per the applicability criteria given under the SEBI circu

• Cipla - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

  29 Apr 2025, 4:22PM <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border='1px'><tr> <td><b>Sr. No.</b></td

• Cipla - Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) R

  24 Apr 2025, 6:40PM Please find enclosed disclosure on ESG rating.

• Cipla - General Updates

  24 Apr 2025, 6:39PM Cipla Limited has informed the Exchange about Intimation under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Re

• Cipla has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

  21 Apr 2025, 5:50PM As of March 2025, 29.20% is owned by Promoters and 70.80% by Public. <p align=justify> Among Promoters holding, Indian Promoters holds 9.16% and Forei

• Cipla - Update On USFDA Inspection At Manufacturing Facility Of Medispray In Kundaim, Goa, India

  17 Apr 2025, 10:49PM Update on USFDA inspection at manufacturing facility of Medispray in Kundaim, Goa, India

• Cipla - Updates

  17 Apr 2025, 10:48PM Cipla Limited has informed the Exchange regarding 'Update on USFDA inspection at manufacturing facility of Medispray in Kundaim, Goa, India'.'.

• Cipla - Analysts/Institutional Investor Meet/Con. Call Updates

  17 Apr 2025, 3:05PM Cipla Limited has informed the Exchange about Schedule of meet

• Cipla - Alteration Of Capital and Fund Raising-XBRL

  17 Apr 2025, 2:46PM CIPLA LIMITED has informed the Exchange regarding Allotment of Securities

• Cipla - ESOP/ESOS/ESPS

  17 Apr 2025, 2:43PM Cipla Limited has informed the Exchange regarding Allotment of 23282 Shares.

• Cipla - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

  17 Apr 2025, 2:43PM In compliance with the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 we hereby notify that

• Cipla - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

  17 Apr 2025, 3:01PM Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are en

• Cipla - Certificate under SEBI (Depositories and Participants) Regulations, 2018

  16 Apr 2025, 4:57PM Cipla Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

• Cipla - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

  16 Apr 2025, 5:04PM Certificate under Regulation 74(5) of SEBI (DP) Regulation, 2018

• Cipla - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

  11 Apr 2025, 8:28AM Company has received final approval from USFDA for ANDA submitted for Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound), 10

• Cipla - Product launch

  11 Apr 2025, 8:27AM Cipla Limited has informed the Exchange about Product launch

• Cipla - Board Meeting Intimation

  8 Apr 2025, 6:39PM CIPLA LIMITED has informed the Exchange about Board Meeting to be held on 13-May-2025 to consider and approve the Yearly Audited Financial results of

• Cipla - Trading Window-XBRL

  8 Apr 2025, 12:28PM Cipla Limited has informed the Exchange about Closure of Trading Window

• Cipla - Board Meeting Intimation for Quarter And Year Ended 31St March 2025 Under SEBI Listing Regulations

  7 Apr 2025, 7:41PM Cipla Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2025 ,inter alia, to consider and approve 1.

• Cipla - Disclosure under SEBI Takeover Regulations

  4 Apr 2025, 7:01PM Dr. Y. K. Hamied and Mr M K Hamied has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) and 31 (5) of the Securities and Exchange

• Cipla - Alteration Of Capital and Fund Raising-XBRL

  19 Mar 2025, 7:28PM CIPLA LIMITED has informed the Exchange regarding Allotment of Securities

• Cipla - ESOP/ESOS/ESPS

  19 Mar 2025, 7:26PM Cipla Limited has informed the Exchange regarding Allotment of 2179 Shares.

• Cipla - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

  19 Mar 2025, 7:23PM In compliance with the provisions of Regulation 30 of SEBI (LODR) Regulations, 2015, we hereby notify that the Operations and Administrative Committee

• Cipla inks licensing agreement with Formosa Pharmaceuticals

  18 Mar 2025, 3:51PM Cipla announced on Tuesday that it has entered into an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals for the commercializati

• Cipla - USFDA Inspection At Analytical Testing Facility Of Sitec In Mahape, Navi Mumbai, India

  20 Feb 2025, 10:55PM USFDA inspection at analytical testing facility of Sitec Labs Limited in Mahape, Navi Mumbai, India

• Cipla - Updates

  20 Feb 2025, 10:54PM Cipla Limited has informed the Exchange regarding 'USFDA inspection at analytical testing facility of Sitec in Mahape, Navi Mumbai, India'.

• Cipla - Product launch

  20 Feb 2025, 9:46PM Cipla Limited has informed the Exchange about Product launch

• Cipla - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

  20 Feb 2025, 9:34PM Company has received final approval from USFDA for NDA submitted for Nilotinib Capsules 50, 150 and 200 mg on 19th February, 2025

• Cipla - Update-Acquisition/Scheme/Sale/Disposal-XBRL

  19 Feb 2025, 6:19PM Cipla Limited has informed the Exchange regarding Update-Acquisition/Scheme/Sale/Disposal-XBRL

• Cipla - General Updates

  18 Feb 2025, 9:38PM Cipla Limited has informed the Exchange about General Updates

• Cipla - Investor Presentation

  18 Feb 2025, 10:44AM Cipla Limited has informed the Exchange about Investor Presentation

• Cipla - Alteration Of Capital and Fund Raising-XBRL

  13 Feb 2025, 7:32PM CIPLA LIMITED has informed the Exchange regarding Allotment of Securities

• Cipla - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

  13 Feb 2025, 7:22PM In compliance with regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby notify that the Operations and

• Cipla - ESOP/ESOS/ESPS

  13 Feb 2025, 7:17PM Cipla Limited has informed the Exchange regarding Allotment of 901 Shares.

• Cipla - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

  10 Feb 2025, 7:28PM Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herein

• Cipla - Analysts/Institutional Investor Meet/Con. Call Updates

  10 Feb 2025, 7:26PM Cipla Limited has informed the Exchange about Schedule of meet

• Cipla - Updates

  8 Feb 2025, 10:56AM Cipla Limited has informed the Exchange regarding 'Update on USFDA Inspection at Company's manufacturing facility in Virgonagar, Bengaluru, India'.

• Cipla - Update On USFDA Inspection At Company'S Manufacturing Facility In Virgonagar, Bengaluru, India

  8 Feb 2025, 10:56AM Update on USFDA Inspection at Company's manufacturing facility in Virgonagar, Bengaluru, India

• Cipla - Acquisition-XBRL

  4 Feb 2025, 11:18AM Cipla Limited has informed the Exchange regarding Acquisition

• Cipla - General Updates

  3 Feb 2025, 3:51PM Cipla Limited has informed the Exchange about General Updates

• Cipla - Announcement under Regulation 30 (LODR)-Acquisition

  3 Feb 2025, 3:51PM Investment in Cipla Medpro South Africa Proprietary Limited, wholly owned subsidiary

• Cipla to infuse ZAR 900 mn in South African arm

  3 Feb 2025, 4:57PM Pharma major Cipla Ltd on Monday said it will invest about ZAR 900 million (nearly Rs 415 crore) in equity share capital of its South African arm Cipl

• Cipla

  21 Apr 2025 , 10:01AM US FDA classified company arm Medispray’s Goa facility as ‘voluntary action indicated’.

• Cipla gets final USFDA nod for Paclitaxel protein-bound particles

  11 Apr 2025 , 9:57AM Paclitaxel is indicated for the treatment of metastatic breast cancer

• Cipla

  21 Feb 2025 , 9:51AM Cipla: It got the US FDA nod for Nilotinib Capsules, used in treating CML disease, a type of blood cancer. Positive

• Cipla

  10 Feb 2025 , 8:53AM Cipla: company said the US FDA classified the manufacturing facility in Virgonagar, Bengaluru as Voluntary Action Indicated (VAI). Positive

• Cipla

  21 Jan 2025 , 10:28AM The US FDA ended its inspection at the company's arm's manufacturing facility in Goa, and issued an observation in form 483. Positive.

• Cipla gets 8 observations from USFDA

  14 Nov 2024 , 12:18PM For its Bengaluru facility

• Stock Update: Cipla Q2FY2025 Results Review

  30 Oct 2024 , 1:58PM Stock Update: Cipla Q2FY2025 Results Review: Margins rebound to levels last seen two years ago

• Cipla

  4 Sep 2024 , 10:12AM MK Hamied Resigns as Vice Chairman & Non-Executive Director of the company w.e.f. October 29, 2024, due to age & health

• Cipla

  15 Jul 2024 , 9:14AM The company had a routine current Good Manufacturing Practices (cGMP) inspection at our Kurkumbh manufacturing facility, we wish to inform you that the United States Food and Drug Administration (USFDA) vide communication dated Friday, 12th July, 2024 (10.18 PM IST) has classified the above referred inspection as Voluntary Action Indicated (“VAI”). (Positive).

• Cipla

  26 Jun 2024 , 12:17PM As per media sources, Following are the USFDA observations for Goa Unit 1) accuracy, specificity of test methods are not established, 2) Aseptic processing areas are deficient to monitor environmental conditions, 3) Aseptics processing areas are deficient to disinfect room and equipment and 4) failed to review batch and components to meet its specifications. (Neutral)

• Cipla

  25 Jun 2024 , 11:48AM In further to Cipla’s intimation dated 4th April 2024, regarding the routine current Good Manufacturing Practices (cGMP) inspection at their Patalganga manufacturing facility, the company wishes to inform that the United States Food and Drug Administration (USFDA) vide communication dated Tuesday, 25th June 2024 has classified the above referred inspection as Voluntary Action Indicated (“VAI”). Positive.

• Cipla

  24 Jun 2024 , 1:50PM The USFDA has conducted an inspection at the Company’s manufacturing facility in Goa, India from 10th – 21st June 2024. On conclusion of the inspection, the Company received 6 (six) inspectional observations in Form 483. The Company will work closely with the USFDA and is committed to address these comprehensively within stipulated time. (Neutral)

• Cipla EU to invest additional EUR 3 million in Ethris

  18 Jun 2024 , 3:03PM Cipla's UK arm to invest an additional €3 million in Ethris GmbH

• Cipla

  22 May 2024 , 11:14AM Cipla and its wholly owned subsidiary Cipla USA Inc. today announced that it has received the final approval for its Abbreviated New Drug Application (ANDA) for Lanreotide Injection 120 mg/0.5 mL, 90 mg/0.3 mL, 60 mg/0.2 mL from the United States Food and Drug Administration (USFDA). n. Lanreotide Injection is supplied as 120 mg/0.5 mL, 90 mg/0.3 mL, 60 mg/0.2 mL single-dose, pre-filled, ready-to[1]inject syringe. Cipla’s Lanreotide injection is indicated for the treatment of patients with Acromegaly and Gastroenteropancreatic Neuroendocrine Tumors. According to IQVIA (IMS Health), Somatuline® Depot (Lanreotide) had US sales of approximately $898M for the 12-month period ending March 2024. (Positive)

• Cipla gets final USFDA nod for Lanreotide Injection

  22 May 2024 , 10:49AM Cipla gets final USFDA nod for Lanreotide Injection used to treat Acromegaly & Gastroenteropancreatic Neuroendocrine Tumors

• Cipla

  21 May 2024 , 11:03AM Exelixis, Inc. has entered into a Settlement and License Agreement (Agreement) with Cipla Ltd. and Cipla USA, Inc. (collectively Cipla). This settlement resolves two patent litigations brought by Exelixis in response to Cipla’s Abbreviated New Drug Application (ANDA) seeking approval to market generic versions of CABOMETYX® (cabozantinib) tablets prior to the expiration of the applicable patents. The first case (Civil Action No. 23-287), filed on March 16, 2023, relates to Cipla’s ANDA for a 60 mg cabozantinib dosage strength. The second case (Civil Action No. 24-565-RGA), filed on May 9, 2024, relates to a recent amendment to Cipla’s ANDA, for the primary purpose of seeking additional approval for 20 mg and 40 mg cabozantinib dosage strengths. Positive

• Cipla

  15 May 2024 , 10:10AM The Promoters Hamied Family, Okasa Pharma Pvt. Ltd. to sell 2.53% stake in the open market. Price range – Rs 1289.5 to Rs 1357.35 – maximum 5% discount. Total block size – Rs 2,637 cr There will be lock-in on sellers of 90 days post block. Kotak Securities is sole broker of the deal.

• Stock update - Cipla

  13 May 2024 , 11:31AM Stock update - Cipla - Meaningful new launches to drive growth.

• Cipla

  16 Apr 2024 , 9:11AM Cipla Health Limited (CHL), the wholly owned subsidiary and consumer healthcare arm of Cipla, has signed a business transfer agreement (BTA) for the purchase of the distribution and marketing business undertaking of cosmetics and personal care business of Ivia Beaute Private Limited, India, including IVIA’s brands namely Astaberry, Ikin, and Bhimsaini on a worldwide basis. uilding on its strong presence through a cluster of brands in Tier 2-6 towns, CHL is strengthening its play in the fast-growing beauty and personal care sector catering to the aspirational consumer of India. The beauty brand has a sales of Rs 55 Crs in FY23 and was acquired for Rs 130 Crs. Positive

• Cipla

  5 Apr 2024 , 10:52AM A routine current Good Manufacturing Practices (cGMP) inspection was conducted by the USFDA at the manufacturing facility of the Company located in Patalganga, Maharashtra, India from 28th March, 2024 to 4th April, 2024. On conclusion of the inspection, the Company has received 6 inspectional observations in Form 483. Negative.

• Stock Update: Cipla

  15 Mar 2024 , 12:09PM Stock Update: Cipla - Complex respiratory portfolio growth to drive margins.

• Cipla

  4 Mar 2024 , 12:40PM • The Company has completed the transfer of Generics Business Undertaking as a going concern on a slump sale basis to Cipla Pharma and Life Sciences Limited, a wholly owned subsidiary of the Company on 1st March, 2024. (Positive)

• Cipla

  4 Mar 2024 , 10:31AM A pre-approval inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of Cipla (Jiangsu) Pharmaceutical Co., Ltd. (subsidiary of the Company) located in Qidong, Jiangsu Province, China from 26th February, 2024 to 1st March, 2024. The inspection concluded with zero Form 483 observations. (Positive)

• Cipla

  16 Feb 2024 , 10:53AM Cipla announced that the company has entered into a collaborative research agreement with CSIR-Central Drug Research Institute (CSIR-CDRI), a constituent laboratory of the Council of Scientific and Industrial Research, Government of India, to jointly develop a novel ophthalmic formulation for fungal keratitis. The collaboration aims to leverage the combined expertise and resources of both organizations to develop a safe and efficacious drug for fungal keratitis. Globally, approximately 1.2 million cases of fungal keratitis are reported every year with tropical countries recording a higher incidence. Fungal keratitis often occurs following ocular trauma and exposure to fungal pathogens from organic matter, thus putting agricultural workers at greater risk. (Positive)

• Cipla

  29 Jan 2024 , 10:19AM Samina Hamied stepping down as VC of Cipla is part of a larger promoter plan, promoters would like Cipla to be handled by professionals. Samina Hamied stepping down is not part of any stake sale plan. The company would like to model Cipla as a conglomerate like Tata. (Positive)

• Cipla

  9 Jan 2024 , 11:51AM Cipla (EU) Limited, UK a wholly owned subsidiary of Cipla Limited (BSE:500087; NSE: Cipla EQ], hereinafter referred to as Cipla has announced a strategic collaboration with Kemwell Biopharma Private Limited (through its subsidiary Kemwell Biopharma UK Limited) and Manipal Education & Medical Group (through its subsidiary MNI Ventures, Mauritius) to incorporate a joint venture in the United States. The primary goal of this joint venture is to develop and commercialise novel Cell therapy products for major unmet medical needs in the United States, Japan, and EU regions. Positive.

• Cipla

  8 Jan 2024 , 10:05AM Cipla Technologies a wholly owned step-down subsidiary of Cipla Limited and Pulmatrix Inc., have completed an amendment to the agreement for the development and commercialization of Pulmazole. The parties have now agreed to terminate the Phase 2b clinical trial for development of Pulmazole by 30th July, 2024 and Cipla shall now have exclusive rights for the development and commercialisation of Pulmazole in all countries except United States of America. (Positive)

• Cipla

  15 Dec 2023 , 12:36PM Further to the intimation dated 10th June 2020 and 27th June 2022, Cipla has entered into definitive agreements on 14th December 2023 for further investment of INR 42 crores (approx.) in GoApptiv Private Limited. Goapp belongs to the Digi-tech and Healthcare Industry. Cipla’s stake in GoApptiv post completion of acquisition and subscription of additional shares would be 22.99%, on a fully diluted basis. GoApptiv is an associate of the Company and hence the said acquisition would fall within the purview of related party transactions. (Positive)

• Cipla

  11 Dec 2023 , 11:16AM Cipla’s wholly-owned subsidiary, InvaGen Pharmaceuticals Inc., USA is voluntarily recalling one lot of Vigabatrin for Oral Solution, USP 500mg, to the consumer level. Vigabatrin for Oral Solution, USP 500 mg has been found to have seal integrity issues allowing for powder leakage from the pouch. (Neutral)

• Cipla

  24 Nov 2023 , 10:43AM After yesterday’s correction of 8% in the stock, the management issued clarification to the exchange “The Warning Letter received from US FDA was in continuation of observations received in Form 483 on 17th February, 2023 and inspection classification of the said facility as Official Action Indicated (“OAI”) received on 5 th August, 2023. The news article covers the same event and there is no new development requiring additional disclosure by the Company. we once again confirm that we do not see material risk to our existing commercial product portfolio. The Company is in the process of executing de-risking plan for its new products and simultaneously addressing the observations expeditiously. The company uphold quality and compliance with utmost importance and remain committed to be compliant with the cGMP quality standards. The Company is in process of submitting requisite response to the Warning Letter within the stipulated timelines and shall work closely with the USFDA to address the concerns.” (Positive)

• Cipla

  23 Nov 2023 , 11:13AM The Company has received a Warning Letter from United States Food and Drug Administration (USFDA) for the routine current Good Manufacturing Practices (cGMP) inspection conducted at Pithampur manufacturing facility between 6th – 17th February, 2023. This Warning Letter summarizes contraventions regarding methods or controls followed at the facility which do not conform to the prescribed cGMP regulations and contains directional guidance for necessary corrections (Negative)

• Cipla

  20 Nov 2023 , 11:43AM The Company has received a Warning Letter dated 17th November, 2023 from United States Food and Drug Administration (USFDA) for the routine current Good Manufacturing Practices (cGMP) inspection conducted at Pithampur manufacturing facility between 6th – 17th February, 2023. This Warning Letter summarizes contraventions regarding methods or controls followed at the facility which do not conform to the prescribed cGMP regulations and contains directional guidance for necessary corrections. (Negative)

• Cipla

  7 Nov 2023 , 10:32AM Cipla - approved the transfer of Generics Business Undertaking as a going concern on a slump sale basis to Cipla Pharma and Life Sciences Limited (CPLS), a wholly owned subsidiary of the Company. Cipla’s generic business was 9% of the sales to Rs 1445 crs. The generic business has been sold for Rs 350 Crs. The transaction is a related party transaction. (Negative)

• Stock Update – Cipla

  30 Oct 2023 , 12:07PM Stock Update – Cipla - Strong Q2 earnings on all fronts, operating margin guidance increased to 24%

• Cipla

  12 Oct 2023 , 11:30AM United States Food and Drug Administration (USFDA) inspection at the manufacturing facility of InvaGen Pharmaceuticals Inc., wholly owned subsidiary of the Company (“InvaGen) located in Central Islip, Long Island, New York, USA, the Company has received the EIR (Establishment Inspection Report) from the USFDA on the classification of the above-referred inspection as Voluntary Action Indicated (VAI). (Positive).

• Cipla

  5 Sep 2023 , 10:31AM The company to acquire South Africa based Actor Pharma, which is the fifth largest privately owned OTC player in the South African market. The acquired company specialises in OTC and generic medicine where they have established strong consumer brands and identified niche prescription markets in categories of woman’s health, nasal, cough and cold and baby and child. This is a strategic acquisition for Cipla South Africa to unlock future growth opportunities and leverage cost synergies in the South African market.

• Cipla

  24 Aug 2023 , 10:27AM The company has received a communication from US FDA that they have determined the inspection classification of Piparia (Silvassa) manufacturing facility as Voluntary Action Indicated (VAI). Based on this facility considered to be in minimally acceptable state of compliance with regards to current good manufacturing practices – Positive read through for the stock as plant was under import alert and now received VAI certification, which will lead to potential resolution.

• Cipla

  7 Aug 2023 , 10:51AM Cipla Ltd. informed that its Pithampur, Indore facility has received official Action indicated (OAI) status from the USFDA. The said facility was inspected for cGMP inspection in Feb 2023 and had been issued 8 observations on form 483. The current OAI status indicates that still the company has not met the regulatory requirements

• Cipla

  27 Jul 2023 , 3:20PM Cipla Ltd.’s associate company GoApptiv Pvt Ltd has formed another company called Practiv Healthcare Pvt Ltd., as its wholly owned subsidiary. Positive read through as it will help GoApptiv to segregate its business into technology and pharmaceuticals leading to more efficient operations.

• Cipla

  27 Jul 2023 , 2:28PM Cipla Ltd. has clarified that it is unaware of the media news around promoters looking to sell a part stake in the promoters’ shareholding to private equity investors with some deal and believes that there is no event with which it need to make any disclosure as per listing regulation. Neutral read through

• Cipla

  7 Jul 2023 , 10:10AM Cipla Ltd. announced that its wholly owned subsidiary, Cipla USA Inc. is voluntarily recalling 6 batches of Albuterol Sulfate inhalation aerosol, 90 mcg (200 metered inhalation) manufactured in November 2021 to the consumer level. There were no adverse incidences reported for Albuterol Sulfate Inhalation Aerosol 90 mcg related to this recall, but the use of such faulty device could be life threatening. The company initiated a recall in the US due to market complaint for one single inhaler where leakage was observed through inhaler valve. To be cautious the company is recalling the 6 batches of it.

• Cipla

  1 Jun 2023 , 10:06AM Proposed stake sale in its step-down subsidiary Cipla Quality Chemical Industries Limited (CQCIL) in Uganda is to complete before July 31, 2023.

• Cipla

  3 May 2023 , 9:13AM Cipla's Invagen Pharma, US facility, has been inspected by the USFDA with zero observations. Positive development. However, given that its other key facilities such as Goa and Pithampur in India continue to be under the USFDA scanner, we continue to maintain Hold on the shares with a PT of Rs. 1080.

• Cipla

  26 Apr 2023 , 11:57AM Cipla Ltd. informed that its wholly owned step-down subsidiary called Madison Pharma from the US will be dissolved with effect from 28th April 2023. As Madison was a dormant entity Cipla believes it will not affect its revenue. Neutral impact on the stock.

• Cipla

  10 Apr 2023 , 2:37PM Cipla Ltd. has signed a perpetual license agreement with Novartis Pharma AG (Switzerland) today to manufacture and market Galvus and Galvus combination brands used in the treatment of Type 2 diabetes from January 1, 2026. In the meantime, the company will continue to market and distribute Galvus branded products. Currently, the market size for Galvus brands is Rs. 268 Cr as per IQVIA MAT Feb 2023.

• Cipla signs licence agreement with Novartis AG

  10 Apr 2023 , 12:53PM Cipla signs perpetual licensing agreement with Novartis Pharma AG for Galvus range for diabetes therapy in India

• Cipla

  15 Mar 2023 , 10:32AM Cipla sells 51.2% stake in its subsidiary, Cipla Quality Chemical Industries Ltd. (CQCIL) at Uganda, Africa for a consideration of USD 25-30 million (Rs. 206 - Rs. 247 Cr) to Africa Capitalworks Holdings or its subsidiary Africa Capitalworks SSA 3. CQCIL contributed 1.62% of total net worth and 2.57% of total revenue of Consolidated Cipla. The transaction is likely to complete by the end of May 23. The transaction has no impact on valuation. We continue to maintain Hold on the shares with a PT of 1,080.

• Cipla

  28 Feb 2023 , 10:37AM Cipla Ltd., as per media reports, its USFDA Form 483 observations for Pithampur plant have been declared such as procedures for handling written or oral complaints are deficiently written or followed, field report not submitted as required under SOP, responsibilities, and procedures applicable to quality unit not fully followed, lab records do not include complete data.

• Stock Update: Cipla

  21 Feb 2023 , 11:04AM Stock Update: Cipla Ltd. – Pithampur site under the USFDA scanner

• Cipla

  20 Feb 2023 , 12:31PM Cipla has received 8 observations with Form 483 on conclusion of the inspection by the USFDA for its Pithampur manufacturing facility. It’s a negative read through for the stock.

• Cipla

  18 Jan 2023 , 11:49AM India Ratings and Research (Ind-Ra) has affirmed Cipla Limited’s Long-Term Issuer Rating at ‘IND AAA’. The Outlook is Stable. It was driven by robust credit metrics, sharp sales growth, strong business risk profile and regulatory risks. Our view: Positive for the stock

• Cipla launches Cippoint

  18 Jan 2023 , 11:11AM Cipla launches Cippoint, a point-of-care device for non-communicable, infectious & other health issues

• Cipla

  18 Jan 2023 , 10:50AM Cipla Ltd. announced the launch of Cippoint, a point of care testing device, which offers a wide range of testing parameters including cardiac markers, diabetes, infectious diseases, fertility, thyroid function, inflammation, metabolic markets, and coagulation markets.

• Cipla EU to invest EUR 15 million in Ethris

  30 Dec 2022 , 10:58AM Cipla EU to invest EUR 15 million in Ethris, initiating a strategic collaboration

• Cipla EU to invest EUR 15 million in Ethris

  30 Dec 2022 , 10:58AM Cipla EU to invest EUR 15 million in Ethris, initiating a strategic collaboration

• Cipla

  30 Dec 2022 , 9:43AM Cipla has announced that its subsidiary in the UK called Cipla EU Ltd. has invested EUR 15 million (Rs. 132 Cr) in Ethris GmBH, which is into development of delivery of mRNA directly into respiratory system. mRNA molecules have the genetic information needed to make proteins. It is a beginning of a long-term strategic partnership between Cipla and Ethris to develop mRNA-based therapies and enables Cipla to market Ethris’ products in Cipla’s key emerging markets. Our view: We believe it is positive as over the past decade mRNA is believed to be a promising therapeutic tool in the fields of vaccine development and protein replacement therapy.

• Cipla

  28 Dec 2022 , 9:44AM Cipla's Chief Technology Officer (CTO) Geena Malhotra mentions in the media that Cipla's capex on automation will continue for 3 - 4 years. This will help the company to produce high quality products which are sustainable and affordable. As a part of the automation initiative the company has been using robotics and the assignment of work to workers is being done by the system.

• Stock update – Cipla

  15 Dec 2022 , 2:38PM Stock update – Cipla: Potential product launch delays earnings downgrade risk

• Cipla

  30 Nov 2022 , 10:02AM Cipla: Company launches specialty injectable product in the US. Company has announced the launch of Leuprolide Acetate injection depot 22.5 mg, which has been a specialty product approved under 505(b)(2) regulatory pathway (novel new molecular entity - not strictly a generic version), which is used for palliative treatment of advanced prostate cancer. It is a generic of Lupron Depot of AbbVie. Hence, it has no competition as of now. It is highly positive for Cipla as the market for Lupron Depot was USD 197 Mn for the LTM ended Sep 22. Positive read through for the stock

• Cipla launches Leuprolide Acetate injection depot, 22.5 mg

  29 Nov 2022 , 10:01AM Leuprolide Acetate injection is used to treat Endometriosis

• Cipla

  3 Oct 2022 , 10:37AM The company has announced that following the product specific PreApproval Inspection (PAI) by the USFDA at the Indore plant from 27th June, 2022 to 1st July, 2022, the company has received the Establishment Inspection Report (EIR) indicating closure of the inspection - Positive for the stock.

• Cipla

  23 Sep 2022 , 10:34AM The company's Indore plant receives (EIR) Establishment Inspection Report for its Indore plant indicating closure of Inspection - Positive read thru for the stock

• Stock Update - Annual Report Review – Cipla

  12 Sep 2022 , 2:09PM Stock Update - Annual Report Review – Cipla Limited: Growth prospects stay bright

• Stock Update - Annual Report Review – Cipla

  12 Sep 2022 , 12:09PM Stock Update - Annual Report Review – Cipla Limited: Growth prospects stay bright

• Cipla

  7 Sep 2022 , 3:00PM Cipla: Gets USFDA approval for its ANDA for Lenalidomide (Revlimid) Capsule strength - 5 mg, 10 mg, 15 mg and 25 mg. Lenalidomide is an immunomodulatory prescription drug which is indicated for several hematological malignancies in adults such as Multiple Myeloma, Myelodysplastic syndromes, Mantle cell, which are types of cancers. The addressable market size for the drug in the US is $ 2.85 bn, which is strong. Positive

• Cipla gets USFDA nod for generic version of Revlimid

  7 Sep 2022 , 2:37PM Revlimid is used to treat various types of cancers

• Cipla

  29 Aug 2022 , 10:10AM The USFDA inspected Cipla’s Goa plant between 16 to 26 August 2022, after the plant was issues a warning letter in February 2020. The inspection ended with form 483 and 6 observations and some of the observations have a reference to inspections done by the USFDA in September 2019. Though in this inspection there are no data integrity issues being reported and the management is committed to addressing the issues in the stipulated time frame. As there are no data integrity observations being reported, we await further clarity on this. Stock to remain in Focus

• Cipla

  17 Aug 2022 , 12:21PM As per media reports the USFDA has commenced the inspection of the company’s Goa plant which was under a Warning Letter since February 2020. The final outcome of the same is awaited. Also the company has appointed Mr Ashish Adukia as its new global chief financial officer. Stock to remain in focus.

• Cipla

  5 Aug 2022 , 1:00PM Cipla: Wholly owned subsidiary - Cipla (EU) Limited, to acquire an additional 19.16% stake in Cipla Maroc SA, joint venture and subsidiary of Cipla EU in Morocco. Cipla Maroc SA was incorporated in 2015, in Morocco, as a joint venture between Cipla EU Limited, The Pharmaceutical Institute (PHI) and Societe Marocaine De Cooperation Pharmaceutique (Cooper Pharma) for the purpose of manufacturing, marketing and distribution of pharmaceutical products in Morocco. The JV Co. has enabled Cipla establish a front-end presence in Morocco’s pharmaceutical market. PHI has sold its entire stake in the company and the balance two stake holders would ne buyoing out the stake in their existing proportion. The cash consideration for the stake stands at MAD 102.90 million or ~ RS 80 cr and post the completion of the deal, Cipla EU would hold 79.16% stake in company. Positive read thru

• Cipla

  27 Jul 2022 , 1:27PM Cipla: lnvaGen Pharmaceuticals Inc - wholly owned step-down subsidiary in USA has entered into a Share Repurchase Agreement on 25th July 2022 with Avenue Therapeutics, Inc and Fortress Biotech, Inc for sale of 5,833,333 shares representing 25.93% of equity stake held in Avenue for a consideration of $ 3 million and an additional amount upto $ 4 million on satisfaction of certain conditions. Post the completion of the transaction, the Avenue shall cease to be an associate of the Company. Earlier in the past the company had terminated this transaction which in now re-initiated.

• Cipla

  15 Jul 2022 , 11:16AM Cipla: wholly owned subsidiary and consumer healthcare arm – Cipla Health Limited (CHL), definitive agreements for acquisition of Endura Mass, a renowned nutritional supplement brand in the category of weight gain from Medinnbelle Herbalcare Private Limited. The acquisition includes “Endura” and all other associated trademarks. This acquisition is in line with Cipla's strategic imperative to augment the Company's wellness portfolio. Positive

• Cipla Health signs agreement to acquire Endura Mass

  15 Jul 2022 , 10:29AM Cipla Health forays into the 'nutritional wellness' segment, signs agreement to acquire Endura Mass

• Cipla

  5 Jul 2022 , 11:23AM The Indore plant underwent a pre approval inspection between 27th June 2022 to 1st July 2022 and the inspection ended with a form 483 being issued with 2 observations, none of which are related to data integrity issues. The company would be submitting its responses in the stipulated time frame. The receipt of Form 483 with 2 observations is negative

• Cipla

  20 Jun 2022 , 10:39AM Has signed definitive agreements for acquisition of 21.05% stake on a fully diluted basis for an amount of INR 25 crores in Achira Labs Private Limited, which is engaged in development and commercialization of point of care (PoC) medical test kits in India. This investment will facilitate a Cipla’s strategic participation in the Poc diagnostics and AMR (anti-microbial resistance) space through the design, development, and manufacturing of microfluidics based technologies. Achira is developing POC immunoassays and molecular assays across the clinical areas of infectious diseases, AMR and hormone analysis. The transaction is expected to be complete within 60 days from the signing of definitive agreements. Positive read thru as the acquisition of the stake would enable Cipla’s entry on the PoC diagnostics space

• Cipla

  15 Jun 2022 , 9:58AM The South African Health Products Regulatory Authority has approved a sweet-tasting, heat-stable, 4-in-1 fixed-dose combination of four antiretroviral treatments composed of abacavir, lamivudine, lopinavir, and ritonavir that is specifically designed for infants and young children with HIV, which is developed jointly by Cipla and not-for-profit Drugs for Neglected Diseases initiative (DNDi). The country has 238,000 children under the age of 15 living with HIV – the highest in the world. The approval is positive for Cipla as the new formulation has significant improvement over existing ones and it would broaden the product offerings as well

• Cipla

  2 Jun 2022 , 2:52PM The company has commissioned additional capacity of captive renewable energy power plant in Maharashtra & Karnataka. In Jan’21, Cipla had commissioned 30 MWp solar project at Tuljapur, and now further added 16 MWp of solar capacity for supplying the renewable energy for its manufacturing units/ facilities in Maharashtra. In Karnataka wind solar hybrid captive power plant with capacity as 9 MWp solar and 2.7 MVA of wind has been commissioned. With the commissioning of the renewable power plants the company would be in a position to switch partial consumption of power to these green sources. We have a Buy recommendation on Cipla

• Cipla adds capacity of captive renewable energy power plant

  2 Jun 2022 , 9:59AM Cipla adds capacity of captive renewable energy power plant in #Maharashtra & Karnataka

• Stock Update – Cipla Q4FY22 Result Update

  11 May 2022 , 10:39AM Stock Update – Cipla Q4FY22 Result Update: Healthy Q4; growth prospects stay bright

• Stock Update – Cipla

  1 Apr 2022 , 10:07AM Stock Update – Cipla Limited: Growth prospects stay bright

• Cipla

  25 Feb 2022 , 9:42AM Gets an approval from the Subject matter Expert Committee (SEC) of the CDSCO to conduct local trials on anti Covid-19 pill – Paxlovid. The SEC granted approval to the company to conduct bioavailability and bio equivalence (BA/BE) studies and in addition to Cipla two more companies Hetero Labs and Optimus Pharma are also conducting the trials for the launch of the generic Paxlovid. Subject to successful completion of trials, the drug could be launched in India. Positive read thru

• Cipla

  15 Feb 2022 , 10:56AM As per media news, the promoters of the company would be selling 2% of their stake to institutional investors at with an option to increase the deal size to 2.5%. The price range is between Rs 904.8 to Rs 916.7 per shares and is at a discount of 4% - 5% to the previous closing price of Rs 955.25 per share (as on 14 Feb 2022). The selling of the stake at a discount to the CMP could be a negative read thru

• Cipla

  28 Dec 2021 , 3:15PM Gets Emergency Use Authorisation(EUA) from the Drug Controller General of India (DCGI) for the launch of Molnupiravir in India under the brand name Cipmolnu. Molnupiravir is the first oral antiviral approved for the treatment of mild-to-moderate COVID-19 patients at high risk of developing severe disease. The regulatory approval comes on the back of a five-month collaborative trial conducted by a consortium of companies. The approval is positive and could add to the topline growth, given the rising covid cases.

• Cipla gets EUA to launch oral antiviral drug Cipmolnu

  28 Dec 2021 , 2:16PM Cipla global gets emergency authorisation usage (EUA) approval by DCGI for Molnupiravir in India, used to treat mild-to-moderate COVID

• Cipla gets final nod for Lanreotide Injection

  20 Dec 2021 , 10:50AM Lanreotide Injection use for the treatment of patients with Acromegaly and Gastroenteropancreatic Neuroendocrine Tumors

• Cipla

  20 Dec 2021 , 9:45AM Cipla: Gets USFDA approval for its ANDA - Lanreotide Injection. The ANDA application was submitted under the 505(b)(2) filing pathway. The injection would be available in strength - 60 mg/0.2 mL, 90 mg/0.3 mL, and 120 mg/0.5 mL single dose pre-filled syringes and is indicated for the treatment of patients with Acromegaly and Gastroenteropancreatic Neuroendocrine Tumors. The reference listed drug SOMATULINE DEPOT had reported US sales of approximately $867M for the 12-month period ending October 2021. The approval is positive given the substantial addressable market size and would also widen the company’s complex product pipeline.

• Cipla

  16 Dec 2021 , 10:25AM Cipla: Teva has received approval for its respiratory asset –gAdvair, which it could launch ahead of Cipla. Hence could be a negative read thru for Cipla.

• Cipla

  16 Nov 2021 , 9:38AM Would be a part of the S&P Dow Jones Sustainability Index (DJSI) for the Emerging Markets for 2021. DJSI is the gold standard for corporate sustainability, and is highly regarded by global investors looking at ESG based investments. The inclusion of Cipla in the DJSI index is positive and can attract higher attention of the global investors following the ESG theme

• Cipla

  10 Nov 2021 , 12:16PM Subsidiary company - Cipla Technologies LLC, which is a clinical stage biopharmaceutical company, will continue to reimburse Pulmatrix Inc for 50% of all third-party costs for the development of Pulmazole, which would include 40% of dedicated personnel and consulting costs and another 10% upon the timely achievement of certain development milestones. Pulmatrix has also granted Cipla Technologies exclusive rights to develop and sell Pulmazole in India, Nepal, Yemen, Iran, South Africa, Sri Lanka, Mynmar and Algeria for 2% royalty. This is Long term potential positive subject to successful development and approval of Pulmazole.

• Cipla

  1 Oct 2021 , 9:38AM As per The company has built a war chest for pursuing potential inorganic opportunities in the domestic markets as well as in the US. This points at potential growth opportunities for the company and hence is positive.

• Cipla

  7 Sep 2021 , 10:31AM The DCGI has issued an Emergency Use Authorization for the generic version of Tocilizumab in India for treating hospitalized Covid 19 patients. Tocilizumab is Roche’s drug and licensed to Cipla for marketing in india. Hetero is the second player after Cipla to get the approval for Tocilizumab and points at emerging competition for the drug for Cipla, hence negative.

• Cipla

  3 Sep 2021 , 9:47AM As per media news, the company has partnered with Clensta International, an IIT Delhi supported healthcare startup for marketing and distributing their products based on waterless technology. Clensta operates in the personal care and home care space and has developed products like waterless body bath, waterless shampoo and CoV-Guard Protection Lotion with Prolonged Antiviral Protection Technology. Cipla will run an intensive marketing drive to educate the right buyers such as hospitals, pharmacies, defense forces and various institutions. This could enable Cipla widen their product offerings and hence could be potential positive

• Cipla

  25 Aug 2021 , 4:39PM Cipla: enters in to a Joint venture with Kemwell Biopharma Private Limited, a leading biopharmaceutical CDMO player to develop, manufacture and commercialise biosimilars for global markets. For this purpose, a joint venture company shall be incorporated with an aim to enter the respiratory biosimilars space. Cipla would be holding 60% stake in the JV company and plans for further infusion to be made in one or more tranches subject to satisfaction of certain conditions. This is a potential positive for Cipla as it marks the foray in the biosimilar space and would also further strengthen the company’s respiratory franchise.

• Cipla, Kemwell Biopharma announce execution of a joint venture agreement

  25 Aug 2021 , 3:34PM Cipla to form a JV co with Kemwell Biopharma for undertaking biologic pdt biz

• Cipla Limited Q1FY22 Result Update

  6 Aug 2021 , 11:25AM Cipla Limited Q1FY22 Result Update: Strong quarter; growth prospects stay bright

• Cipla

  26 Jul 2021 , 11:00AM Cipla is recalling 7,228 bottles of Solifenacin Succinate tablets, a medicine used to treat overactive bladder, in the US market due to manufacturing issues – CGMP deviations. As per USFDA the company is recalling bottles with 10 mg, 30-count bottles in the US. The batches were manufactured at the company’s Goa plant and then Shipped to the US arm – Cipla USA inc. The USFDA has classified the recall as a class II recall and hence the same is unlikely to have any material impact on the financial performance of the company.

• Cipla

  12 Jul 2021 , 9:46AM As per media news, the Government of India has approved Moderna’s Covid – 19 Vaccine for emergency use in India and the Government is working towards ways to import the Vaccine in India and making it available. Also the clause of indemnity has been met, which was a condition put forth by Moderna. This is positive for Cipla as it has a tie up with Moderna for laters Covod vaccine. Also this could have a positive rub off effect on other MNC players – Pfizer India and J&J as they could be granted the indemnity for importing the covid vaccines.

• Cipla

  8 Jul 2021 , 12:44PM As per media news, Moderna’s M-RNA vaccine for Covid has received emergency use authorization from the DCGI and consequently Cipla would be procuring 7 mn doses of the vaccine initially. The receipt of emergency use authorization is positive as it could open up sizeable growth opportunities for Cipla

• Cipla

  30 Jun 2021 , 9:40AM As per media reports the regulator has granted an emergency Use approval for Moderna’s Covid Vaccine in India. Cipla would be importing the Moderna’s Vaccine in India but has mentioned that at this stage there is no definitive agreement on commercial supplies. Also Cipla is pursuing a separate tie-up with Moderna to undertake large-scale fill-and-finish, distribution and commercialization of its mRNA vaccines. The nod for importing the vaccine in India is positive as going ahead could open up potential growth opportunities for Cipla.

• Cipla

  29 Jun 2021 , 2:19PM As per media reports the company has applied to the DCGI seeking nod to import Moderna’s Covid 19 vaccine in to India. Further DCGI is likely to grant the permission to import the vaccine soon. If the permission is granted to import the vaccine, it opens up a sizeable growth opportunity, hence positive

• Cipla receives final approval for generic version of Sunovion Pharmaceuticals

  23 Jun 2021 , 11:39AM Cipla gets USFDA nod for Arformoterol Tartrate Inhalation Solution, used for treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease

• Cipla

  17 Jun 2021 , 10:28AM As per media reports, the company has launched two new products under its Maxirich brand. Cipla has launched Maxirich Vitamin C Chewable Tablets and Maxirich Gold Advanced daily Supplement, thereby extending the brands immunity products offerings. The products act as a catalyst in reducing stress levels, boosting energy, building immunity, bolstering memory and concentration. The new product launches would strengthen the immunity boosting products segment of the company, hence positive

• Cipla arm’s drug nod to be delayed

  15 Jun 2021 , 2:45PM USFDA letter reports insufficient information on drug’s effectiveness

• Pfizer, Cipla

  11 Jun 2021 , 11:21AM As per media reports, the government is of India is close to agreeing to grant protection against legal liability (Indemnity) to foreign vaccine makers so that their vaccine can be a part of the immunization program in India. If the indemnity is granted by the Government, then it would be positive for Pfizer India and Cipla as Moderna and Cipla are in talks to introduce Moderna’s vaccine in India.

• Cipla

  1 Jun 2021 , 10:25AM Cipla: The company is in talks with Moderna to launch the laters single dose vaccine for Covid 19 in India. Consequent to this the company has requested the government for indemnification and exemptions from price capping, bridging trials and basic customs duty for the vaccine as it was close to committing USD 1 Bn (RS 7250 crore) to the US based Moderna. If the government approves the conditions, could be positive for Cipla as it could then pursue the vaccination opportunity.

• Cipla

  26 May 2021 , 9:20AM As per media news, Moderna s expecting to launch a single-dose COVID-19 vaccine in India next year and is in talks with Cipla among other Indian firms for the same. Further Moderna has said that it does not have Vaccines to be supplied in 2021 and hence would be able to supply the vaccines from the next year. Cipla has further shown interest in procuring 5 crore doses from Moderna for 2022 and has requested confirmation from the central government in respect of stability in regulatory requirements/policy regime. This could be positive for Cipla subject to receipt of the necessary regulatory approvals

• Cipla

  24 May 2021 , 12:06PM Cipla: Announced that the first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 200,000 patients as each of the 100,000 packs that will be available in India offers treatment for two patients. Cipla will distribute the product by leveraging its strong distribution strengths across the country. The drug will be available through leading hospitals and COVID treatment centers. The antibody cocktail has received an Emergency Use Authorization in India and also in the US and several other countries. The launch of the drug is positive as it would strengthen the company’s covid portfolio and also help grow the domestic revenues.

• Cipla

  21 May 2021 , 9:17AM Cipla: Has received an approval from the USFDA for its Abbreviated New Drug Application for Dolutegravir Sodium. The drug – Dolutegravir is been used with other medications to control HIV infections. The approval is positive for Cipla as it would widen the company’s product offerings in the US markets.

• Cipla launches ViraGen a polymerase chain reaction test

  20 May 2021 , 10:26AM Cipla launches 'ViraGen' a polymerase chain reaction (Covid-19 RT-PCR) test

• Cipla

  20 May 2021 , 9:13AM Cipla: Has announced the commercialization of a polymerase chain reaction (RT-PCR) test kit ‘ViraGen’ for COVID-19 in India, The Kit is developed in partnership with Ubio Biotechnology Systems Pvt. Ltd. ViraGen is Cipla’s third offering in the Covid-19 testing segment and the test kit helps to identify and detect SARS CoV-2 N Gene and ORF Lab Gene with the sensitivity of 98.6% and the specificity of 98.8% as compared to a standard ICMR test. As per the agreement Cipla would be responsible for manufacturing and distribution of Viragen in India through its wide distribution channel. This is positive as it would further strengthen Cipla’s Covid led portfolio and would also help grow the India business.

• Cipla Limited: Q4FY2021 Result Update

  17 May 2021 , 10:34AM Cipla Limited: Q4FY2021 Result Update - Q4 misses estimates; but growth prospects stay bright

• Cipla

  10 May 2021 , 1:58PM Cipla: Enters into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly for the manufacture and commercialization of Eli Lily’s drug baricitinib for Covid-19 indication. Baricitinib is issued Emergency Use Approval in India for use in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation. This collaboration is a step further in Cipla’s efforts to enhance access to critical treatments for patients affected by the pandemic. Cipla will leverage its extensive distribution footprint to make this therapy accessible to more patients and markets, hence positive

• Cipla enters into licensing pact with Eli Lilly

  10 May 2021 , 10:50AM Cipla enters into a Licensing Agreement with Lilly to expand access to COVID-19 treatment in India

• Cipla

  6 May 2021 , 9:35AM Roche India has announced that the CDSCO (Central Drugs Standards Control Organisation) has provided an Emergency Use Authorization for Roche’s antibody cocktail (Casirivimab and Imdevimab) in India. The Authorization will now enable Roche to import the globally manufactured product batches to India and will be marketed as well as distributed in India through a strategic partnership with Cipla. The antibody cocktail drug is to be administered for treatment of mild to moderate Covid positive patients including pediatric patients above 12 years of age. Recently, Roche has announced that a large Phase III trial for the combination drug has met its primary endpoint and significantly reduced the risk of hospitalization or death by 70%. Given the surge in Covid cases in India, the demand for the drug is expected to be very strong, hence positive for Cipla.

• Cipla

  29 Apr 2021 , 11:31AM Cipla: Has signed a non-exclusive licensing agreement with Merck for the manufacturing and distribution of Molnupiravir, the investigational oral antiviral drug currently in Phase 3 trial for the treatment of non-hospitalized Covid positive patients. As part of the agreement, Cipla will be permitted to manufacture, market and distribute Molnupiravir in India and more than 100 low and middle income countries. Molnupiravir has been shown to be active in several variants of SARS-CoV-2, including for prophylaxis, treatment and prevention of transmission. The development is positive for Cipla as it could offer potential growth opportunities for Cipla given the wide spread of Covid.

• Cipla : Promising growth outlook

  19 Apr 2021 , 11:12AM Cipla : Promising growth outlook

• Cadila, Cipla, Lupin, Sun Pharma, Torrent Pharma, Dr Reddys

  5 Apr 2021 , 10:40AM The investee entity - ABCD Technologies LLP (to be renamed as IndoHealth Services LLP) has through its wholly-owned entity DigiHealth Technologies LLP, acquired 100% interest in Pharmarack Technologies Pvt Ltd in tranches. Pharmarack operates a digital platform aimed at integrating and solving problems across the pharmaceutical supply chain. Its platform offers / proposes to offer products across supply chain including order automation, fulfilment services & optimization, digital payments, working capital optimization, analytics and market insights. Pharmarack technologies has a turnover of Rs 4.04 cr, RS 2.14 Cr and Rs 64.9 Lakhs for FY20/FY19/FY18. We believe this to be a neutral read thru

• Cipla

  23 Mar 2021 , 9:40AM Cipla Therapeutic, which is a division of Cipla USA Inc, and SIGA Technologies, a commercial stage pharma company, have entered into a strategic partnership to deliver sustained innovation and access to novel antibacterial drugs, particularly against bio-threats. The World Health Organisation (WHO) has declared anti-microbial resistance (AMR) as one of the top 10 global public health threats. Cipla’s focus on AMR segment along with SIGAs drug development and US experience creates a unique and strong partnership, basis which the partnership would deliver solutions for biothreats and public needs. Positive for Cipla as it would help strengthen its presence in the US and also grow the US revenues.

• Cipla

  8 Mar 2021 , 11:19AM Cipla: The company has voluntarily liquidated its wholly owned step down subsidiary company - Cipla (UK) Limited as a part of the internal reorganization process. This would not have any affect on the performance or revenue of the company.

• Cipla

  2 Mar 2021 , 12:01PM As per media news, Cipla’s subsidiary company – Cipla Gulf FZ LCC is expanding its partnership with Alvotech for the marketing and distribution of four biosimilars in Australia and New Zealand. As per the terms of the agreement, cipla would be responsible for commercialization of patented biosimilars - Aflibercept, Ustekimumab, Denosumab and Golimumab, covering therapy areas of immunology, osteoporosis, oncology as well as ophthalmology. The aggregate sales of these innovative products stood at $700 mn in Australia in 2020. This is a positive development as it would strengthen Cipla’s biosimilar pipeline and also enable it to establish a pan therapy presence.

• Cipla Gulf expands partnership with Alvotech

  2 Mar 2021 , 10:20AM Cipla Gulf Expands Partnership with Alvotech for Commercialization of Biosimilars in Australia and New Zealand

• Cipla

  18 Dec 2020 , 2:44PM Associate company Avenue Therapeutics has requested a Type A meeting with the USFDA relating to a path forward for IV tramadol and to address the Complete Response Letter (CRL) it received from the USFDA for IV Tramadol. Avenue Therapeutics intends to resubmit the New drug Application (NDA) in February 2021. Post the re-submission, if the NDA is approved it would be positive, though the benefits are likely over the long term

• Cipla

  16 Dec 2020 , 9:33AM Cipla: has launched “CIPTest” – is a rapid antigen detection test for Covid 19 diagnosis. The company plans to commence the supply of the antigen test commencing from this week. This is a positive development as the demand for these tests would be substantial given the no of Covid cases and would add to the revenues of the company .

• Cipla announces settlement of REVLIMID capsules patent litigation

  14 Dec 2020 , 10:24AM Cipla settles its patent litigation with Celgene Corporation with a Bristol Myers Squibb (BMS) subsidiary on Revilimid or a drug for blood cancer

• Cipla

  14 Dec 2020 , 9:43AM Cipla: Settles patent litigation of Revlimid (Lenalidomide) capsules with Celgene; Positive

• Cipla, Cadila

  24 Nov 2020 , 10:50AM AstraZeneca PLC’s COVID-19 vaccine candidate being developed by the University of Oxford has shown an average efficacy of 70% and there were no serious safety issues being observed for the vaccine. In India, Serum Institute of India has tie up and would be manufacturing as well as distributing the vaccine. Once the Vaccine is approved it could impact the sales of Remdesivir, which is a drug used to treat Covid patients. Hence can impact Cipla and Cadila financial performance as both the companies were involved in manufacturing and selling the drug.

• Cipla

  18 Nov 2020 , 12:30PM Cipla: Has entered in to a licensing agreement with a Belgium-based firm - Multi G for the distribution of their COVID-19 Rapid Antibody test kits. As part of the agreement Cipla would be responsible for the distribution of the Rapid Antibody test kits across 25+ markets in Asia, Middle-East and North Africa, Latin America, EU and Australia. The test kits reveals the results in 10 mins time. Given the surge in the no of Covid cases globally, the demand for the test kits is expected to be higher. Further with Cipla’s wide spread distribution network across various markets, it would be able to cater to the demand from these markets, hence positive.

• Cipla launches 'Covi-G' for COVID-19 rapid antibody detection

  18 Nov 2020 , 10:40AM Cipla signs a licensing agreement with MultiG for COVID-19 rapid antibody test kit

• Cipla

  9 Nov 2020 , 8:58AM Cipla Q2 Net profit up 41.2% to Rs 665.4 crore Revenue up 14.6% to Rs 5,038.3 crore Ebitda margin at 23% from 21%

• Cipla introduces Nintib to treat Idiopathic Pulmonary Fibrosis

  21 Oct 2020 , 9:42AM Cipla launches Nintib to treat Idiopathic Pulmonary Fibrosis, in continuation of its fight against rare lung diseases

• Cipla

  21 Oct 2020 , 9:37AM Has launched generic of Nintedanib capsules – 100mg and 150 mg, for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The Product would be marketed under the brand name Nintib. IPF is a rare and chronic form of lung disease that impacts ten in one lakh people. The launch of nintib is in line with the company’s efforts of providing effective and affordable treatment to IPF patients. Cipla’s Nintib is priced at Rs. 69 (100 mg) and Rs. 85 (150 mg) per capsule. The launch is positive for the company as It would add to the topline.

• Pharma stocks tumble

  14 Oct 2020 , 2:13PM Pharma stocks under pressure

• Cipla

  13 Oct 2020 , 9:16AM Avenue Therapeutics, a step down associate company of Cipla in the US, gets complete response letter (CRL) from USFDA for IV Tramdol. The letter states that the application cannot be accepted in its present form. The drug is intended to treat patients in acute pain who require an opioid and is not safe for the intended patient population. According to the letter from USFDA, it requires an adequate terminal sterlisation validation prior to the NDA approval, which has been planned for later this quarter. The receipt of CRL is an adverse development and could slow down the topline growth as the product launch could be delayed, which was expected in April 2021.

• Dr Reddy’s, Cipla, Cadila

  25 Sep 2020 , 11:28AM As per media reports, the Remdesivir, the antiviral drug used in the treatment of Covid-19, is in shortage again due to increasing no of cases and delayed supplies from the companies. Cipla has said that its supplies are up to date. Amidst rising no of cases, the companies are augmenting their capacities to meet the rising demand.

• Cipla

  25 Sep 2020 , 11:23AM As per media reports, government may review inclusion of tocilizumab in its treatment protocol for Covid-19 once again Tocilizumab is a rheumatoid arthritis drug manufactured by Swiss drug maker Roche under the brand name Actemra. If the drug is included as a part of protocol to treat Covid patients, it could lead to a surge in demand for the drug. Since Roche has an arrangement with Cipla, the developmet can be positive for Cipla.

• Cipla

  25 Sep 2020 , 10:17AM Received an approval from USFDA for Dimethyl Fumarate DR Capsules 120 mg, 240 mg. the drug is indicated for treatment of relapsing forms of multiple sclerosis. The approval is positive as it would translate in to better sales growth in the US

• Cipla gets USFDA nod for Dimethyl Fumarate DR Capsules

  25 Sep 2020 , 10:10AM Cipla gets USFDA nod for Dimethyl Fumarate DR Capsules for treatment of relapsing forms of multiple sclerosis

• Cipla

  23 Sep 2020 , 10:09AM As per media reports Competitor Hikma has received a CRL for Advair, leading to a likely delay in launch. This is Positive for Cipla as this would result in reduced competition for the product, though Cipla is yet to the launch it.

• Cipla

  20 Aug 2020 , 1:40PM Partner Stempeutics Research Pvt. Ltd has received regulatory approval from the Drug Controller General of India to launch Stempeucel in India. The product is indicated for the treatment of CLI (Critical Limb Ischemia). It is the first allogeneic cell therapy product to be approved for commercial use in India and the first stem cell product to be approved globally for CLI treatment. Basis the agreement, between the companies, Cipla has exclusive rights to market and distribute the product in India. This is positive for Cipla’s India business as it would widen the product kitty. India business accounts for around 38% of the overall sales

• Cipla, Stempeutics collaborate for launch of Stempeucel

  20 Aug 2020 , 1:35PM Cipla to market and distribute the drug in India to provide patient access

• Cipla

  20 Aug 2020 , 11:48AM wholly owned subsidiary company - Cipla Medpro South Africa Proprietary Limited (CMSA), has signed an agreement with Regipharm Medical Proprietary Limited, South Africa, to sell its entire equity stake in Anmaraté Proprietary Limited, South Africa, which is also a wholly owned subsidiary of CMSA. The stake is unlikely to have any material impact on the financials of Cipla given the lower sales contribution to Cipla’s topline

• Cipla

  12 Aug 2020 , 11:46AM As per media news, Teva Pharmaceuticals sues Cipla to block proposed generic version of Qvar, asthma inhaler. Teva has said that Cipla’s proposed generic version of the inhaler infringes six patents of its Qvar inhaler. 5 of these patents are expiring in May 2031 while one in January 2032. Qvar has reported North America sales of $97 mn in 1HCY2020. Cipla has a strong franchise in the respiratory space in US and this development is unlikely to have any material impact on the financial performance of Cipla.

• Cipla

  10 Aug 2020 , 11:54AM Cipla: Q1FY2021 Result Update - Well placed to harness growth opportunities

• Cipla

  10 Aug 2020 , 11:53AM Cipla: Q1FY2021 Result Update - Well placed to harness growth opportunities

• Cipla

  4 Aug 2020 , 11:39AM The company has witnessed three major exits from the India leadership team. The exits come as a surprise as the company’s india business had delivered good performance. The exits include Mr Nikhil Chopra (CEO India business), Mr Nikhil Lalwani, (head of India prescriptions business) and Mr Kunal Khanna (Head of Chronic & Emerging Business)

• Cipla

  27 Jul 2020 , 11:30AM Gets regulatory approval by the DCGI for the launch of Favipiravir in the country under the brand name Ciplenza. The accelerated approval for manufacturing and marketing of the drug is aimed at meeting the urgent and unmet medical need for COVID-19 treatment options in the country through restricted emergency use. Cipla to commercially launch the drug in first week of August and would be pricing it at Rs 68 per tablet, lower than the one priced by Glenmark. The price erosion is in line with estimates.

• Cipla

  24 Jul 2020 , 9:55AM To launch Favipiravir – an anti viral drug which has shown promising results in clinical trials for treatment of mild to moderate Covid 19 patients. The drug is developed by the Council of Scientific and Industrial Research (CSIR) in a cost-effective process and has transferred the technology to cipla. Given the increasing cases of Covid in India, this is positive as it could result in a surge in demand for the medicine

• Cipla

  24 Jul 2020 , 9:42AM To launch Favipiravir – an anti viral drug which has shown promising results in clinical trials for treatment of mild to moderate Covid 19 patients. The drug is developed by the Council of Scientific and Industrial Research (CSIR) in a cost-effective process and has transferred the technology to cipla. Given the increasing cases of Covid in India, this is positive as it could result in a surge in demand for the medicine

• Cipla

  22 Jul 2020 , 11:39AM Step down and wholly owned subsidiary company Cipla Pharma Lanka (Private) Limited (CPL)is amalgamated with another step-down wholly owned subsidiary, Breathe Free Lanka (Private) Limited (BFL) , with effect from May 01, 2020. CPL was created as a (60:40) JV between Cipla (EU) Ltd, wholly owned subsidiary of Cipla Limited, and the local distributer (JV partner). In November 2019, Cipla EU acquired JV partner’s 40% stake and consequently CPL became a wholly owned subsidiary. The amalgamation of the two entities would help to realise operational efficiencies for Cipla EU.

• Cipla

  20 Jul 2020 , 1:51PM A Civil action filed by Cipla Limited in the US district court of Delaware in January 2019 involving generic Cinacalcet hydrochloride tablet, has been resolved as between Cipla and Amgen Inc. A formal stipulation of dismissal has been filed with the Court and is awaiting signature by the presiding Judge. Basis the resolution Cipla and its affiliates would be able to continue importing, marketing, and selling its generic Cinacalcet hydrochloride tablets 30mg, 60mg and 90mg in the United States

• Cipla

  14 Jul 2020 , 11:33AM Gets final approval for its Abbreviated New Drug Application (ANDA) for Icatibant Injectable 30mg/3mL . Drug is a generic version of Shire’s Firazyr Icatibant injection and is indicated for the treatment of acute attacks of hereditary angioedema in adults. According to IQVIA (IMS Health), Firazyr and its generic equivalents had US sales of approximately $270M for the 12-month period ending May 2020. The approval is positive as it would add to the growth in the US business

• Cipla gets final nod for generic version of Shire's Firazyr

  14 Jul 2020 , 10:03AM Drug maker gets final nod for its ANDA for Icatibant injectable

• Cipla

  14 Jul 2020 , 9:18AM US subsidiary Cipla Technologies LLC had entered in to definitive agreement in April 2019 with Pulmatrix, Inc., USA for the co-development and commercialization of Pulmazole (PUR 1900) for treating patients with Asthma. Now the discussions to renegotiate the terms of the Agreement are in progress. The company has said that due to the delays in patient enrolment for the Phase 2a clinical it has terminated the Phase 2a clinical study and would commence a new Phase 2b study with longer dose duration and efficacy endpoints, upon Agreement negotiations with Pulmatrix being successful. Positive for Cipla, if the negotiations are successful.

• Cipla

  9 Jul 2020 , 11:13AM Has launched its generic version of Remdesivir priced at Rs 4000 per 100 mg vial, which is amongst the lowest priced in the market. Competitors have priced their products at around Rs 5000 per vial. Cipla is looking to supply over 80,000 vials within the first month. This is positive as given the surging Covid cases in India, the demand for Remdesivir is likely to surge substantially.

• Cipla

  9 Jul 2020 , 9:16AM Has launched its generic version of Remdesivir priced at Rs 4000 per 100 mg vial, which is amongst the lowest priced in the market. Competitors have priced their products at around Rs 5000 per vial. Cipla is looking to supply over 80,000 vials within the first month. This is positive as given the surging Covid cases in India, the demand for Remdesivir is likely to surge substantially.

• Cipla

  7 Jul 2020 , 12:36PM Mylan has received DCGI (Drug controller General of India) approval for to manufacture and market remdesivir for restricted emergency use in India for the treatment of COVID-19. The drug will be priced at Rs 4,800 per 100 mg vial and would be available. Domestic player Cipla, would also be launching its version of Remdesivir and has said that it would be pricing the drug lower of Rs 5000.

• Cipla

  29 Jun 2020 , 1:40PM Has announced a partnership in India with Boehringer Ingelheim India Pvt. Ltd to co-market three new oral anti-diabetics drugs Oboravo (Empagliflozin), Oboravo Met (Empagliflozin+Metformin) and Tiptengio (Empagliflozin+Linagliptin). The drugs are indicated for the treatment of Type 2 diabetes. The oral anti-diabetic market in India is valued at Rs 10,735.4 crore and growing at 11.34% (IMS MAT May 2020). India accounts for around 40% of the company’s revenues. New products in the high growth chronic segment and the new partnership (would improve the reach and accessibility of the medicines to the patients) is positive as it would drive the overall revenues.

• Cipla, Boehringer Ingelheim forge in partnership

  29 Jun 2020 , 12:49PM Cipla, Boehringer Ingelheim forge partnership to co-market three oral anti-diabetic drugs

• Cipla

  24 Jun 2020 , 10:49AM As per media reports, Cipla to price its generic version of the Gilead’s Remdesivir for use in COVID-19 patients at less than Rs 5000. Hetero another company to get an approval for the same drug expects to price it in the range of Rs 5000 to Rs 6000 for a similar dose of around 100 milligram. Apparently Cipla’s pricing could be competitive as compared to Hetero and could drive the demand.

• Cipla launches generic remdesivir for COVID-19 treatment

  22 Jun 2020 , 9:46AM Cipla launches Cipremi the only USFDA approved Emergency Use Authorisation (EUA) treatment for patients with severe COVID-19 disease

• Cipla

  22 Jun 2020 , 9:33AM Has announced the launch of CIPREMI (remdesivir lyophilised powder for injection 100 mg) for treatment of patients with severe Covid 19 disease. The USFDA had issued an Emergeny Use Authorization for Remdesivir to Gilead Sciences Inc, for the treatment of hospitalized Covid-19 patients. Cipla has been granted regulatory approval by the Drug Controller General of India (DCGI) for restricted emergency use of the medicine in India as part of the accelerated approval process considering the urgent and unmet medical need. Given the surge in the number of covid 19 cases, the demand is likely to increase, hence the approval is positive

• Cipla

  19 Jun 2020 , 9:57AM Has enetered in to a distribution agreement with Roche Products (India) Pvt. Ltd to market and distribute Roche’s oncology drugs - Trastuzumab (Herclon), Bevacizumab (Avastin) and Rituximab (Ristova) in India. The companies had previously also entered in to an agreement in February 2018 to distribute Tocilizumab (Actemra) and other products. The India formulations constitutes around 40% of the total sales and new arrangement would improve the growth of the India business so is Positive

• Cipla signs a distribution agreement with Roche Products

  19 Jun 2020 , 9:41AM Cipla expands partnership with Roche Pharma India to further improve access to key oncology medicines

• Cipla

  10 Jun 2020 , 12:11PM Cipla has entered in to an agreement to acquire 21.85% stake in GoApptiv Private Limited for a consideration of Rs 9 crore. The acquisition of the stake would be done in two tranches comprising of 27,706 compulsorily convertible preference shares and 6927 equity shares. Go Apptiv offers digital solutions for integrated brand sales management, digital marketing, channel engagement for pharmaceutical companies. This is Positive as through this acquisition, Cipla would be able to widen reach of its key brands and would be able to tap tier 3+ towns in India. Domestic formulations constitutes around 40% of its sales.

• Cipla to acquire stake in GoApptiv

  10 Jun 2020 , 10:26AM Cipla to acquire 21.85% stake in GoApptiv

• Cipla

  26 May 2020 , 9:51AM As per media reports, India’s drug regulator has approved applications of Cipla Ltd and Hetero Labs to manufacture and sell remdesivir, while waiving the requirement for undertaking local clinical trials, in a move to get Indian patients faster access to the Covid-19 drug. However, these companies will be required to conduct Phase-IV trials (post treatment) in India to help identify any unforeseen side effects on patients. For Cipla, the domestic formulations segment constitutes around 38-40% of the total sales and with the approval for Remdesivir, the growth could be higher. Positive

• Cipla gets final nod for generic version of Migranal

  21 May 2020 , 9:49AM Cipla receives final approval for generic version of Migranal with a Competitive Generic Therapy Designation

• Cipla

  21 May 2020 , 9:18AM The company has received a final approval from the USFDA for its ANDA for Dihydroergotamine Mesylate Nasal Spray 4mg/mL, with a Competitive generic therapy. The drug is is indicated for the acute treatment of migraine headaches with or without aura and is a AB rated generic equivalent of Bausch Health LLC’s Migranal. Migranal and its authorized generic equivalent had reported a US sales of approx. USD 102 mn for the 12 month period ending ending March. Positive as this would strengthen the US business of the company.

• Cipla

  20 May 2020 , 10:20AM As per media reports has Filed ANDA for generic version of GSK’s Advair Diskus, with the USFDA. Positive as this would strengthen the respiratory franchise in the US business

• Cipla

  18 May 2020 , 11:24AM Cipla: Q4FY2020 Result Update – On the Growth Path

• Cipla

  18 May 2020 , 10:14AM Has submitted its ANDA to USFDA for Fluticasone propionate and Salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg). The product is a generic version of Advair Duskus, and the generic drug has reported a sale of USD 2.9 bn for 12 month period ending March 2020. The drug is used to treat asthma and in the long term to treat chronic obstructive pulmonary disease (COPD). Positive as this would strengthen the company’s respiratory franchise in the US markets, once approved.

• Cipla files ANDA for generic version of GSK's Advair Diskus

  18 May 2020 , 9:57AM Phase-3 clinical study for generic version completed in first attempt

• Cipla files ANDA for generic version of GSK's Advair Diskus

  18 May 2020 , 9:43AM Phase-3 clinical study for generic version completed in first attempt

• Jubilant Life Sciences, Cipla

  13 May 2020 , 9:12AM Gilead, US based pharma co has entered in to non-exclusive voluntary licensing arrangement with Jubilant Life Sciences, Cipla, Hetero Labs, Mylan and Ferozsons Labs to manufacture and market Remdesivir, a drug which received emergency approval from USFDA for treatment of Covid-19. Under the agreement, the companies would be able to distribute the drug to 127 countries and also receive a technology transfer from Gilead to enabe them to scale up the process quickly. Move opens up substantial growth opportunity for the companies. - Positive

• Cipla

  11 May 2020 , 11:55AM A meeting of the board of directors is scheduled on 15 May 2020 Obtain an enabling approval from the shareholders at the forthcoming AGM regarding the proposal of raising of funds through issue of securities either by way of a public issue or by way of a private placement (including through a qualified institutions placement)

• Cipla

  11 May 2020 , 10:45AM The company’s API manufacturing facility at Bommasandra, Bangalore was inspected by the USFDA from 20 Jan 2020 to 24th Jan 2020. The Inspection is successful closed and the USFDA has issued an Establishment Inspection report (EIR). Positive

• Cipla gets EIR for Bommasandra API plant

  11 May 2020 , 9:56AM Receipt of Establishment Inspection Report

• Cipla

  28 Apr 2020 , 11:14AM As per media news, drug Actemra (by Roche) underwent phase 2 trials under randomised patients and met its primary endpoint and was the 1st customised trial to show improvement. Cipla being one of the manufacturers of the drug, could benefit cipla, if drug clears trials and is approved.

• Cipla

  28 Apr 2020 , 10:28AM As per media news, drug Actemra (by Roche) underwent phase 2 trials under randomised patients and met its primary endpoint and was the 1st customised trial to show improvement. Cipla being one of the manufacturers of the drug, could benefit cipla, if drug clears trials and is approved.

• Cipla

  22 Apr 2020 , 12:44PM As per media news, Actemra (by Roche) is under clinical trials for treating covid-19. The initial results are bringing some benefits and if approved, would be positive for Cipla (one of the manufacturers of the drug) as it would lead to a surge in Actemra’s demand.

• Cipla

  9 Apr 2020 , 9:54AM Has received USFDA approval for its ANDA for Albuterol Sulfate Inhalation Aerosol 90mcg (base)/actuation. The approval comes well ahead of the expected timeline of H2FY21. The drug is the first AB rated generic therapeutic equivalent version of Proventil HFA Inhalation Aerosol. Proventil HFA ingalation Aerosol had US sales of $153 mn while the entire Albuterol Sulfate HFA Inhalation Aerosol market had US sales of ~ $ 2.8 bn for 12 months ending February 2020 as per IQVIA. Considering an earlier than expected approval and the size of the market for the medicine, new approval is a significant one for Cipla as it would substantially boost US revenues. We have a buy recommendation on Cipla.

• Cipla gains as USFDA nod first generic version

  9 Apr 2020 , 9:39AM Cipla receives final approval for generic version of Proventil HFA Inhalation Aerosol

• Cipla

  7 Apr 2020 , 9:18AM Cipla: Stock Update – Gaining Traction

• Cipla

  3 Apr 2020 , 10:05AM Cipla has successfully completed a phase 3 clinical study for fluticasone propionate and salmeterol inhalation powder (100/50 mcg). The drug are generic versions of GSK’s Advair Diskus. The medicine is indicated to treat asthma in patients 4 years and older and in long term to treat chronic obstructive pulmonary disease (COPD), including chronic bronchitis, emphysema, or both, for better breathing. Successful completion is a key milestone achieved as this would strengten the US respiratory franchise of the company. As per IQVIA Advair Diskus had US sales of approximately US$2.9bn for the 12-month period ending February 2020, which points at alikely strong growth potential and is positive

• Cipla

  30 Mar 2020 , 12:20PM As per media news, Cipla gets final approval for generic version of Nexium. Positive

• Cipla

  26 Mar 2020 , 9:43AM Gets a final ANDA approval for Esomeprazole for Oral Suspension 10mg, 20mg and 40mg from the USFDA. Cipla is the first company to file for a 10 mg strength. Esomeprazole is AB-rated generic therapeutic equivalent version of AstraZeneca Pharmaceutical’s - Nexium. It is a proton pump inhibitor indicated for Treatment of gastroesophageal reflux disease (GERD), Risk reduction of NSAID-associated gastric ulcer, H. pylori eradication to reduce the risk of duodenal ulcer recurrence and athological hypersecretory conditions, including Zollinger-Ellison syndrome. According to IQVIA Nexium and its generic equivalents had US sales of approximately $70M for the 12-month period ending November 2019. Positive as this would strengthen Cipla’s US presence.

• Cipla gets final nod for generic version of AstraZeneca Pharmaceutical's Nexium

  26 Mar 2020 , 9:40AM Cipla is the first company to file for the 10mg strength

• Cipla

  17 Feb 2020 , 12:01PM The USFDA has announced switching over of gVoltaren gel from Rx (prescription) to OTC mode. This is expected to have an adverse impact for Cipla as the gel constitutes around USD 40 mn of annualized sales and ~8% of profits of the company. Negative

• Cipla

  17 Feb 2020 , 10:46AM As per media news the company has received approval from the USFDA for Deferasirox. The drug is used to treat iron overload caused by blood transfusions in adults and children at least 2 years. It is also used to treat chronic iron overload syndrome caused by a genetic blood disorder in adults and children who are at least 10 years old. Positive for the company as this would strengthen Cipla’s US presence.

• Cipla

  11 Feb 2020 , 10:54AM Has signed an agreement to market and distribute anti-psychotic drug – Quetiapine in South Africa and neighbouring nations – Positive as this would widen the product offerings

• CIPLA

  10 Feb 2020 , 1:14PM Expands woman’s health portfolio through acquisition of 4 key brands from Wanbury – Positive as this would enable Cipla to strengthen its portfolio in the woman’s health space

• Cipla

  6 Feb 2020 , 12:41PM Cipla: Q3FY2020 result Update - Growth levers intact

• Cipla

  28 Jan 2020 , 11:55AM As per media news Cipla and Asian buyout fund PAG are vying with each other to buy out Wockhardt’s domestic formulation business for around Rs 2100-2800 cr. Both the players have submitted a binding offer for the same. Wockhardts domestic formulation business consists of various therapies including cardiology, dermatology, diabetes, respiratory diseases and ophthalmology. Acquisition, if done would enable Cipla to strengthen its presence in the domestic business. Further Clarity on this is awaited from the management. We have a Buy recommendation on Cipla

• Cipla gets EIR from USFDA for Invagen manufacturing facility

  28 Jan 2020 , 11:14AM Receipt of Establishment Inspection Report

• Cipla

  27 Jan 2020 , 11:08AM The US FDA has inspected the company’s API manufacturing facility in Bangalore between 20 Jan 2020 to 24 Jan 2020. The inspection ended with 4 observations which were procedural in nature and none of which relate to data integrity. The Management is committed to submitting the response in the stipulated time frame. The receipt of 4 observations is potential negative for Cipla.

• Cipla

  23 Jan 2020 , 10:30AM The US-FDA has classified the company’s Goa plant as OAI (Official Action Indicated). The Goa plant was inspected between 16-27 September 2019. This is Negative as it could adversely impact the business.

• Cipla receives USFDA observations for its Goa facility

  23 Jan 2020 , 10:23AM USFDA inspection at Cipla's manufacturing facility in Goa

• Cipla gets EIR from USFDA

  20 Jan 2020 , 10:16AM Closure of USFDA inspection at Patalganga Manufacturing facility

• Cipla

  14 Jan 2020 , 10:35AM As per media sources, the company gets USFDA nod for Pregabalin Capsules (25-300 Mg). Pregabalin is used to treat epilepsy, neuropathic pain, fibromyalgia. Positive read through.

• Cipla

  8 Jan 2020 , 10:43AM As per media news, the company has received an approval from US FDA for Bosentan drug which is used to treat arterial hypertension. Positive

• Cipla

  17 Dec 2019 , 11:03AM The company has acquired brand name and trademark rights for Vysov ® & Vysov M® (Vildagliptin + Metformin) of the anti-diabetic drug, Vildagliptin for the Indian market. Cipla has been co marketing the drug with Novartis and has witnessed a sharp traction in the Indian markets in the past couple of years. Positive read thru

• Cipla acquires trademark rights of Vysov

  17 Dec 2019 , 10:24AM Cipla acquires India trademark rights for anti-diabetic drug from Novartis

• Cipla

  12 Dec 2019 , 11:39AM Associate company Avenue Therapeutics, Inc which is focused on the development of intravenous ("IV") tramadol for the U.S. market, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for IV tramadol for the management of moderate to moderately severe pain in adults in a medically supervised health care setting. Sentimentally positive.

• Cipla arm to acquire remaining stake in Cipla Pharma Lanka

  28 Nov 2019 , 10:41AM Post-acquisition, Cipla Pharma Lanka will become a wholly owned subsidiary

• Cipla

  27 Nov 2019 , 12:36PM As per media reports, the USFDA has inspected Cipla’s Patalganga plant (both the formulation and API plants) between November 4-13, 2019.

• Cipla

  15 Nov 2019 , 11:54AM USFDA conducted a routine cGMP inspection for both Formulations and APIs at manufacturing facility in Patalganga from November 4 to 13, 2019. The inspection ended with 4 observations. None of the observations relate to data integrity issues and the company is committed to addressing the issues and submitting responses in a timely manner. Sentimentally Negative

• Cipla drops after USFDA inspection

  15 Nov 2019 , 10:19AM Cipla slips over 3% to Rs. 435.6, fter USFDA had issues 4 observations

• Cipla

  6 Nov 2019 , 3:18PM Cipla Q2FY2020: Strong performance; PAT beats estimates

• Cipla

  18 Oct 2019 , 11:18AM Acquires anti-infective drug Elores from Venus Remedies limited for less than Rs 100 crore. Elores is a novel combination of Ceftriaxone (a third generation beta-lactam cephalosporin), Sulbactam (a beta-lactamase inhibitor) and Disodium EDTA (an Antibiotic Resistance Breaker). Elores is indicated for the treatment of life threatening infections caused by gram-negative bacteria and would add to Cipla’s branded portfolio of anti-infectives in India. Cipla has stated that the medicine is a part of its strategy to fight anti-microbial resistance. The drug was launched in India in 2013. Positive read thru

• Cipla acquires novel anti-infective drug Elores from Venus Remedies

  18 Oct 2019 , 10:23AM Cipla acquires novel anti-infective Elores to further antimicrobial stewardship in critical care in India

• USFDA Cgmp inspection completed at Cipla's manufacturing facility in Goa

  11 Oct 2019 , 10:17AM Cipla announces that USFDA conduct a cGMP inspection at Goa manufacturing facility

• Cipla falls on receiving 12 observations by USFDA

  30 Sep 2019 , 10:39AM Cipla slips by 5% to Rs. 418, after company receiving 12 observations for its Goa facility

• Cipla launches Daptomycin Injection

  26 Sep 2019 , 10:45AM Cipla: Company launches Daptomycin Injection (to treat certain blood infections or serious skin infections caused by bacteria) in the US. The drug had US sales of ~ Rs 4300 crore for 12 month period ending June 2019. The product will be shipped immediately – Positive.

• Cipla introduces Daptomycin for injection

  26 Sep 2019 , 10:33AM Cipla announces the launch of Daptomycin for injection, 500 mg/vial, single-dose vials

• Cipla announces closure of USFDA inspection at Bengaluru facility

  23 Sep 2019 , 11:15AM Closure of USFDA inspection at API manufacturing facility in Virgonagar

• Cipla, Alvotech enter into partnership

  29 Jul 2019 , 11:18AM Alovtech, Cipla Gulf enter into a partnership for the Commercialization of Key Biosimilar in select emerging markets

• USFDA inspection at the Cipla’s API facility in Bangalore

  22 Jul 2019 , 1:31PM Cipla: USFDA inspection at the Cipla’s API facility in Bangalore ended with 7 observations, none of which were repeat or related to data integrity – Sentimentally negative.

• Alembic Pharmaceuticals gets USFDA approval for New Drug Application

  22 Jul 2019 , 10:42AM Alembic Pharmaceuticals receives USFDA Approval for Pregabalin Capsules

• Cipla unit gets final approval for Pregabalin Capsules

  22 Jul 2019 , 10:35AM Cipla's wholly owned step down subsidiary InvaGen gets final nod for generic version of Pfizer's Lyrica Pregabalin Capsules

• Cipla to set up JV company in China

  16 Jul 2019 , 11:10AM Cipla: The drug maker will set up a joint venture (JV) company in China with Jiangsu Acebright, in which Cipla EU will hold 80% stake. Cipla EU is set to invest up to $24 million in the JV over a period of four years, long term positive for the company

• Cipla enters JV with Jiangsu Acebright

  16 Jul 2019 , 10:46AM Cipla inks pact with Acebright Group to build respiratory biz in China

• Cipla signs agreement to buy stake in AMPSolar

  24 May 2019 , 10:32AM The Company has signed an agreement to acquire 26 per cent stake on a fully diluted basis in AMPSolar Power Systems Pvt for a cash consideration of up to Rs 12.90 crore - neutral for the stock as acquisition is in line with Cipla's commitment to enhance the proportion of renewable (solar) based power consumption and to comply with regulatory requirement for captive power consumption under electricity laws

• Cipla announces phased launch of generic version of Sensipar

  3 May 2019 , 10:25AM Cipla: US District Court of Delaware denied Amgen, Inc.'s request for preliminary injunction to stop Cipla's continued sale of its generic Cinacalcet hydrochloride (gSensipar) tablets in the US – Positive for Cipla

• Cipla's arm recalls over 7.8 lakh vials of Testosterone Cypionate injection

  30 Apr 2019 , 10:15AM Cipla: Co’s subsidiary InvaGen Pharmaceuticals, recalls over 7.8 lakh vials of Testosterone Cypionate injection, used to treat low testosterone levels in men; The vials were manufactured by Cipla at its Verna facility in Goa – Negative read thru.

• Cipla receives final approval for generic version of Gilead Sciences

  30 Apr 2019 , 9:30AM Cipla gets USFDA nod for generic of Letairis, used to treat pulmonary hypertension

• Cipla launches Niveoli, India's First Extrafine ICS-LABA combination HFA inhaler

  12 Apr 2019 , 10:36AM First extra-fine ICS-LABA combination to be launched in India

• Cipla surges on EIR from USFDA

  5 Apr 2019 , 10:15AM Cipla rises over 3% to Rs. 535.60, after receiving the Establishment Inspection Report from the USFDA

• Cipla gets Form 483 for its Kurkumbh facility with 18 observations

  1 Apr 2019 , 9:11AM Cipla: Company gets Form 483 for its Kurkumbh facility with 18 observations (8 for GMP inspection & 10 Product Approval Inspection –PAI) , although none relate to data integrity – Sentimentally negative.

• Cipla introduces cinacalcet hydrochloride tablets

  6 Mar 2019 , 10:18AM Cipla's cinacalcet hydrochloride tablets is AB-rated generic therapeutic equivalent version

• Cipla arm to acquire stake in Wellthy Therapeutic

  19 Feb 2019 , 10:46AM Cipla arm will acquire 11.7% stake in Wellthy Therapeutics (Digital therapeutics) for Rs 10.5 crore of cash consideration. The deal is expected to be completed before March 10,2019. The company also stated that its South African arm has won a share of South African government’s tender for four HIV drugs whose contract will start from July 2019, for a period of three years – Positive read thru.

• Cipla and Lupin in focus

  13 Feb 2019 , 11:51AM As per media reports, Mylan launches gAdvair in US at 70% discount – Negative for Cipla & Lupin as both these companies have the mentioned drug still under developmental pipeline / await USFDA approval.

• Cipla gets USFDA no for Tadalafil Tablets

  7 Feb 2019 , 10:54AM Cipla receives USFDA approval for Tadalafil Tablets (gAdcirca), used to treat pulmonary arterial hypertension and improve exercise capacity in men and women; Mentioned drug has US sales of ~Rs 3500 crore and the product is available for shipment immediately- Positive for Cipla; We have a Buy recommendation stock with PT of Rs 635.

• Cipla gets USFDA nod for gDepo-Provera

  28 Jan 2019 , 11:04AM Cipla received USFDA approval for gDepo-Provera (Medroxyprogesterone Injectable), indicated only for the prevention of pregnancy; product has market sales of ~ Rs 1125 crore – Positive

• Cipla's subsidiary announces acquisition agreemtnt with Avenue

  13 Nov 2018 , 10:32AM Cipla enters into definitive agreements with two closing stages for a proposed acquisition of Avenue Therapeutics

• Cipla gets final USFDA nod for Valganciclovir tablets

  12 Nov 2018 , 11:45AM Cipla receives final approval for generic version of Roche's Valcyte (Valganciclovir Tablets 450mg)

• Cipla gets USFDA nod for Albenza generic version

  24 Sep 2018 , 12:22PM Drug, manufactured by US' Impax Labs, clocked sales of about $99 mn in the year ended July 2018

• Cipla gets nod HIV treatment

  12 Sep 2018 , 10:19AM Cipla received approval for HIV treatment combination medicine ‘TLD’ (Tenofovir, Lamivudine and Dolutegravir combination) from the South African Health Products Regulatory Authority. This drug will be manufactured at the companies’ Durban and Uganda plants – Positive; We have a buy recommendation on the stock with PT of Rs 720.

• Cipla gets USFDA nod for anti-retroviral drug

  11 Sep 2018 , 10:30AM Cipla gets USFDA approval for anti-retroviral drug Zidovudine tablets – Positive read thru.

• Cipla gets final approval for generic Reyataz

  13 Aug 2018 , 10:37AM Cipla gets final approval for generic Reyataz; partners with MSN Laboratories for marketing and distribution of generic Xeloda – Positive for Cipla; We have a buy recommendation on the stock with PT of Rs 720.

• Cipla: Numbers below expectation

  9 Aug 2018 , 11:53AM Cipla: Numbers below expectation; Stable outlook

• Cipla gets USFDA nod for Diclofenac Sodium Topical Gel

  7 Aug 2018 , 11:30AM Cipla gets USFDA approval for Diclofenac Sodium Topical Gel; a non-steroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints – Positive for Cipla; Drug has market size of ~Rs 2400 crore.

• Cipla receives final nod for Generic Voltaren

  7 Aug 2018 , 11:06AM Cipla receives final approval on August 3, 2018, for its Abbreviated New Drug Application (ANDA) for Diclofenac Sodium Topical Gel

• Cipla gets USFDA nod for Caspofungin Acetate injection

  17 Jul 2018 , 11:45AM Cipla gets USFDA approval for Caspofungin Acetate injection

• Pharma Q1FY19 Preview

  5 Jul 2018 , 11:35AM Preferred Picks in the sector are Biocon, Cadila, Cipla and Sun Pharma

• Cipla gets final nod for Generic Isuprel®

  14 Jun 2018 , 10:40AM Cipla receives approval from the US drug regulator for Isoproterenol Hydrochloride injection

• Cipla receives USFDA approval for generic Tsuprel injection

  14 Jun 2018 , 10:36AM Positive for Cipla

• Cipla reports quarter numbers below expectations

  23 May 2018 , 12:08PM We maintain our buy rating with marginal downward revision of price target to Rs 665 valuing it 18x FY2020E earnings.

• Cipla enters into agreement with MannKind Corp

  10 May 2018 , 11:10AM Cipla enters into an exclusive marketing and distribution agreement with US-based MannKind Corporation for Afrezza® in India

• Cipla partners with Mankind for exclusive marketing

  10 May 2018 , 10:56AM Positive read through for Cipla.

• Cipla Indore plant gets Form 483

  18 Apr 2018 , 11:18AM We continue to maintain our earnings estimates for FY2018E, FY2019E and FY2020E and also our Buy rating with unchanged price target (PT) of Rs. 685

• USFDA inspection of Cipla's Indore unit completes successfully

  16 Apr 2018 , 10:01AM Positive read through for Cipla

• Cipla's Goa plant gets Form 483 with 8 observations

  21 Mar 2018 , 10:32AM No critical observations for Cipla.

• Cipla falls on USFDA observations for Goa unit

  20 Mar 2018 , 11:33AM Cipla share price declines over 6% at Rs523, after the US health regulator issued observations to company's Goa unit

• Cipla enters into agreement with Roche Pharma India

  28 Feb 2018 , 2:42PM Cipla enters into agreement with Roche Pharma India to create greater access to key medicines

• Cipla enters into agreement with Roche Pharma

  28 Feb 2018 , 10:04AM Positive read through for Cipla as it enters into agreement with Roche Pharma India to create greater access to key medicines.

• CIPLA gets USFDA nod for HIV infection medicine

  29 Jan 2018 , 10:12AM Positive for Cipla, as the medicine is to be commercialized immediately.

• Cipla gets USFDA approval for Darunavir Hydrate

  18 Dec 2017 , 9:29AM Positive read through for Cipla as it gets USFDA approval for Darunavir Hydrate.

• Cipla strenghtens after USFDA nod

  17 Nov 2017 , 11:28AM Cipla rises over 3% to Rs612.55, after receiving final approval from the USFDA for its abbreviated new drug application for Budesonide Inhalation Suspension

• Cipla gets USFDA approval for Budesonide Inhalation Suspension

  17 Nov 2017 , 9:52AM Positive news for Cipla as it gets USFDA approval for Budesonide Inhalation Suspension (generic version of AstraZeneca’s Pulmicort Respules) indicated for the maintenance treatment of asthma for children of 12 months to 8 years of age.

• Cipla posts strong Q2 operational performance

  8 Nov 2017 , 12:03PM The management maintains a guidance of double-digit growth in the US and India businesses despite a challenging environment on the back of new product launches planned for FY18 and FY19 (one niche product every quarter).

• Cipla Q2 results above our expectation

  7 Nov 2017 , 3:07PM Cipla sales for the quarter grew by 8.8% to Rs 4082.4 crore.

• Cipla gets USFDA approval for zoledronic acid

  31 Oct 2017 , 8:48AM Positive news for Cipla as it gets USFDA approval for zoledronic acid, used to treat certain bone disease.

• Cipla: Stable outlook: profit better than expectation

  14 Aug 2017 , 11:27AM Maintain hold with unchanged TP of Rs.585

• Cipla Q1FY2018 adjusted profit better than expectation

  11 Aug 2017 , 3:10PM Operating profit grew by 5.7% to Rs 646 crore, translating into an increase of 197 BPS in OPM to 18.3%.

• Cipla gets USFDA approval for HIV drug Nevirapine

  8 Aug 2017 , 8:56AM Cipla gets USFDA approval for HIV drug Nevirapine – Positive for cipla.

• Cipla: Weak performance but outlook stable

  26 May 2017 , 11:05AM The Cipla management has guided for a double digit growth in the US and India businesses despite a challenging environment, spurred by new product launches planned for FY2018 and FY2019.

Load More

Show Less

Key fundamentals

Evaluate the intrinsic value of Cipla Ltd stock 

Standalone

Consolidated

Name	March-24	March-23	March-22	March-21	March-20
Assets	27973.92	24638.09	22513.55	19927.56	17409.02
Liabilities	27973.92	24638.09	22513.55	19927.56	17409.02
Equity	161.47	161.43	161.36	161.29	161.25
Gross Profit	4484.15	3792.58	3366.47	3721.56	2707.29
Net Profit	4077.25	2513.47	2957.93	2468.28	2318.17
Cash From Operating Activities	3726.77	3035.05	2773.43	3460.31	2018.14
NPM(%)	24.59	15.91	22.59	17.75	18.31
Revenue	16574.34	15790.6	13091.79	13900.58	12659.15
Expenses	12090.19	11998.02	9725.32	10179.02	9951.86
ROE(%)	14.37	8.86	10.42	8.7	8.17

Name	March-24	March-23	March-22	March-21	March-20
Assets	27049.35	24233.9	21941.52	20123.07	18873.71
Liabilities	27049.35	24233.9	21941.52	20123.07	18873.71
Equity	161.47	161.43	161.36	161.29	161.25
Gross Profit	6291.05	5026.97	4552.78	4252.43	3205.99
Net Profit	4121.55	2801.91	2516.75	2404.87	1546.52
Cash From Operating Activities	4133.91	3237.65	3325.9	3755.2	3068.45
NPM(%)	15.99	12.31	11.56	12.55	9.02
Revenue	25774.09	22753.12	21763.34	19159.59	17131.99
Expenses	19483.04	17726.15	17210.56	14907.16	13926
ROE(%)	14.53	9.87	8.87	8.47	5.45

Shareholding Pattern

Promotors

29.13%

Institutions

54.32%

Public

14.32%

Others

2.23%

Corporate Action

Dividend History

Equity History

Bonus/Split History

Institutional Holdings

XD-Date	Dividend-Amount	Dividend-%	Dividend Yield(%GE)	Price on that day
02 Aug 2024	13	650	0.84	1339.55
21 Jul 2023	8.5	425	0.84	937.45
08 Aug 2022	5	250	0.84	974.05
09 Aug 2021	5	250	0.84	904.05
19 Mar 2020	3	150	0.84	435.75
31 Jul 2019	3	150	0.84	553
13 Aug 2018	3	150	0.84	524
26 Jul 2017	2	100	0.84	504
12 Sep 2016	2	100	0.84	494.05
11 Aug 2015	2	100	0.84	650.45
06 Aug 2014	2	100	0.84	372.45
06 Aug 2013	2	100	0.84	401.7
01 Aug 2012	2	100	0.84	308
09 Aug 2011	2	100	0.84	332.2
03 Sep 2010	0.8	40	0.84	308.8
23 Jul 2010	2	100	0.84	338
10 Aug 2009	2	100	0.84	272.15
12 Aug 2008	2	100	0.84	215.1
08 Aug 2007	2	100	0.84	200.95
18 Aug 2006	2	100	0.84	219.8
19 Aug 2005	3.5	175	0.84	340.85
19 Aug 2004	3	150	0.84	240.15
22 Aug 2003	10	100	0.84	825.6
14 Aug 2002	0	70	0.84	933
	0	50	0.84	1024.8
06 Aug 2001	0	45	0.84	1058.35
	0	55	0.84	1027.6
	0	75	0.84	1979.7
	0	55	0.84	827.15

From Year	To Year	Class of Share	Authorized Capital(Crores)	Issued Capital(Crores)	Paid Up Shares(NOS)	Paid Up Face Value	Paid Up Capital(Crores)
2023	2024	Equity Share	175.00	161.47	807367062.00	2	161.47
2022	2023	Equity Share	175.00	161.43	807150593.00	2	161.43
2021	2022	Equity Share	175.00	161.36	806814036.00	2	161.36
2020	2021	Equity Share	175.00	161.29	806463279.00	2	161.29
2019	2020	Equity Share	175.00	161.25	806235329.00	2	161.25
2018	2019	Equity Share	175.00	161.14	805701266.00	2	161.14
2017	2018	Equity Share	175.00	161.02	805119164.00	2	161.02
2016	2017	Equity Share	175.00	161.10	804510074.00	2	160.90
2015	2016	Equity Share	175.00	160.88	803384282.00	2	160.68
2014	2015	Equity Share	175.00	160.79	802960440.00	2	160.59
2013	2014	Equity Share	175.00	160.78	802921357.00	2	160.58
2012	2013	Equity Share	175.00	160.78	802921357.00	2	160.58
2011	2012	Equity Share	175.00	160.78	802921357.00	2	160.58
2010	2011	Equity Share	175.00	160.78	802921357.00	2	160.58
2009	2010	Equity Share	175.00	160.78	802921357.00	2	160.58
2008	2009	Equity Share	175.00	155.66	777291357.00	2	155.46
2007	2008	Equity Share	175.00	155.66	777291357.00	2	155.46
2006	2007	Equity Share	175.00	155.66	777291357.00	2	155.46
2005	2006	Equity Share	175.00	60.17	299870233.00	2	59.97
2004	2005	Equity Share	65.00	60.17	299870233.00	2	59.97
2003	2004	Equity Share	65.00	60.17	59972349.00	10	59.97
2002	2003	Equity Share	65.00	60.17	59972349.00	10	59.97
2001	2002	Equity Share	65.00	60.17	59972349.00	10	59.97
2000	2001	Equity Share	65.00	60.17	59972349.00	10	59.97
1995	1999	Equity Share	25.00	20.19	19990783.00	10	19.99
1994	1995	Equity Share	25.00	18.70	18647400.00	10	18.65
1993	1994	Equity Share	25.00	3.16	3107900.00	10	3.11
1992	1993	Equity Share	10.00	3.16	310790.00	100	3.11
1991	1992	Equity Share	1.94	1.61	155395.00	100	1.55
1987	1991	Equity Share	1.94	1.55	150184.00	100	1.50
1985	1987	Equity Share	1.94	0.80	75092.00	100	0.75
1979	1985	Equity Share	0.54	0.43	37546.00	100	0.38
1962	1979	Equity Share	0.24	0.24	18773.00	100	0.19
1947	1962	Equity Share	0.24	0.24	17464.00	100	0.17
1945	1947	Equity Share	0.24	0.15	15000.00	100	0.15
1944	1945	Equity Share	0.06	0.06	6000.00	100	0.06
1943	1944	Equity Share	0.06	0.03	3000.00	100	0.03
1935	1943	Equity Share	0.06	0.03	1108.00	50	0.01

Announcement Date	Price	Bonus Ratio	Record Date
23 Mar 2004	1156.35	Stock Split from Rs. 10/- to Rs. 2/-	19 May 2004
07 Oct 1999	4293.6		05 Nov 1999

Fund	Market Value(CR)	% Hold
NipponInd NiftyPharm (G)	92.49	10.80
ICICI PruNifPharma (G)	8.65	10.73
ICICI PruNifPharma (I)	8.65	10.73
ICICI PruNifPharmaDP (G)	8.65	10.73
ICICI PruNifPharmaDP (I)	8.65	10.73
AxisNifHealthcareETF (G)	1.79	9.47
DSP NiftyHealthcaETF (G)	0.87	8.95
ICICI NiftyHealthETF (G)	11.69	8.95
AdityaBSL NifHealthC (G)	3.16	8.94
ICICI Pru PHD (G)	434.83	8.85
ICICI Pru PHD (I)	434.83	8.85
ICICI Pru PHD DP (G)	434.83	8.85
ICICI Pru PHD DP (I)	434.83	8.85
DSP Healthcare (G)	258.22	8.55
DSP Healthcare (I)	258.22	8.55
DSP Healthcare DP (G)	258.22	8.55
DSP Healthcare DP (I)	258.22	8.55
AdityaBSL Phar&Hea (G)	68.81	8.44
AdityaBSL Phar&Hea (I)	68.81	8.44
AdityaBSL Phar&HeaDP (G)	68.81	8.44
AdityaBSL Phar&HeaDP (I)	68.81	8.44
Bajaj Healthcare (G)	24.05	7.82
Bajaj Healthcare (I)	24.05	7.82
Bajaj Healthcare DP (G)	24.05	7.82
Bajaj Healthcare DP (I)	24.05	7.82
WhiteOakPar&Health (G)	22.44	7.39
WhiteOakPar&HealthDP (G)	22.44	7.39
HDFC Pharma&Health (G)	117.44	7.19
HDFC Pharma&Health (I)	117.44	7.19
HDFC Pharma&HealthDP (G)	117.44	7.19
HDFC Pharma&HealthDP (I)	117.44	7.19
MiraeAsset Health (G)	184.32	6.91
MiraeAsset Health (I)	184.32	6.91
MiraeAsset Health DP (G)	184.32	6.91
MiraeAsset Health DP (I)	184.32	6.91
Bandhan BSEHealthC (G)	1.14	6.57
Bandhan BSEHealthCDP (G)	1.14	6.57
Motilal BSEHealthETF (G)	1.82	6.57
Kotak Healthcare (G)	24.81	6.03
Kotak Healthcare (I)	24.81	6.03
Kotak Healthcare DP (G)	24.81	6.03
Kotak Healthcare DP (I)	24.81	6.03
Tata IndiaPharma (G)	72.49	5.98
Tata IndiaPharma (I)	72.49	5.98
Tata IndiaPharma (I-Rein)	72.49	5.98
Tata IndiaPharma DP (G)	72.49	5.98
Tata IndiaPharma DP (I-Payo)	72.49	5.98
Tata IndiaPharma DP (I-Rein)	72.49	5.98
UTI Healthcare (G)	60.57	5.81
UTI Healthcare (I)	60.57	5.81
UTI Healthcare (I-Rein)	60.57	5.81
UTI Healthcare DP (G)	60.57	5.81
UTI Healthcare DP (I)	60.57	5.81
Edel MSCI DomWH45 (G)	9.17	5.74
Edel MSCI DomWH45 (I)	9.17	5.74
Edel MSCI DomWH45 DP (G)	9.17	5.74
Edel MSCI DomWH45 DP (I)	9.17	5.74
Nippon Pharma (B)	461.50	5.71
Nippon Pharma (G)	461.50	5.71
Nippon Pharma (I)	461.50	5.71
Nippon Pharma DP (B)	461.50	5.71
Nippon Pharma DP (G)	461.50	5.71
Nippon Pharma DP (I)	461.50	5.71
HDFC NifGrSect15ETF (G)	0.72	5.11
SBI HealthcareOpp (G)	177.53	5.04
SBI HealthcareOpp (I)	177.53	5.04
SBI HealthcareOpp (IDCWR)	177.53	5.04
SBI HealthcareOppDP (G)	177.53	5.04
SBI HealthcareOppDP (I)	177.53	5.04
SBI HealthcareOppDP (IDCWR)	177.53	5.04
HDFC ELSS TaxSaver (G)	778.79	5.01
HDFC ELSS TaxSaver (I)	778.79	5.01
HDFC ELSS TaxSaver (IDCWR)	778.79	5.01
HDFC ELSS TaxSaverDP (G)	778.79	5.01
HDFC ELSS TaxSaverDP (I)	778.79	5.01
HDFC ELSS TaxSaverDP (IDCWR)	778.79	5.01
Franklin FocuseEq DP (G)	504.77	4.43
Franklin FocuseEq DP (I)	504.77	4.43
Franklin FocuseEq DP (IDCWR)	504.77	4.43
Franklin FocusEq (G)	504.77	4.43
Franklin FocusEq (I)	504.77	4.43
Franklin FocusEq (I-Rein)	504.77	4.43
LIC Healthcare (G)	3.52	4.26
LIC Healthcare (I)	3.52	4.26
LIC Healthcare DP (G)	3.52	4.26
LIC Healthcare DP (I)	3.52	4.26
DSP Large Cap (G)	209.84	4.14
DSP Large Cap (I)	209.84	4.14
DSP Large Cap (IDCWR)	209.84	4.14
DSP Large Cap DP (G)	209.84	4.14
DSP Large Cap DP (I)	209.84	4.14
DSP Large Cap DP (IDCWR)	209.84	4.14
NipponETFNif50Sharia (G)	1.33	4.11
InvescoManufacturiDP (G)	30.22	4.05
InvescoManufacturiDP (I)	30.22	4.05
InvescoManufacturing (G)	30.22	4.05
InvescoManufacturing (I)	30.22	4.05
HDFC Flexi Cap DP (G)	2769.02	3.98
HDFC Flexi Cap DP (I)	2769.02	3.98
HDFC Flexi Cap DP (IDCWR)	2769.02	3.98
HDFC Flexi Cap RP (G)	2769.02	3.98
HDFC Flexi Cap RP (I)	2769.02	3.98
HDFC Flexi Cap RP (IDCWR)	2769.02	3.98
HDFC Focused 30 (G)	648.99	3.77
HDFC Focused 30 (I)	648.99	3.77
HDFC Focused 30 (IDCWR)	648.99	3.77
HDFC Focused 30 DP (G)	648.99	3.77
HDFC Focused 30 DP (I)	648.99	3.77
HDFC Focused 30 DP (IDCWR)	648.99	3.77
HDFC Manufacturing (G)	411.03	3.54
HDFC Manufacturing (I)	411.03	3.54
HDFC ManufacturingDP (G)	411.03	3.54
HDFC ManufacturingDP (I)	411.03	3.54
DSP Multicap (G)	68.68	3.51
DSP Multicap (I)	68.68	3.51
DSP Multicap DP (G)	68.68	3.51
DSP Multicap DP (I)	68.68	3.51
DSP BSESenNxt30IndDP (G)	0.28	3.49
DSP BSESenNxt30IndDP (I)	0.28	3.49
DSP BSESenNxt30Indx (G)	0.28	3.49
DSP BSESenNxt30Indx (I)	0.28	3.49
Templeton I Value (G)	72.11	3.47
Templeton I Value (I)	72.11	3.47
Templeton I Value (I-Rein)	72.11	3.47
Templeton I Value DP (G)	72.11	3.47
Templeton I Value DP (I)	72.11	3.47
DSP BSESenNxt30ETF (G)	0.59	3.46
Mirae Nif100LowVol30 (G)	1.25	3.06
ICICI Nif100L30ETF (G)	105.84	3.06
BandhanNif100Low (G)	41.78	3.06
BandhanNif100Low (I)	41.78	3.06
BandhanNif100LowDP (G)	41.78	3.06
BandhanNif100LowDP (I)	41.78	3.06
HDFC Nif100LowV30ETF (G)	0.45	3.06
HDFCNif100LowVol30 (G)	10.24	3.06
HDFCNif100LowVol30DP (G)	10.24	3.06
KotakNif100LowV30ETF (G)	4.99	3.06
KotakNif100LV30IndDP (G)	3.12	3.05
KotakNif100LV30IndDP (I)	3.12	3.05
KotakNif100LV30Index (G)	3.12	3.05
KotakNif100LV30Index (I)	3.12	3.05
Bajaj Large&MidCap (G)	53.03	3.01
Bajaj Large&MidCap (I)	53.03	3.01
Bajaj Large&MidCapDP (G)	53.03	3.01
Bajaj Large&MidCapDP (I)	53.03	3.01
Quantum ELSSTaxSav (G)	6.29	3.01
Quantum ELSSTaxSav (I)	6.29	3.01
Quantum ELSSTaxSavDP (G)	6.29	3.01
Quantum ELSSTaxSavDP (I)	6.29	3.01
DSP AggressHybrid (G)	311.01	2.98
DSP AggressHybrid (I)	311.01	2.98
DSP AggressHybrid (IDCWR)	311.01	2.98
DSP AggressHybrid DP (G)	311.01	2.98
DSP AggressHybrid DP (I)	311.01	2.98
DSP AggressHybrid DP (IDCWR)	311.01	2.98
Quantum Value DP (G)	33.15	2.95
Quantum Value DP (I)	33.15	2.95
Quantum Value RP (G)	33.15	2.95
Quantum Value RP (I)	33.15	2.95
Quantum Value RP (I-Rein)	33.15	2.95
Taurus Largecap (G)	1.37	2.91
Taurus Largecap (I)	1.37	2.91
Taurus Largecap (I-Rein)	1.37	2.91
Taurus Largecap DP (G)	1.37	2.91
Taurus Largecap DP (I)	1.37	2.91
SBI EqMin Variance (G)	6.21	2.90
SBI EqMin Variance (I)	6.21	2.90
SBI EqMin VarianceDP (G)	6.21	2.90
SBI EqMin VarianceDP (I)	6.21	2.90
PGIM Healthcare (G)	2.84	2.73
PGIM Healthcare (I)	2.84	2.73
PGIM Healthcare DP (G)	2.84	2.73
PGIM Healthcare DP (I)	2.84	2.73
Taurus ELSS TaxSav (G)	1.99	2.63
Taurus ELSS TaxSav (I)	1.99	2.63
Taurus ELSS TaxSavDP (G)	1.99	2.63
Taurus ELSS TaxSavDP (I)	1.99	2.63
BajajFins BalAdva (G)	30.39	2.47
BajajFins BalAdva (I)	30.39	2.47
BajajFins BalAdva DP (G)	30.39	2.47
BajajFins BalAdva DP (I)	30.39	2.47
Navi AggresHybrid (G)	2.86	2.47
Navi AggresHybrid (I)	2.86	2.47
Navi AggresHybrid (I-Annu)	2.86	2.47
Navi AggresHybrid (I-Half)	2.86	2.47
Navi AggresHybrid (I-Mont)	2.86	2.47
Navi AggresHybrid (I-Quar)	2.86	2.47
Navi AggresHybrid DP (G)	2.86	2.47
Navi AggresHybrid DP (I)	2.86	2.47
Navi AggresHybrid DP (I-Annu)	2.86	2.47
Navi AggresHybrid DP (I-Half)	2.86	2.47
Navi AggresHybrid DP (I-Mont)	2.86	2.47
Navi AggresHybrid DP (I-Quar)	2.86	2.47
DSP Flexi Cap (G)	273.10	2.45
DSP Flexi Cap (I)	273.10	2.45
DSP Flexi Cap (IDCWR)	273.10	2.45
DSP Flexi Cap DP (G)	273.10	2.45
DSP Flexi Cap DP (I)	273.10	2.45
DSP Flexi Cap DP (IDCWR)	273.10	2.45
Axis India Manufac (G)	130.47	2.36
Axis India Manufac (I)	130.47	2.36
Axis India ManufacDP (G)	130.47	2.36
Axis India ManufacDP (I)	130.47	2.36
Mirae NifIndManufETF (G)	4.76	2.35
UTI Dividend Yield (G)	90.14	2.34
UTI Dividend Yield (I)	90.14	2.34
UTI Dividend Yield (I-Rein)	90.14	2.34
UTI DividendYield DP (G)	90.14	2.34
UTI DividendYield DP (I)	90.14	2.34
UTI NifManufacturi (G)	0.45	2.34
UTI NifManufacturiDP (G)	0.45	2.34
DSP ELSS Tax Saver (G)	362.71	2.24
DSP ELSS Tax Saver (I)	362.71	2.24
DSP ELSS Tax Saver (IDCWR)	362.71	2.24
DSP ELSS Tax SaverDP (G)	362.71	2.24
DSP ELSS Tax SaverDP (I)	362.71	2.24
DSP ELSS Tax SaverDP (IDCWR)	362.71	2.24
DSP Value (G)	20.51	2.21
DSP Value (I)	20.51	2.21
DSP Value DP (G)	20.51	2.21
DSP Value DP (I)	20.51	2.21
HDFC NIFTY50Val20ETF (G)	0.83	2.19
Kotak NiftyNV20VaETF (I)	2.44	2.19
Nippon Nif50Val20 (G)	20.64	2.19
Nippon Nif50Val20 (I)	20.64	2.19
Nippon Nif50Val20 DP (G)	20.64	2.19
Nippon Nif50Val20 DP (I)	20.64	2.19
NipponETFNif50Valu20 (G)	4.82	2.19
ICICI Nif50V20ETF (G)	3.97	2.19
ICICINif50V20Index (G)	2.21	2.18
ICICINif50V20Index (I)	2.21	2.18
ICICINif50V20IndexDP (G)	2.21	2.18
ICICINif50V20IndexDP (I)	2.21	2.18
Navi NifManufIndex (G)	1.16	2.18
Navi NifManufIndexDP (G)	1.16	2.18
TataNif500MulManuf (G)	2.41	2.09
TataNif500MulManuf (I)	2.41	2.09
TataNif500MulManuf (I-Rein)	2.41	2.09
TataNif500MulManufDP (G)	2.41	2.09
TataNif500MulManufDP (I)	2.41	2.09
TataNif500MulManufDP (I-Rein)	2.41	2.09
SBI Long Term Eq (G)	562.69	2.06
SBI Long Term Eq (I)	562.69	2.06
SBI Long Term Eq (IDCWR)	562.69	2.06
SBI Long Term Eq-DP (G)	562.69	2.06
SBI Long Term Eq-DP (I)	562.69	2.06
SBI Long Term Eq-DP (IDCWR)	562.69	2.06
Kotak ManufinIndia (G)	46.15	2.04
Kotak ManufinIndia (I)	46.15	2.04
Kotak ManufinIndiaDP (G)	46.15	2.04
Kotak ManufinIndiaDP (I)	46.15	2.04
Taurus Ethical (B)	5.56	2.03
Taurus Ethical (G)	5.56	2.03
Taurus Ethical (I)	5.56	2.03
Taurus Ethical DP (B)	5.56	2.03
Taurus Ethical DP (G)	5.56	2.03
Taurus Ethical DP (I)	5.56	2.03
BaroBNP Manufactur (G)	24.81	2.02
BaroBNP Manufactur (I)	24.81	2.02
BaroBNP ManufacturDP (G)	24.81	2.02
BaroBNP ManufacturDP (I)	24.81	2.02
ICICIEqMinimumVari (G)	70.10	2.02
ICICIEqMinimumVari (I)	70.10	2.02
ICICIEqMinimumVariDP (G)	70.10	2.02
ICICIEqMinimumVariDP (I)	70.10	2.02
DSP Equity Savings (G)	50.62	2.01
DSP Equity Savings (I)	50.62	2.01
DSP Equity Savings (I-Mont)	50.62	2.01
DSP Equity Savings (I-Quar)	50.62	2.01
DSP Equity Savings (IDCWR)	50.62	2.01
DSP Equity Savings (MIDCWR)	50.62	2.01
DSP Equity Savings (QIDCWR)	50.62	2.01
DSP Equity SavingsDP (G)	50.62	2.01
DSP Equity SavingsDP (I)	50.62	2.01
DSP Equity SavingsDP (I-Mont)	50.62	2.01
DSP Equity SavingsDP (I-Quar)	50.62	2.01
DSP Equity SavingsDP (IDCWR)	50.62	2.01
DSP Equity SavingsDP (MIDCWR)	50.62	2.01
DSP Equity SavingsDP (QIDCWR)	50.62	2.01
DSP Lar&MidCap (G)	276.78	2.01
DSP Lar&MidCap (I)	276.78	2.01
DSP Lar&MidCap (IDCWR)	276.78	2.01
DSP Lar&MidCap DP (G)	276.78	2.01
DSP Lar&MidCap DP (I)	276.78	2.01
DSP Lar&MidCap DP (IDCWR)	276.78	2.01
AdityaBSL Reti 30s (G)	7.43	2.00
AdityaBSL Reti 30s (I)	7.43	2.00
AdityaBSL Reti 30sDP (G)	7.43	2.00
AdityaBSL Reti 30sDP (I)	7.43	2.00
SBI Nif50EquWeiETFDP (G)	0.46	1.98
SBI Nif50EquWeight (G)	20.68	1.98
SBI Nif50EquWeight (I)	20.68	1.98
SBI Nif50EquWeightDP (G)	20.68	1.98
SBI Nif50EquWeightDP (I)	20.68	1.98
Tata Ethical DP (G)	64.35	1.98
Tata Ethical DP (I)	64.35	1.98
Tata Ethical DP (IDCWR)	64.35	1.98
Tata Ethical RP (G)	64.35	1.98
Tata Ethical RP (I)	64.35	1.98
Tata Ethical RP (IDCWR)	64.35	1.98
UTI Value (G)	187.49	1.98
UTI Value (I)	187.49	1.98
UTI Value (I-Rein)	187.49	1.98
UTI Value DP (G)	187.49	1.98
UTI Value DP (I)	187.49	1.98
Franklin Opportun DP (G)	118.75	1.96
Franklin Opportun DP (I)	118.75	1.96
Franklin Opportuniti (G)	118.75	1.96
Franklin Opportuniti (I)	118.75	1.96
Franklin Opportuniti (I-Rein)	118.75	1.96
Tata BusinessCycle (G)	53.69	1.96
Tata BusinessCycle (I)	53.69	1.96
Tata BusinessCycle (I-Rein)	53.69	1.96
Tata BusinessCycleDP (G)	53.69	1.96
Tata BusinessCycleDP (I)	53.69	1.96
Tata BusinessCycleDP (I-Rein)	53.69	1.96
Axis ESG IntegStra (G)	24.41	1.95
Axis ESG IntegStra (I)	24.41	1.95
Axis ESG IntegStraDP (G)	24.41	1.95
Axis ESG IntegStraDP (I)	24.41	1.95
DSP Quant (G)	18.79	1.93
DSP Quant (I)	18.79	1.93
DSP Quant DP (G)	18.79	1.93
DSP Quant DP (I)	18.79	1.93
UTI Nifty50EquWeig (G)	1.81	1.93
UTI Nifty50EquWeigDP (G)	1.81	1.93
DSP Nif50 EqWeigt (G)	38.10	1.92
DSP Nif50 EqWeigt (I)	38.10	1.92
DSP Nif50 EqWeigtDP (G)	38.10	1.92
DSP Nif50 EqWeigtDP (I)	38.10	1.92
DSP Nif50EqualWeiETF (G)	9.65	1.92
HDFC NIF50 EquWeig (G)	27.03	1.92
HDFC NIF50 EquWeigDP (G)	27.03	1.92
ABSL Nifty50EqWei (G)	6.92	1.92
ABSL Nifty50EqWei (I)	6.92	1.92
ABSL Nifty50EqWei DP (G)	6.92	1.92
ABSL Nifty50EqWei DP (I)	6.92	1.92
ICICI PruNif50EqWt (G)	2.00	1.92
ICICI PruNif50EqWt (I)	2.00	1.92
ICICI PruNif50EqWtDP (G)	2.00	1.92
ICICI PruNif50EqWtDP (I)	2.00	1.92
Kotak Nif50EqulWei (G)	0.22	1.91
Kotak Nif50EqulWei (I)	0.22	1.91
Kotak Nif50EqulWeiDP (G)	0.22	1.91
Kotak Nif50EqulWeiDP (I)	0.22	1.91
Franklin MultiCap (G)	82.61	1.87
Franklin MultiCap (I)	82.61	1.87
Franklin MultiCap DP (G)	82.61	1.87
Franklin MultiCap DP (I)	82.61	1.87
DSP BusinessCycle (G)	17.27	1.77
DSP BusinessCycle (I)	17.27	1.77
DSP BusinessCycle DP (G)	17.27	1.77
DSP BusinessCycle DP (I)	17.27	1.77
Axis Bluechip (G)	555.71	1.72
Axis Bluechip (I)	555.71	1.72
Axis Bluechip (I-Rein)	555.71	1.72
Axis Bluechip DP (G)	555.71	1.72
Axis Bluechip DP (I)	555.71	1.72
ICICI Pru EqSaving (G)	219.80	1.71
ICICI Pru EqSaving (I-Quar)	219.80	1.71
ICICI Pru EqSaving (QIDCWR)	219.80	1.71
ICICI Pru EqSavingDP (G)	219.80	1.71
ICICI Pru EqSavingDP (I-Quar)	219.80	1.71
ICICI Pru EqSavingDP (QIDCWR)	219.80	1.71
HDFC RetireSavEQ RP (G)	100.95	1.69
HDFC RetireSavEQDP (G)	100.95	1.69
HDFC Value Fund RP (G)	115.24	1.69
HDFC Value Fund RP (I)	115.24	1.69
HDFC Value Fund RP (IDCWR)	115.24	1.69
HDFC Value Fund DP (G)	115.24	1.69
HDFC Value Fund DP (I)	115.24	1.69
HDFC Value Fund DP (IDCWR)	115.24	1.69
Navi ELSSTaxSav (G)	0.94	1.69
Navi ELSSTaxSav (I)	0.94	1.69
Navi ELSSTaxSav DP (G)	0.94	1.69
Navi ELSSTaxSav DP (I)	0.94	1.69
MahiManu Large Cap (G)	10.28	1.68
MahiManu Large Cap (I)	10.28	1.68
MahiManu LargeCap DP (G)	10.28	1.68
MahiManu LargeCap DP (I)	10.28	1.68
WhiteOak EquitySav (G)	0.58	1.67
WhiteOak EquitySavDP (G)	0.58	1.67
WhiteOak QualityEq (G)	6.01	1.66
WhiteOak QualityEqDP (G)	6.01	1.66
InvescoIndMultcap-DP (G)	59.70	1.64
InvescoIndMultcap-DP (I)	59.70	1.64
InvescoIndMulticap (G)	59.70	1.64
InvescoIndMulticap (I)	59.70	1.64
InvescoIndMulticap (I-Rein)	59.70	1.64
Shriram AggHyb (G)	0.75	1.63
Shriram AggHyb (I)	0.75	1.63
Shriram AggHyb (IDCWR)	0.75	1.63
Shriram AggHybDP (G)	0.75	1.63
Shriram AggHybDP (I)	0.75	1.63
Shriram AggHybDP (IDCWR)	0.75	1.63
Bajaj ELSSTaxSaver (G)	0.72	1.62
Bajaj ELSSTaxSaver (I)	0.72	1.62
Bajaj ELSSTaxSaverDP (G)	0.72	1.62
Bajaj ELSSTaxSaverDP (I)	0.72	1.62
JM Arbitrage (A)	3.00	1.61
JM Arbitrage (B)	3.00	1.61
JM Arbitrage (B-Annu)	3.00	1.61
JM Arbitrage (B-Half)	3.00	1.61
JM Arbitrage (B-Quar)	3.00	1.61
JM Arbitrage (G)	3.00	1.61
JM Arbitrage (H)	3.00	1.61
JM Arbitrage (I)	3.00	1.61
JM Arbitrage (I-Annu)	3.00	1.61
JM Arbitrage (I-Half)	3.00	1.61
JM Arbitrage (I-Mont)	3.00	1.61
JM Arbitrage (I-Quar)	3.00	1.61
JM Arbitrage (I-Rein)	3.00	1.61
JM Arbitrage (Q)	3.00	1.61
JM Arbitrage DP (B)	3.00	1.61
JM Arbitrage DP (B-Annu)	3.00	1.61
JM Arbitrage DP (B-Half)	3.00	1.61
JM Arbitrage DP (B-Quar)	3.00	1.61
JM Arbitrage DP (G)	3.00	1.61
JM Arbitrage DP (I)	3.00	1.61
JM Arbitrage DP (I-Annu)	3.00	1.61
JM Arbitrage DP (I-Half)	3.00	1.61
JM Arbitrage DP (I-Mont)	3.00	1.61
JM Arbitrage DP (I-Quar)	3.00	1.61
BaroBNP MultiAsset (G)	18.17	1.60
BaroBNP MultiAsset (I)	18.17	1.60
BaroBNP MultiAssetDP (G)	18.17	1.60
BaroBNP MultiAssetDP (I)	18.17	1.60
Tata BalanceAdvant (G)	159.70	1.58
Tata BalanceAdvant (I)	159.70	1.58
Tata BalanceAdvant (I-Rein)	159.70	1.58
Tata BalanceAdvantDP (G)	159.70	1.58
Tata BalanceAdvantDP (I)	159.70	1.58
Tata BalanceAdvantDP (I-Rein)	159.70	1.58
Franklin Flexi Cap (G)	274.02	1.58
Franklin Flexi Cap (I)	274.02	1.58
Franklin Flexi CapDP (G)	274.02	1.58
Franklin Flexi CapDP (I)	274.02	1.58
Kotak ESG Excl Str (G)	12.98	1.53
Kotak ESG Excl Str (I)	12.98	1.53
Kotak ESG Excl StrDP (G)	12.98	1.53
Kotak ESG Excl StrDP (I)	12.98	1.53
MahiManu Flexi Cap (G)	21.42	1.53
MahiManu Flexi Cap (I)	21.42	1.53
MahiManu FlexiCapDP (G)	21.42	1.53
MahiManu FlexiCapDP (I)	21.42	1.53
AdityaBSL FrontlEqDP (G)	426.35	1.52
AdityaBSL FrontlEqDP (I)	426.35	1.52
AdityaBSL FrontlEqDP (IDCWR)	426.35	1.52
AdityaBSL FrontlinEq (AIDCWR)	426.35	1.52
AdityaBSL FrontlinEq (G)	426.35	1.52
AdityaBSL FrontlinEq (I-Annu)	426.35	1.52
BandhanBusinessCyc (G)	23.58	1.48
BandhanBusinessCyc (I)	23.58	1.48
BandhanBusinessCycDP (G)	23.58	1.48
BandhanBusinessCycDP (I)	23.58	1.48
MahiMan ELSSTaxSav (G)	12.93	1.44
MahiMan ELSSTaxSav (I)	12.93	1.44
MahiManuELSSTaxSavDP (G)	12.93	1.44
MahiManuELSSTaxSavDP (I)	12.93	1.44
Sundaram LT TaxAdvSI (G)	0.27	1.40
Sundaram LT TaxAdvSI (I)	0.27	1.40
Sundaram LT TaxASIDP (G)	0.27	1.40
Sundaram LT TaxASIDP (I)	0.27	1.40
HDFC RetireSavHyEQDP (G)	21.63	1.38
HDFC RetireSavHyEQRP (G)	21.63	1.38
DSP Mid Cap (G)	233.57	1.36
DSP Mid Cap (I)	233.57	1.36
DSP Mid Cap (IDCWR)	233.57	1.36
DSP Mid Cap - DP (G)	233.57	1.36
DSP Mid Cap - DP (I)	233.57	1.36
DSP Mid Cap - DP (IDCWR)	233.57	1.36
SBI Contra (G)	567.64	1.36
SBI Contra (I)	567.64	1.36
SBI Contra (IDCWR)	567.64	1.36
SBI Contra DP (G)	567.64	1.36
SBI Contra DP (I)	567.64	1.36
SBI Contra DP (IDCWR)	567.64	1.36
Tata Multicap (G)	39.94	1.36
Tata Multicap (I)	39.94	1.36
Tata Multicap (I-Rein)	39.94	1.36
Tata Multicap DP (G)	39.94	1.36
Tata Multicap DP (I)	39.94	1.36
Tata Multicap DP (I-Rein)	39.94	1.36
Tata ELSS TaxSaver (G)	59.18	1.35
Tata ELSS TaxSaver (I)	59.18	1.35
Tata ELSS TaxSaver (IDCWR)	59.18	1.35
Tata ELSS TaxSaverDP (G)	59.18	1.35
Tata ELSS TaxSaverDP (I)	59.18	1.35
Tata ELSS TaxSaverDP (IDCWR)	59.18	1.35
Sundaram LT TaxAdSII (G)	0.16	1.34
Sundaram LT TaxAdSII (I)	0.16	1.34
Sundaram LTTaxASIIDP (G)	0.16	1.34
Sundaram LTTaxASIIDP (I)	0.16	1.34
Union Value (G)	3.82	1.31
Union Value (I)	3.82	1.31
Union Value Dp (G)	3.82	1.31
Union Value Dp (I)	3.82	1.31
LICMF MulAssetAllo (G)	6.32	1.27
LICMF MulAssetAllo (I)	6.32	1.27
LICMF MulAssetAlloDP (G)	6.32	1.27
LICMF MulAssetAlloDP (I)	6.32	1.27
Taurus Flexi Cap (G)	4.28	1.26
Taurus Flexi Cap (I)	4.28	1.26
Taurus Flexi Cap DP (G)	4.28	1.26
Taurus Flexi Cap DP (I)	4.28	1.26
LIC LargCap (G)	17.26	1.25
LIC LargCap (I)	17.26	1.25
LIC LargCap (I-Rein)	17.26	1.25
LIC LargeCap DP (G)	17.26	1.25
LIC LargeCap DP (I)	17.26	1.25
AdityaBSLElssTaxSa (G)	179.63	1.24
AdityaBSLElssTaxSa (I)	179.63	1.24
AdityaBSLElssTaxSa (IDCWR)	179.63	1.24
AdityaBSLElssTaxSaDP (G)	179.63	1.24
AdityaBSLElssTaxSaDP (I)	179.63	1.24
AdityaBSLElssTaxSaDP (IDCWR)	179.63	1.24
DSP Regular Sav - DP (G)	2.03	1.24
DSP Regular Sav - DP (I-Mont)	2.03	1.24
DSP Regular Sav - DP (I-Quar)	2.03	1.24
DSP Regular Sav - DP (MIDCWR)	2.03	1.24
DSP Regular Sav - DP (QIDCWR)	2.03	1.24
DSP Regular Savings (G)	2.03	1.24
DSP Regular Savings (I-Mont)	2.03	1.24
DSP Regular Savings (I-Quar)	2.03	1.24
DSP Regular Savings (MIDCWR)	2.03	1.24
DSP Regular Savings (QIDCWR)	2.03	1.24
Sundaram Bal Adv DP (G)	18.56	1.24
Sundaram Bal Adv DP (I-Mont)	18.56	1.24
Sundaram Bal Adv DP (I-Mont)	18.56	1.24
Sundaram Bal Adv DP (MIDCWR)	18.56	1.24
Sundaram Balanced Ad (G)	18.56	1.24
Sundaram Balanced Ad (I-Mont)	18.56	1.24
Sundaram Balanced Ad (I-Mont)	18.56	1.24
Sundaram Balanced Ad (MIDCWR)	18.56	1.24
Parag ELSSTaxSav (G)	60.39	1.23
Parag ELSSTaxSavDP (G)	60.39	1.23
ParagPar FlexiCap (G)	1152.92	1.23
ParagPar FlexiCap DP (G)	1152.92	1.23
Quantum MulAssAllo (G)	0.40	1.23
Quantum MulAssAlloDP (G)	0.40	1.23
Union ELSSTaxSaver (G)	10.60	1.23
Union ELSSTaxSaver (I)	10.60	1.23
Union ELSSTaxSaver (IDCWR)	10.60	1.23
Union ELSSTaxSaverDP (G)	10.60	1.23
Union ELSSTaxSaverDP (I)	10.60	1.23
Union ELSSTaxSaverDP (IDCWR)	10.60	1.23
DSP DyAssetAllo (G)	38.71	1.20
DSP DyAssetAllo (I)	38.71	1.20
DSP DyAssetAllo (IDCWR)	38.71	1.20
DSP DyAssetAllo DP (G)	38.71	1.20
DSP DyAssetAllo DP (I)	38.71	1.20
DSP DyAssetAllo DP (IDCWR)	38.71	1.20
Kotak Flexicap DP (G)	591.30	1.20
Kotak Flexicap DP (I)	591.30	1.20
Kotak Flexicap DP (IDCWR)	591.30	1.20
Kotak Flexicap RP (G)	591.30	1.20
Kotak Flexicap RP (I)	591.30	1.20
Kotak Flexicap RP (IDCWR)	591.30	1.20
MahiManu AggHybrid (G)	18.65	1.19
MahiManu AggHybrid (I)	18.65	1.19
MahiManu AggHybridDP (G)	18.65	1.19
MahiManu AggHybridDP (I)	18.65	1.19
Tata MultiAssetOpp (G)	41.17	1.18
Tata MultiAssetOpp (I)	41.17	1.18
Tata MultiAssetOpp (I-Rein)	41.17	1.18
Tata MultiAssetOppDP (G)	41.17	1.18
Tata MultiAssetOppDP (I)	41.17	1.18
Tata MultiAssetOppDP (I-Rein)	41.17	1.18
WhiteOak ESGBestIn (G)	0.70	1.18
WhiteOak ESGBestInDP (G)	0.70	1.18
Axis Consumption (G)	45.42	1.15
Axis Consumption (I)	45.42	1.15
Axis Consumption DP (G)	45.42	1.15
Axis Consumption DP (I)	45.42	1.15
Kotak ELSS Tax SavDP (G)	64.90	1.11
Kotak ELSS Tax SavDP (I)	64.90	1.11
Kotak ELSS Tax Saver (G)	64.90	1.11
Kotak ELSS Tax Saver (I)	64.90	1.11
Kotak ELSS Tax Saver (IDCWR)	64.90	1.11
BarBNP Value (G)	14.42	1.10
BarBNP Value (I)	14.42	1.10
BarBNP Value DP (G)	14.42	1.10
BarBNP Value DP (I)	14.42	1.10
Sundaram Div Eq (G)	15.72	1.10
Sundaram Div Eq (I)	15.72	1.10
Sundaram Div Eq (IDCWR)	15.72	1.10
Sundaram Div Eq DP (G)	15.72	1.10
Sundaram Div Eq DP (I)	15.72	1.10
Sundaram Div Eq DP (IDCWR)	15.72	1.10
Sundaram Flexicap (G)	21.49	1.10
Sundaram Flexicap (I)	21.49	1.10
Sundaram Flexicap (I-Rein)	21.49	1.10
Sundaram FlexicapDP (G)	21.49	1.10
Sundaram FlexicapDP (I)	21.49	1.10
Sundaram FlexicapDP (I-Rein)	21.49	1.10
UTI Equity Savings (G)	7.38	1.10
UTI Equity Savings (I)	7.38	1.10
UTI Equity Savings (I-Mont)	7.38	1.10
UTI Equity Savings (I-Quar)	7.38	1.10
UTI Equity SavingsDP (G)	7.38	1.10
UTI Equity SavingsDP (I)	7.38	1.10
UTI Equity SavingsDP (I-Mont)	7.38	1.10
UTI Equity SavingsDP (I-Quar)	7.38	1.10
SBI InnovativeOppr (G)	81.37	1.09
SBI InnovativeOppr (I)	81.37	1.09
SBI InnovativeOpprDP (G)	81.37	1.09
SBI InnovativeOpprDP (I)	81.37	1.09
Edelweiss BalAdv (G)	129.53	1.06
Edelweiss BalAdv (I)	129.53	1.06
Edelweiss BalAdv (I-Mont)	129.53	1.06
Edelweiss BalAdv (I-Rein)	129.53	1.06
Edelweiss BalAdv DP (G)	129.53	1.06
Edelweiss BalAdv DP (I)	129.53	1.06
Edelweiss BalAdv DP (I-Mont)	129.53	1.06
HDFC DividendYield (G)	62.95	1.06
HDFC DividendYield (I)	62.95	1.06
HDFC DividendYieldDP (G)	62.95	1.06
HDFC DividendYieldDP (I)	62.95	1.06
UTI ChildrenEquity (G)	11.20	1.06
UTI ChildrenEquity (I)	11.20	1.06
UTI ChildrenEquityDP (G)	11.20	1.06
UTI ChildrenEquityDP (I)	11.20	1.06
UTI ELSS TaxSaver (G)	38.21	1.06
UTI ELSS TaxSaver (I)	38.21	1.06
UTI ELSS TaxSaver (I-Rein)	38.21	1.06
UTI ELSS TaxSaver DP (G)	38.21	1.06
UTI ELSS TaxSaver DP (I)	38.21	1.06
CanaraRobeco Eq HyDP (G)	108.17	1.04
CanaraRobeco Eq HyDP (I)	108.17	1.04
CanaraRobecoEq Hy (G)	108.17	1.04
CanaraRobecoEq Hy (I)	108.17	1.04
CanaraRobecoEq Hy (I-Rein)	108.17	1.04
ITI Pharma&HeaCare (G)	2.22	1.04
ITI Pharma&HeaCare (I)	2.22	1.04
ITI Pharma&HeaCareDP (G)	2.22	1.04
ITI Pharma&HeaCareDP (I)	2.22	1.04
SundaramELSSTaxSav (G)	13.41	1.04
SundaramELSSTaxSav (I-Half)	13.41	1.04
SundaramELSSTaxSavDP (G)	13.41	1.04
SundaramELSSTaxSavDP (I-Half)	13.41	1.04
UTI LargeCap (G)	124.38	1.02
UTI LargeCap (I)	124.38	1.02
UTI LargeCap (I-Rein)	124.38	1.02
UTI LargeCap DP (G)	124.38	1.02
UTI LargeCap DP (I)	124.38	1.02
AdityaBSL FlexiCap (G)	220.99	1.02
AdityaBSL FlexiCap (I)	220.99	1.02
AdityaBSL FlexiCap (IDCWR)	220.99	1.02
AdityaBSL FlexiCapDP (G)	220.99	1.02
AdityaBSL FlexiCapDP (I)	220.99	1.02
AdityaBSL FlexiCapDP (IDCWR)	220.99	1.02
Axis RetirementDyn (G)	3.40	1.00
Axis RetirementDyn (I)	3.40	1.00
Axis RetirementDynDP (G)	3.40	1.00
Axis RetirementDynDP (I)	3.40	1.00
Groww AggreHybrid (G)	0.45	1.00
Groww AggreHybrid (I)	0.45	1.00
Groww AggreHybrid (I-Half)	0.45	1.00
Groww AggreHybrid (I-Mont)	0.45	1.00
Groww AggreHybrid (I-Quar)	0.45	1.00
Groww AggreHybrid DP (G)	0.45	1.00
Groww AggreHybrid DP (I)	0.45	1.00
Groww AggreHybrid DP (I-Half)	0.45	1.00
Groww AggreHybrid DP (I-Mont)	0.45	1.00
Groww AggreHybrid DP (I-Quar)	0.45	1.00
Sundaram Div Yie (G)	8.65	1.00
Sundaram Div Yie (I)	8.65	1.00
Sundaram Div Yie (IDCWR)	8.65	1.00
Sundaram Div Yie (IDCWS)	8.65	1.00
Sundaram Div Yie DP (G)	8.65	1.00
Sundaram Div Yie DP (I)	8.65	1.00
Sundaram Div Yie DP (IDCWR)	8.65	1.00
Sundaram Div Yie DP (IDCWS)	8.65	1.00
WhiteOak Arbitrage (G)	3.75	1.00
WhiteOak ArbitrageDP (G)	3.75	1.00
Canara BalancedAdv (G)	14.13	0.98
Canara BalancedAdv (I)	14.13	0.98
Canara BalancedAdvDP (G)	14.13	0.98
Canara BalancedAdvDP (I)	14.13	0.98
CanaraRob Manufact (G)	14.76	0.98
CanaraRob Manufact (I)	14.76	0.98
CanaraRob ManufactDP (G)	14.76	0.98
CanaraRob ManufactDP (I)	14.76	0.98
FranklinELSSTaxSav (G)	61.29	0.96
FranklinELSSTaxSav (I)	61.29	0.96
FranklinELSSTaxSav (I-Rein)	61.29	0.96
FranklinELSSTaxSavDP (G)	61.29	0.96
FranklinELSSTaxSavDP (I)	61.29	0.96
BarBNP LargeCap (G)	23.36	0.96
BarBNP LargeCap (I)	23.36	0.96
BarBNP LargeCap DP (G)	23.36	0.96
BarBNP LargeCap DP (I)	23.36	0.96
Canara Rob Value (G)	11.50	0.96
Canara Rob Value (I)	11.50	0.96
Canara Rob ValueDP (G)	11.50	0.96
Canara Rob ValueDP (I)	11.50	0.96
Sundaram NIFTY 100 (G)	0.95	0.96
Sundaram NIFTY 100 (I)	0.95	0.96
Sundaram NIFTY 100 (IDCWR)	0.95	0.96
Sundaram NIFTY 100 (IDCWS)	0.95	0.96
Sundaram NIFTY 100DP (G)	0.95	0.96
Sundaram NIFTY 100DP (I)	0.95	0.96
Sundaram NIFTY 100DP (IDCWR)	0.95	0.96
Sundaram NIFTY 100DP (IDCWS)	0.95	0.96
UTI MastrEqPlUnSch (I)	27.18	0.96
BarBNP BusinessCyc (G)	5.19	0.95
BarBNP BusinessCyc (I)	5.19	0.95
BarBNP BusinessCycDP (G)	5.19	0.95
BarBNP BusinessCycDP (I)	5.19	0.95
HDFC Nif100EqlWgt (G)	3.19	0.95
HDFC Nif100EqlWgtDP (G)	3.19	0.95
Kotak Nif100EqlWei (G)	0.09	0.95
Kotak Nif100EqlWei (I)	0.09	0.95
Kotak Nif100EqlWeiDP (G)	0.09	0.95
Kotak Nif100EqlWeiDP (I)	0.09	0.95
KotakNif100EqWeETF (G)	0.01	0.95
SBI Balanced Adv (G)	316.14	0.95
SBI Balanced Adv (I)	316.14	0.95
SBI Balanced Adv DP (G)	316.14	0.95
SBI Balanced Adv DP (I)	316.14	0.95
Axis Value (G)	7.39	0.94
Axis Value (I)	7.39	0.94
Axis Value DP (G)	7.39	0.94
Axis Value DP (I)	7.39	0.94
Bandhan Retirement (G)	1.60	0.93
Bandhan Retirement (I)	1.60	0.93
Bandhan RetirementDP (G)	1.60	0.93
Bandhan RetirementDP (I)	1.60	0.93
Kotak EquityOppo DP (G)	230.75	0.93
Kotak EquityOppo DP (I)	230.75	0.93
Kotak EquityOppo RP (G)	230.75	0.93
Kotak EquityOppo RP (I)	230.75	0.93
Kotak EquityOppo RP (IDCWR)	230.75	0.93
Axis Business Cycles (G)	21.72	0.91
Axis Business Cycles (I)	21.72	0.91
Axis BusinessCycleDP (G)	21.72	0.91
Axis BusinessCycleDP (I)	21.72	0.91
Axis RetirementAgg (G)	7.42	0.90
Axis RetirementAgg (I)	7.42	0.90
Axis RetirementAggDP (G)	7.42	0.90
Axis RetirementAggDP (I)	7.42	0.90
Navi Flexi Cap (G)	2.16	0.90
Navi Flexi Cap (I)	2.16	0.90
Navi Flexi Cap (I-Annu)	2.16	0.90
Navi Flexi Cap (I-Half)	2.16	0.90
Navi Flexi Cap (I-Mont)	2.16	0.90
Navi Flexi Cap (I-Quar)	2.16	0.90
Navi Flexi Cap DP (G)	2.16	0.90
Navi Flexi Cap DP (I)	2.16	0.90
Navi Flexi Cap DP (I-Annu)	2.16	0.90
Navi Flexi Cap DP (I-Half)	2.16	0.90
Navi Flexi Cap DP (I-Mont)	2.16	0.90
Navi Flexi Cap DP (I-Quar)	2.16	0.90
Axis Arbitrage (G)	51.83	0.89
Axis Arbitrage (I-Mont)	51.83	0.89
Axis Arbitrage DP (G)	51.83	0.89
Axis Arbitrage DP (I-Mont)	51.83	0.89
BaroBNP Retirement (G)	3.17	0.89
BaroBNP Retirement (I)	3.17	0.89
BaroBNP RetirementDP (G)	3.17	0.89
BaroBNP RetirementDP (I)	3.17	0.89
Groww Large Cap (G)	1.07	0.89
Groww Large Cap (H)	1.07	0.89
Groww Large Cap (I)	1.07	0.89
Groww Large Cap (I-Half)	1.07	0.89
Groww Large Cap (I-Mont)	1.07	0.89
Groww Large Cap (I-Quar)	1.07	0.89
Groww Large Cap (I-Rein)	1.07	0.89
Groww Large Cap (M)	1.07	0.89
Groww Large Cap (Q)	1.07	0.89
Groww Large Cap DP (G)	1.07	0.89
Groww Large Cap DP (I)	1.07	0.89
Groww Large Cap DP (I-Half)	1.07	0.89
Groww Large Cap DP (I-Mont)	1.07	0.89
Groww Large Cap DP (I-Quar)	1.07	0.89
AdityaBSL BusinCyc (G)	14.89	0.88
AdityaBSL BusinCyc (I)	14.89	0.88
AdityaBSL BusinCycDP (G)	14.89	0.88
AdityaBSL BusinCycDP (I)	14.89	0.88
Axis Balanced Adv (G)	23.07	0.87
Axis Balanced Adv (I)	23.07	0.87
Axis Balanced Adv DP (G)	23.07	0.87
Axis Balanced Adv DP (I)	23.07	0.87
Axis AggressiveHyb (G)	13.11	0.86
Axis AggressiveHyb (I)	13.11	0.86
Axis AggressiveHyb (I-Mont)	13.11	0.86
Axis AggressiveHyb (I-Quar)	13.11	0.86
Axis AggressiveHybDP (G)	13.11	0.86
Axis AggressiveHybDP (I)	13.11	0.86
Axis AggressiveHybDP (I-Mont)	13.11	0.86
Axis AggressiveHybDP (I-Quar)	13.11	0.86
MiraeNif100ESGSETF (G)	0.99	0.85
Axis ELSS TaxSaver (G)	294.23	0.85
Axis ELSS TaxSaver (I)	294.23	0.85
Axis ELSS TaxSaver (I-Rein)	294.23	0.85
Axis ELSS TaxSaverDP (G)	294.23	0.85
Axis ELSS TaxSaverDP (I)	294.23	0.85
Axis EquitySavings (G)	8.23	0.85
Axis EquitySavings (I)	8.23	0.85
Axis EquitySavings (I-Mont)	8.23	0.85
Axis EquitySavings (I-Quar)	8.23	0.85
Axis EquitySavings (I-Rein)	8.23	0.85
Axis EquitySavings (M)	8.23	0.85
Axis EquitySavings (Q)	8.23	0.85
Axis EquitySavingsDP (G)	8.23	0.85
Axis EquitySavingsDP (I)	8.23	0.85
Axis EquitySavingsDP (I-Mont)	8.23	0.85
Axis EquitySavingsDP (I-Quar)	8.23	0.85
AxisChildrenComLocDP (G)	7.36	0.85
AxisChildrenComLocDP (I)	7.36	0.85
AxisChildrenComLock (G)	7.36	0.85
AxisChildrenComLock (I)	7.36	0.85
AxisChildrenNoLock (G)	7.36	0.85
AxisChildrenNoLock (I)	7.36	0.85
AxisChildrenNoLockDP (G)	7.36	0.85
AxisChildrenNoLockDP (I)	7.36	0.85
Axis Growth Oppo (G)	110.90	0.82
Axis Growth Oppo (I)	110.90	0.82
Axis Growth Oppo DP (G)	110.90	0.82
Axis Growth Oppo DP (I)	110.90	0.82
Sundaram Arbitrage (G)	2.34	0.81
Sundaram Arbitrage (I-Mont)	2.34	0.81
Sundaram Arbitrage (I-Mont)	2.34	0.81
Sundaram Arbitrage (M)	2.34	0.81
Sundaram ArbitrageDP (G)	2.34	0.81
Sundaram ArbitrageDP (I-Mont)	2.34	0.81
Sundaram ArbitrageDP (I-Mont)	2.34	0.81
Axis Multicap (G)	54.00	0.80
Axis Multicap (I)	54.00	0.80
Axis Multicap DP (G)	54.00	0.80
Axis Multicap DP (I)	54.00	0.80
CanaraRob MultiCap (G)	30.29	0.79
CanaraRob MultiCap (I)	30.29	0.79
CanaraRob MultiCapDP (G)	30.29	0.79
CanaraRob MultiCapDP (I)	30.29	0.79
HDFC Arbitr WP DP (G)	143.24	0.78
HDFC Arbitr WP DP (I)	143.24	0.78
HDFC Arbitr WP DP (I-Mont)	143.24	0.78
HDFC Arbitrage - WP (G)	143.24	0.78
HDFC Arbitrage - WP (I)	143.24	0.78
HDFC Arbitrage - WP (I-Mont)	143.24	0.78
HDFC Arbitrage - WP (MIDCWR)	143.24	0.78
HDFC Arbitrage DP (G)	143.24	0.78
HDFC Arbitrage DP (I-Quar)	143.24	0.78
HDFC Arbitrage DP (QIDCWR)	143.24	0.78
HDFC Arbitrage RP (G)	143.24	0.78
HDFC Arbitrage RP (I-Mont)	143.24	0.78
HDFC Arbitrage RP (I-Quar)	143.24	0.78
ICICI Pru EqArbit (G)	199.11	0.77
ICICI Pru EqArbit (I)	199.11	0.77
ICICI Pru EqArbit (IDCWR)	199.11	0.77
ICICI Pru EqArbit DP (G)	199.11	0.77
ICICI Pru EqArbit DP (I)	199.11	0.77
ICICI Pru EqArbit DP (IDCWR)	199.11	0.77
Axis Nifty 50 ETF (G)	5.21	0.77
Axis Nifty50Index (G)	4.64	0.77
Axis Nifty50Index (I)	4.64	0.77
Axis Nifty50IndexDP (G)	4.64	0.77
Axis Nifty50IndexDP (I)	4.64	0.77
BarBnp Nifty 50 (G)	0.50	0.77
BarBnp Nifty 50 (I)	0.50	0.77
BarBnp Nifty 50 DP (G)	0.50	0.77
BarBnp Nifty 50 DP (I)	0.50	0.77
LIC MF Nifty 50ETF (G)	6.29	0.77
SBI Nifty50 ETF (G)	1459.39	0.77
SBI NiftyIndex (G)	67.38	0.77
SBI NiftyIndex (I)	67.38	0.77
SBI NiftyIndex (IDCWR)	67.38	0.77
SBI NiftyIndex DP (G)	67.38	0.77
SBI NiftyIndex DP (I)	67.38	0.77
SBI NiftyIndex DP (IDCWR)	67.38	0.77
Tata Nifty50 ETF (G)	5.17	0.77
Tata Nifty50IndexDP (G)	8.55	0.77
Tata Nifty50IndexRP (G)	8.55	0.77
MiraeAssetNifty50ETF (G)	32.74	0.76
ICICI Pru Nifty50ETF (G)	202.10	0.76
AdityaBSLNifty50ETF (G)	23.35	0.76
Motilal NiftyM50ETF (G)	0.39	0.76
Aditya BSL Nifty50 (G)	7.58	0.76
Aditya BSL Nifty50 (I)	7.58	0.76
Aditya BSL Nifty50 (IDCWR)	7.58	0.76
Aditya BSL Nifty50DP (G)	7.58	0.76
Aditya BSL Nifty50DP (I)	7.58	0.76
Aditya BSL Nifty50DP (IDCWR)	7.58	0.76
Mirae Nif50 Index (G)	0.19	0.76
Mirae Nif50 Index (I)	0.19	0.76
Mirae Nif50 IndexDP (G)	0.19	0.76
Mirae Nif50 IndexDP (I)	0.19	0.76
MotilalOsw Nifty50 (G)	4.88	0.76
MotilalOsw Nifty50DP (G)	4.88	0.76
ICICI Nifty50Index (G)	96.07	0.76
ICICI Nifty50Index (I)	96.07	0.76
ICICI Nifty50Index (IDCWR)	96.07	0.76
ICICI Nifty50IndexDP (G)	96.07	0.76
ICICI Nifty50IndexDP (I)	96.07	0.76
ICICI Nifty50IndexDP (IDCWR)	96.07	0.76
BajajFins Nif50ETF (G)	1.48	0.76
Bandhan Nifty 50 (G)	13.28	0.76
Bandhan Nifty 50 (I)	13.28	0.76
Bandhan Nifty 50 (IDCWR)	13.28	0.76
Bandhan Nifty 50 DP (G)	13.28	0.76
Bandhan Nifty 50 DP (I)	13.28	0.76
Bandhan Nifty50 ETF (G)	0.20	0.76
DSP Nifty50ETF (G)	2.61	0.76
DSP Nifty50Index (G)	5.20	0.76
DSP Nifty50Index (I)	5.20	0.76
DSP Nifty50Index DP (G)	5.20	0.76
DSP Nifty50Index DP (I)	5.20	0.76
Edelweiss Nifty 50 (G)	1.16	0.76
Edelweiss Nifty 50 (I)	1.16	0.76
Edelweiss Nifty 50DP (G)	1.16	0.76
Edelweiss Nifty 50DP (I)	1.16	0.76
HDFC Nifty50 ETF (G)	32.09	0.76
HDFC Nifty50 Index (G)	145.59	0.76
HDFC Nifty50 IndexDP (G)	145.59	0.76
HSBC Nifty 50 (G)	2.40	0.76
HSBC Nifty 50 (I)	2.40	0.76
HSBC Nifty 50 DP (G)	2.40	0.76
HSBC Nifty 50 DP (I)	2.40	0.76
Invesco Nifty50ETF (G)	0.67	0.76
Kotak Nifty50 ETF (G)	21.96	0.76
Kotak Nifty50 Index (G)	6.16	0.76
Kotak Nifty50 Index (I)	6.16	0.76
Kotak Nifty50IndexDP (G)	6.16	0.76
Kotak Nifty50IndexDP (I)	6.16	0.76
Navi ELSSTaxSavN50 (G)	0.66	0.76
Navi ELSSTaxSavN50 (I)	0.66	0.76
Navi ELSSTaxSavN50DP (G)	0.66	0.76
Navi ELSSTaxSavN50DP (I)	0.66	0.76
Navi Nifty50Index (G)	22.28	0.76
Navi Nifty50Index DP (G)	22.28	0.76
Nippon IndexNif50 (B)	17.53	0.76
Nippon IndexNif50 (G)	17.53	0.76
Nippon IndexNif50 (I-Annu)	17.53	0.76
Nippon IndexNif50 (I-Half)	17.53	0.76
Nippon IndexNif50 (I-Quar)	17.53	0.76
Nippon IndexNif50DP (B)	17.53	0.76
Nippon IndexNif50DP (G)	17.53	0.76
Nippon IndexNif50DP (I-Annu)	17.53	0.76
Nippon IndexNif50DP (I-Half)	17.53	0.76
Nippon IndexNif50DP (I-Quar)	17.53	0.76
NipponETFNif50BeSE (G)	332.08	0.76
Quantum Nif 50 ETF (G)	0.48	0.76
TaurusNifty50Index (G)	0.04	0.76
TaurusNifty50Index (I)	0.04	0.76
TaurusNifty50Index (I-Rein)	0.04	0.76
TaurusNifty50IndexDP (G)	0.04	0.76
TaurusNifty50IndexDP (I)	0.04	0.76
UTI Nifty50 ETF (G)	443.78	0.76
UTI Nifty50 Index (G)	162.87	0.76
UTI Nifty50 Index (I)	162.87	0.76
UTI Nifty50 Index (I-Rein)	162.87	0.76
UTI Nifty50 Index DP (G)	162.87	0.76
UTI Nifty50 Index DP (I)	162.87	0.76
FranklinNSENifty50 (G)	5.26	0.75
FranklinNSENifty50 (I)	5.26	0.75
FranklinNSENifty50 (I-Rein)	5.26	0.75
FranklinNSENifty50DP (G)	5.26	0.75
FranklinNSENifty50DP (I)	5.26	0.75
360 ONE ELSS Tax DP (G)	0.59	0.75
360 ONE ELSS Tax DP (I)	0.59	0.75
360 ONE ELSS Tax Sav (G)	0.59	0.75
360 ONE ELSS Tax Sav (I)	0.59	0.75
LIC MF Nifty 50 Inde (G)	2.34	0.74
LIC MF Nifty 50 Inde (I)	2.34	0.74
LIC MF Nifty 50 Inde (I-Rein)	2.34	0.74
LIC MF Nifty 50 InDP (G)	2.34	0.74
LIC MF Nifty 50 InDP (I)	2.34	0.74
Bandhan MulAssAllo (G)	13.21	0.73
Bandhan MulAssAllo (I)	13.21	0.73
Bandhan MulAssAlloDP (G)	13.21	0.73
Bandhan MulAssAlloDP (I)	13.21	0.73
BajajFinsArbitrage (G)	6.37	0.71
BajajFinsArbitrage (I)	6.37	0.71
BajajFinsArbitrageDP (G)	6.37	0.71
BajajFinsArbitrageDP (I)	6.37	0.71
HDFC Multi Asset DP (G)	28.84	0.71
HDFC Multi Asset DP (I)	28.84	0.71
HDFC Multi Asset DP (IDCWR)	28.84	0.71
HDFC Multi Asset RP (G)	28.84	0.71
HDFC Multi Asset RP (I)	28.84	0.71
HDFC Multi Asset RP (IDCWR)	28.84	0.71
ICICI PruValDisco (G)	334.75	0.68
ICICI PruValDisco (I)	334.75	0.68
ICICI PruValDisco (IDCWR)	334.75	0.68
ICICI PruValDisco DP (G)	334.75	0.68
ICICI PruValDisco DP (I)	334.75	0.68
ICICI PruValDisco DP (IDCWR)	334.75	0.68
Axis RetirementCon (G)	0.41	0.68
Axis RetirementCon (I)	0.41	0.68
Axis RetirementConDP (G)	0.41	0.68
Axis RetirementConDP (I)	0.41	0.68
Axis MulAsset All (G)	8.88	0.67
Axis MulAsset All (I-Mont)	8.88	0.67
Axis MulAsset All DP (G)	8.88	0.67
Axis MulAsset All DP (I-Mont)	8.88	0.67
CanaraRob BluchiEq (G)	100.23	0.67
CanaraRob BluchiEq (I)	100.23	0.67
CanaraRob BluchiEq (I-Rein)	100.23	0.67
CanaraRob BluchiEqDP (G)	100.23	0.67
CanaraRob BluchiEqDP (I)	100.23	0.67
ITI Large Cap (G)	3.18	0.67
ITI Large Cap (I)	3.18	0.67
ITI Large Cap DP (G)	3.18	0.67
ITI Large Cap DP (I)	3.18	0.67
FranklinInd EqSav (G)	4.22	0.66
FranklinInd EqSav (I)	4.22	0.66
FranklinInd EqSav (I-Mont)	4.22	0.66
FranklinInd EqSav (I-Quar)	4.22	0.66
FranklinInd EqSav (IDCWR)	4.22	0.66
FranklinInd EqSavDP (G)	4.22	0.66
FranklinInd EqSavDP (I)	4.22	0.66
FranklinInd EqSavDP (I-Mont)	4.22	0.66
FranklinInd EqSavDP (I-Quar)	4.22	0.66
HDFC Multi Cap (G)	103.84	0.65
HDFC Multi Cap (I)	103.84	0.65
HDFC Multi Cap DP (G)	103.84	0.65
HDFC Multi Cap DP (I)	103.84	0.65
WhiteoakLar&MidCap (G)	9.94	0.65
WhiteoakLar&MidCapDP (G)	9.94	0.65
ICICI PruNifty100ETF (G)	0.70	0.63
Zerodha Nifty 100ETF (G)	0.31	0.63
Axis Nifty100Index (G)	10.58	0.63
Axis Nifty100Index (G)	10.58	0.63
Axis Nifty100Index (I)	10.58	0.63
Axis Nifty100Index (I)	10.58	0.63
Bandhan Nifty100 (G)	1.03	0.63
Bandhan Nifty100 (I)	1.03	0.63
Bandhan Nifty100 DP (G)	1.03	0.63
Bandhan Nifty100 DP (I)	1.03	0.63
HDFC Nifty 100 ETF (G)	0.18	0.63
HDFC Nifty100Index (G)	2.01	0.63
HDFC Nifty100IndexDP (G)	2.01	0.63
Nippon ETFNifty100 (G)	1.84	0.63
SBI BSE100 ETF (G)	0.06	0.63
HDFC Eq Savings DP (G)	33.72	0.62
HDFC Eq Savings DP (I)	33.72	0.62
HDFC Eq Savings DP (IDCWR)	33.72	0.62
HDFC EquitySavingsRP (G)	33.72	0.62
HDFC EquitySavingsRP (I)	33.72	0.62
HDFC EquitySavingsRP (IDCWR)	33.72	0.62
LIC MF Nifty 100ETF (G)	4.34	0.62
Kotak MSCIIndiaETF (G)	6.20	0.61
MiraeAssetEqSaving (G)	8.25	0.61
MiraeAssetEqSaving (I)	8.25	0.61
MiraeAssetEqSavingDP (G)	8.25	0.61
MiraeAssetEqSavingDP (I)	8.25	0.61
UTI Balance Advan (G)	17.31	0.60
UTI Balance Advan (I)	17.31	0.60
UTI Balance Advan DP (G)	17.31	0.60
UTI Balance Advan DP (I)	17.31	0.60
HDFC Large&MidCap (G)	137.97	0.59
HDFC Large&MidCap (I)	137.97	0.59
HDFC Large&MidCap (IDCWR)	137.97	0.59
HDFC Large&MidCap DP (G)	137.97	0.59
HDFC Large&MidCap DP (I)	137.97	0.59
HDFC Large&MidCap DP (IDCWR)	137.97	0.59
WhiteOak BalAdv (G)	8.15	0.59
WhiteOak BalAdv DP (G)	8.15	0.59
WhiteOak LargeCap (G)	4.62	0.59
WhiteOak LargeCap (I)	4.62	0.59
WhiteOak LargeCapDP (G)	4.62	0.59
WhiteOak LargeCapDP (I)	4.62	0.59
CanaraRob FlexiCap (G)	70.67	0.58
CanaraRob FlexiCap (I)	70.67	0.58
CanaraRob FlexiCapDP (G)	70.67	0.58
CanaraRob FlexiCapDP (I)	70.67	0.58
WhiteOak FlexiCap (G)	25.46	0.58
WhiteOak FlexiCap (I)	25.46	0.58
WhiteOak FlexiCapDP (G)	25.46	0.58
WhiteOak FlexiCapDP (I)	25.46	0.58
MiraeAsset BalAdv (G)	9.99	0.57
MiraeAsset BalAdv (I)	9.99	0.57
MiraeAsset BalAdvDP (G)	9.99	0.57
MiraeAsset BalAdvDP (I)	9.99	0.57
Edelweiss ElssTaxSav (G)	2.15	0.56
Edelweiss ElssTaxSav (I)	2.15	0.56
Edelweiss ElssTaxSav (I-Rein)	2.15	0.56
Edelweiss ElssTaxSDP (G)	2.15	0.56
Edelweiss ElssTaxSDP (I)	2.15	0.56
HDFC Hybrid Debt DP (G)	18.61	0.56
HDFC Hybrid Debt DP (I-Mont)	18.61	0.56
HDFC Hybrid Debt DP (I-Quar)	18.61	0.56
HDFC Hybrid Debt DP (MIDCWR)	18.61	0.56
HDFC Hybrid Debt DP (QIDCWR)	18.61	0.56
HDFC Hybrid Debt RP (G)	18.61	0.56
HDFC Hybrid Debt RP (I-Mont)	18.61	0.56
HDFC Hybrid Debt RP (I-Quar)	18.61	0.56
HDFC Hybrid Debt RP (MIDCWR)	18.61	0.56
HDFC Hybrid Debt RP (QIDCWR)	18.61	0.56
Axis ConservatHyb (A)	1.48	0.55
Axis ConservatHyb (G)	1.48	0.55
Axis ConservatHyb (H)	1.48	0.55
Axis ConservatHyb (I-Annu)	1.48	0.55
Axis ConservatHyb (I-Half)	1.48	0.55
Axis ConservatHyb (I-Quar)	1.48	0.55
Axis ConservatHyb (Q)	1.48	0.55
Axis ConservatHybDP (G)	1.48	0.55
Axis ConservatHybDP (I-Annu)	1.48	0.55
Axis ConservatHybDP (I-Half)	1.48	0.55
Axis ConservatHybDP (I-Quar)	1.48	0.55
MiraeAsset ArbitraDP (G)	17.06	0.55
MiraeAsset ArbitraDP (I)	17.06	0.55
MiraeAsset Arbitrage (G)	17.06	0.55
MiraeAsset Arbitrage (I)	17.06	0.55
Groww Nifty200ETF (G)	0.07	0.52
Union Arbitrage (G)	1.55	0.51
Union Arbitrage (I)	1.55	0.51
Union Arbitrage DP (G)	1.55	0.51
Union Arbitrage DP (I)	1.55	0.51
WhiteOak BalHybrid (G)	0.86	0.51
WhiteOak BalHybridDP (G)	0.86	0.51
Union Retirement (G)	0.77	0.50
Union Retirement (I)	0.77	0.50
Union Retirement DP (G)	0.77	0.50
Union Retirement DP (I)	0.77	0.50
Edelweiss AggHy (G)	12.06	0.48
Edelweiss AggHy (I)	12.06	0.48
Edelweiss AggHy DP (G)	12.06	0.48
Edelweiss AggHy DP (I)	12.06	0.48
Edelweiss AggHyPlanB (G)	12.06	0.48
Edelweiss AggHyPlanB (I)	12.06	0.48
Edelweiss LarCap (G)	5.53	0.48
Edelweiss LarCap (I)	5.53	0.48
Edelweiss LarCap (I-Rein)	5.53	0.48
Edelweiss LarCap B (G)	5.53	0.48
Edelweiss LarCap B (I)	5.53	0.48
Edelweiss LarCap B (I-Rein)	5.53	0.48
Edelweiss LarCap C (G)	5.53	0.48
Edelweiss LarCap C (I)	5.53	0.48
Edelweiss LarCap C (I-Rein)	5.53	0.48
Edelweiss LarCapDP (G)	5.53	0.48
Edelweiss LarCapDP (I)	5.53	0.48
LIC MF Arbitrage (G)	1.59	0.48
LIC MF Arbitrage (I-Mont)	1.59	0.48
LIC MF Arbitrage (I-Week)	1.59	0.48
LIC MF Arbitrage DP (G)	1.59	0.48
LIC MF Arbitrage DP (I-Mont)	1.59	0.48
LIC MF Arbitrage DP (W)	1.59	0.48
UTI ConservaHybrid (G)	7.93	0.48
UTI ConservaHybrid (I-Flex)	7.93	0.48
UTI ConservaHybrid (I-Mont)	7.93	0.48
UTI ConservaHybrid (P-Mont)	7.93	0.48
UTI ConservaHybridDP (G)	7.93	0.48
UTI ConservaHybridDP (I-Flex)	7.93	0.48
UTI ConservaHybridDP (I-Mont)	7.93	0.48
UTI ConservaHybridDP (P-Mont)	7.93	0.48
HDFC BSE500 Index (G)	0.97	0.47
HDFC BSE500 IndexDP (G)	0.97	0.47
Mirae BSE200EqlETF (G)	0.07	0.47
ICICIPru BSE500ETF (G)	1.60	0.47
Axis Nifty500Index (G)	0.99	0.46
Axis Nifty500IndexDP (G)	0.99	0.46
HDFC BSE500 ETF (G)	0.07	0.46
SBI Nif500 Index (G)	3.71	0.46
SBI Nif500 Index (I)	3.71	0.46
SBI Nif500 IndexDP (G)	3.71	0.46
SBI Nif500 IndexDP (I)	3.71	0.46
UTI Arbitrage (G)	30.61	0.46
UTI Arbitrage (I)	30.61	0.46
UTI Arbitrage (I-Rein)	30.61	0.46
UTI Arbitrage DP (G)	30.61	0.46
UTI Arbitrage DP (I)	30.61	0.46
Motilal Nifty500ETF (G)	0.54	0.46
Motilal Os Nif500 (G)	9.63	0.46
Motilal Os Nif500DP (G)	9.63	0.46
ICICI Pru Nifty500 (G)	0.09	0.45
ICICI Pru Nifty500 (I)	0.09	0.45
ICICI Pru Nifty500DP (G)	0.09	0.45
ICICI Pru Nifty500DP (I)	0.09	0.45
Helios BalancedAdv (G)	1.31	0.45
Helios BalancedAdv (I)	1.31	0.45
Helios BalancedAdvDP (G)	1.31	0.45
Helios BalancedAdvDP (I)	1.31	0.45
Groww NifTotalMar (G)	1.21	0.44
Groww NifTotalMar (I)	1.21	0.44
Groww NifTotalMarDP (G)	1.21	0.44
Groww NifTotalMarDP (I)	1.21	0.44
Mirae NifTotMarket (G)	0.16	0.44
Mirae NifTotMarket (I)	0.16	0.44
Mirae NifTotMarketDP (G)	0.16	0.44
Mirae NifTotMarketDP (I)	0.16	0.44
Bandhan ELSSTaxSav (G)	28.84	0.44
Bandhan ELSSTaxSav (I)	28.84	0.44
Bandhan ELSSTaxSav (IDCWR)	28.84	0.44
Bandhan ELSSTaxSavDP (G)	28.84	0.44
Bandhan ELSSTaxSavDP (I)	28.84	0.44
BandhanNifTotalMar (G)	0.16	0.44
BandhanNifTotalMarDP (G)	0.16	0.44
Kotak DebtHybrid DP (G)	12.84	0.43
Kotak DebtHybrid DP (I-Mont)	12.84	0.43
Kotak DebtHybrid RP (G)	12.84	0.43
Kotak DebtHybrid RP (I-Mont)	12.84	0.43
Kotak DebtHybrid RP (MIDCWR)	12.84	0.43
SBI Arbitrage Oppr (G)	137.27	0.43
SBI Arbitrage Oppr (I)	137.27	0.43
SBI Arbitrage Oppr (IDCWR)	137.27	0.43
SBI Arbitrage OpprDP (G)	137.27	0.43
SBI Arbitrage OpprDP (I)	137.27	0.43
SBI Arbitrage OpprDP (IDCWR)	137.27	0.43
UTI ChildrenHybrid (G)	18.98	0.43
UTI ChildrenHybrid (I)	18.98	0.43
UTI ChildrenHybridDP (G)	18.98	0.43
UTI ChildrenHybridDP (I)	18.98	0.43
WhiteOakELSSTaxSav (G)	1.46	0.43
WhiteOakELSSTaxSav (I)	1.46	0.43
WhiteOakELSSTaxSavDP (G)	1.46	0.43
WhiteOakELSSTaxSavDP (I)	1.46	0.43
AdityaBSL ESGIntSt (G)	2.55	0.42
AdityaBSL ESGIntSt (I)	2.55	0.42
AdityaBSL ESGIntStDP (G)	2.55	0.42
AdityaBSL ESGIntStDP (I)	2.55	0.42
AdityaBSL Arbit (G)	58.73	0.41
AdityaBSL Arbit (I)	58.73	0.41
AdityaBSL Arbit (IDCWR)	58.73	0.41
AdityaBSL Arbit DP (G)	58.73	0.41
AdityaBSL Arbit DP (I)	58.73	0.41
AdityaBSL Arbit DP (IDCWR)	58.73	0.41
Nippon Vision (B)	21.63	0.40
Nippon Vision (G)	21.63	0.40
Nippon Vision (I)	21.63	0.40
Nippon Vision (I-Rein)	21.63	0.40
Nippon Vision DP (B)	21.63	0.40
Nippon Vision DP (G)	21.63	0.40
Nippon Vision DP (I)	21.63	0.40
BOI Balan Adv (G)	0.50	0.38
BOI Balan Adv (I)	0.50	0.38
BOI Balan Adv (I-Rein)	0.50	0.38
BOI Balan Adv DP (G)	0.50	0.38
BOI Balan Adv DP (I)	0.50	0.38
AdityaBSL Bal Adv (G)	27.18	0.37
AdityaBSL Bal Adv (I)	27.18	0.37
AdityaBSL Bal Adv (IDCWR)	27.18	0.37
AdityaBSL BalAdv DP (G)	27.18	0.37
AdityaBSL BalAdv DP (I)	27.18	0.37
AdityaBSL BalAdv DP (IDCWR)	27.18	0.37
InvescoInd ArbitraDP (B-Annu)	72.74	0.37
InvescoInd ArbitraDP (G)	72.74	0.37
InvescoInd ArbitraDP (I)	72.74	0.37
InvescoInd Arbitrage (G)	72.74	0.37
InvescoInd Arbitrage (I)	72.74	0.37
InvescoInd Arbitrage (I-Rein)	72.74	0.37
Bandhan EqSavings (AIDCWR)	0.98	0.36
Bandhan EqSavings (G)	0.98	0.36
Bandhan EqSavings (I-Annu)	0.98	0.36
Bandhan EqSavings (I-Mont)	0.98	0.36
Bandhan EqSavings (I-Quar)	0.98	0.36
Bandhan EqSavings (MIDCWR)	0.98	0.36
Bandhan EqSavings DP (AIDCWR)	0.98	0.36
Bandhan EqSavings DP (G)	0.98	0.36
Bandhan EqSavings DP (I-Annu)	0.98	0.36
Bandhan EqSavings DP (I-Mont)	0.98	0.36
Bandhan EqSavings DP (I-Quar)	0.98	0.36
Edelweiss EqSav (B)	2.10	0.36
Edelweiss EqSav (G)	2.10	0.36
Edelweiss EqSav (I)	2.10	0.36
Edelweiss EqSav (I-Mont)	2.10	0.36
Edelweiss EqSav DP (B)	2.10	0.36
Edelweiss EqSav DP (G)	2.10	0.36
Edelweiss EqSav DP (I)	2.10	0.36
Edelweiss EqSav DP (I-Mont)	2.10	0.36
Union Balanced Advan (G)	4.69	0.34
Union Balanced Advan (I)	4.69	0.34
Union Balanced AdvDP (G)	4.69	0.34
Union Balanced AdvDP (I)	4.69	0.34
ParagPar Arbitrage (G)	4.31	0.33
ParagPar ArbitrageDP (G)	4.31	0.33
AdityaBSL Reti 40s (G)	0.35	0.32
AdityaBSL Reti 40s (I)	0.35	0.32
AdityaBSL Reti 40sDP (G)	0.35	0.32
AdityaBSL Reti 40sDP (I)	0.35	0.32
EdelNifLar&Midcap (G)	0.76	0.32
EdelNifLar&Midcap (I)	0.76	0.32
EdelNifLar&MidcapDP (G)	0.76	0.32
EdelNifLar&MidcapDP (I)	0.76	0.32
HDFC Nif500MulticaDP (G)	1.30	0.32
HDFC Nif500Multicap (G)	1.30	0.32
HDFC NifLarMC250 (G)	1.41	0.32
HDFC NifLarMC250DP (G)	1.41	0.32
Mirae NifLarMid250 (G)	0.05	0.32
Mirae NifLarMid250 (I)	0.05	0.32
Mirae NifLarMid250DP (G)	0.05	0.32
Mirae NifLarMid250DP (I)	0.05	0.32
ICICI NifLarMid250 (G)	0.60	0.32
ICICI NifLarMid250 (I)	0.60	0.32
ICICI NifLarMid250DP (G)	0.60	0.32
ICICI NifLarMid250DP (I)	0.60	0.32
Zerodha ELSSTaxSavDP (G)	0.56	0.32
Zerodha NifLarMid DP (G)	2.60	0.32
Mirae Nif500MultiCap (G)	0.14	0.32
BandhanSterlingVal (G)	28.84	0.31
BandhanSterlingVal (I)	28.84	0.31
BandhanSterlingVal (IDCWR)	28.84	0.31
BandhanSterlingValDP (G)	28.84	0.31
BandhanSterlingValDP (I)	28.84	0.31
Navi Nif500MulticaDP (G)	0.07	0.31
Navi Nif500Multicap (G)	0.07	0.31
NJ Arbitrage (G)	0.84	0.29
NJ Arbitrage DP (G)	0.84	0.29
Kotak BalanceAdvan (G)	46.12	0.28
Kotak BalanceAdvan (I)	46.12	0.28
Kotak BalanceAdvanDP (G)	46.12	0.28
Kotak BalanceAdvanDP (I)	46.12	0.28
WhiteOak MultiCap (G)	4.41	0.28
WhiteOak MultiCap DP (G)	4.41	0.28
EdelweissLar&MiCap (G)	9.62	0.27
EdelweissLar&MiCap (I)	9.62	0.27
EdelweissLar&MiCap (I-Rein)	9.62	0.27
EdelweissLar&MiCapDP (G)	9.62	0.27
EdelweissLar&MiCapDP (I)	9.62	0.27
Kotak Equity Savings (G)	21.89	0.27
Kotak Equity Savings (I-Mont)	21.89	0.27
Kotak Equity Savings (MIDCWR)	21.89	0.27
Kotak EquitySavingDP (G)	21.89	0.27
Kotak EquitySavingDP (I-Mont)	21.89	0.27
WhiteOak MulAsAllo (G)	4.34	0.26
WhiteOak MulAsAlloDP (G)	4.34	0.26
HDFC BalanceAdva DP (G)	239.02	0.25
HDFC BalanceAdva DP (I)	239.02	0.25
HDFC BalanceAdva DP (IDCWR)	239.02	0.25
HDFC BalanceAdva RP (G)	239.02	0.25
HDFC BalanceAdva RP (I)	239.02	0.25
HDFC BalanceAdva RP (IDCWR)	239.02	0.25
Union EquSavings (G)	0.35	0.25
Union EquSavings (I)	0.35	0.25
Union EquSavings DP (G)	0.35	0.25
Union EquSavings DP (I)	0.35	0.25
Aditya MultiAssAll (G)	9.16	0.24
Aditya MultiAssAll (I)	9.16	0.24
Aditya MultiAssAllDP (G)	9.16	0.24
Aditya MultiAssAllDP (I)	9.16	0.24
DSP Arbitrage (G)	14.01	0.23
DSP Arbitrage (I)	14.01	0.23
DSP Arbitrage (I-Mont)	14.01	0.23
DSP Arbitrage - DP (G)	14.01	0.23
DSP Arbitrage - DP (I)	14.01	0.23
DSP Arbitrage - DP (I-Mont)	14.01	0.23
InvescoMulAsseAllo (G)	0.76	0.22
InvescoMulAsseAllo (I)	0.76	0.22
InvescoMulAsseAlloDP (G)	0.76	0.22
InvescoMulAsseAlloDP (I)	0.76	0.22
ICICI Pru BharatCoDP (G)	6.50	0.22
ICICI Pru BharatCoDP (I)	6.50	0.22
ICICI Pru BharatCon (G)	6.50	0.22
ICICI Pru BharatCon (I)	6.50	0.22
CanaraRob Emerg Eq (G)	48.34	0.21
CanaraRob Emerg Eq (I)	48.34	0.21
CanaraRob EmergEq DP (G)	48.34	0.21
CanaraRob EmergEq DP (I)	48.34	0.21
Edelweiss ArbitragDP (G)	28.92	0.21
Edelweiss ArbitragDP (I)	28.92	0.21
Edelweiss ArbitragDP (I-Mont)	28.92	0.21
Edelweiss Arbitrage (B)	28.92	0.21
Edelweiss Arbitrage (G)	28.92	0.21
Edelweiss Arbitrage (I)	28.92	0.21
Edelweiss Arbitrage (I-Mont)	28.92	0.21
Edelweiss Arbitrage (I-Rein)	28.92	0.21
Nippon Eq Hybrid (G)	7.68	0.21
Nippon Eq Hybrid (I)	7.68	0.21
Nippon Eq Hybrid (I-Mont)	7.68	0.21
Nippon Eq Hybrid (I-Quar)	7.68	0.21
Nippon Eq Hybrid (I-Rein)	7.68	0.21
Nippon Eq Hybrid (M)	7.68	0.21
Nippon Eq Hybrid (Q)	7.68	0.21
Nippon Eq HybridDP (G)	7.68	0.21
Nippon Eq HybridDP (I)	7.68	0.21
Nippon Eq HybridDP (I-Mont)	7.68	0.21
Nippon Eq HybridDP (I-Quar)	7.68	0.21
Nippon EqHyb SP1 (G)	7.68	0.21
Nippon EqHyb SP1 (I)	7.68	0.21
Nippon EqHyb SP1 (I-Mont)	7.68	0.21
Nippon EqHyb SP1 (I-Quar)	7.68	0.21
Nippon EqHyb SP1 DP (G)	7.68	0.21
Nippon EqHyb SP1 DP (I)	7.68	0.21
Nippon EqHyb SP1 DP (I-Mont)	7.68	0.21
Nippon EqHyb SP1 DP (I-Quar)	7.68	0.21
ICICI PruMultAsset (G)	112.49	0.20
ICICI PruMultAsset (I)	112.49	0.20
ICICI PruMultAsset (IDCWR)	112.49	0.20
ICICI PruMultAssetDP (G)	112.49	0.20
ICICI PruMultAssetDP (I)	112.49	0.20
ICICI PruMultAssetDP (IDCWR)	112.49	0.20
Nippon Nif500EqlWeDP (G)	0.72	0.19
Nippon Nif500EqlWeDP (I)	0.72	0.19
Nippon Nif500EqlWeig (G)	0.72	0.19
Nippon Nif500EqlWeig (I)	0.72	0.19
Mirae MulAsseAllco (G)	3.45	0.19
Mirae MulAsseAllco (I)	3.45	0.19
Mirae MulAsseAllcoDP (G)	3.45	0.19
Mirae MulAsseAllcoDP (I)	3.45	0.19
Nippon Arbitrage (G)	24.51	0.18
Nippon Arbitrage (I)	24.51	0.18
Nippon Arbitrage (I-Mont)	24.51	0.18
Nippon Arbitrage (I-Rein)	24.51	0.18
Nippon Arbitrage (M)	24.51	0.18
Nippon ArbitrageDP (G)	24.51	0.18
Nippon ArbitrageDP (I)	24.51	0.18
Nippon ArbitrageDP (I-Mont)	24.51	0.18
AdityaBSL Reti 50s (G)	0.05	0.18
AdityaBSL Reti 50s (I)	0.05	0.18
AdityaBSL Reti 50sDP (G)	0.05	0.18
AdityaBSL Reti 50sDP (I)	0.05	0.18
Kotak Eq Arbitrage (G)	100.21	0.17
Kotak Eq Arbitrage (I)	100.21	0.17
Kotak Eq Arbitrage (IDCWR)	100.21	0.17
Kotak EquityArbit DP (G)	100.21	0.17
Kotak EquityArbit DP (I)	100.21	0.17
ICICI Pru BalanceAdv (G)	99.33	0.16
ICICI Pru BalanceAdv (I)	99.33	0.16
ICICI Pru BalanceAdv (I-Mont)	99.33	0.16
ICICI Pru BalanceAdv (IDCWR)	99.33	0.16
ICICI Pru BalanceAdv (MIDCWR)	99.33	0.16
ICICI Pru BalnAdv DP (G)	99.33	0.16
ICICI Pru BalnAdv DP (I)	99.33	0.16
ICICI Pru BalnAdv DP (I-Mont)	99.33	0.16
ICICI Pru BalnAdv DP (IDCWR)	99.33	0.16
ICICI Pru BalnAdv DP (MIDCWR)	99.33	0.16
Bandhan Arbitrage (AIDCWR)	11.72	0.15
Bandhan Arbitrage (G)	11.72	0.15
Bandhan Arbitrage (I-Annu)	11.72	0.15
Bandhan Arbitrage (I-Mont)	11.72	0.15
Bandhan Arbitrage (MIDCWR)	11.72	0.15
Bandhan Arbitrage DP (AIDCWR)	11.72	0.15
Bandhan Arbitrage DP (G)	11.72	0.15
Bandhan Arbitrage DP (I-Annu)	11.72	0.15
Bandhan Arbitrage DP (I-Mont)	11.72	0.15
MahiManu Arbitrag (G)	0.14	0.14
MahiManu Arbitrag (I)	0.14	0.14
MahiManu ArbitragDP (G)	0.14	0.14
MahiManu ArbitragDP (I)	0.14	0.14
ICICI Pru Bluechip (G)	84.99	0.13
ICICI Pru Bluechip (I)	84.99	0.13
ICICI Pru Bluechip (IDCWR)	84.99	0.13
ICICI Pru BluechipDP (G)	84.99	0.13
ICICI Pru BluechipDP (I)	84.99	0.13
ICICI Pru BluechipDP (IDCWR)	84.99	0.13
Nippon HybBond (G)	0.85	0.10
Nippon HybBond (I-Mont)	0.85	0.10
Nippon HybBond (I-Quar)	0.85	0.10
Nippon HybBond (M)	0.85	0.10
Nippon HybBond (Q)	0.85	0.10
Nippon HybBond DP (G)	0.85	0.10
Nippon HybBond DP (I-Mont)	0.85	0.10
Nippon HybBond DP (I-Quar)	0.85	0.10
Mirae Aggr Hybrid (G)	7.93	0.09
Mirae Aggr Hybrid (I)	7.93	0.09
Mirae Aggr Hybrid (I-Rein)	7.93	0.09
Mirae Aggr Hybrid DP (G)	7.93	0.09
Mirae Aggr Hybrid DP (I)	7.93	0.09
AdityaBSL EqSav (G)	0.48	0.08
AdityaBSL EqSav (I)	0.48	0.08
AdityaBSL EqSav (IDCWR)	0.48	0.08
AdityaBSL EqSav DP (G)	0.48	0.08
AdityaBSL EqSav DP (I)	0.48	0.08
AdityaBSL EqSav DP (IDCWR)	0.48	0.08
BarBnp Arbit (A)	0.42	0.04
BarBnp Arbit (G)	0.42	0.04
BarBnp Arbit (I-Mont)	0.42	0.04
BarBnp Arbit (I-Quar)	0.42	0.04
BarBnp Arbit DP (A)	0.42	0.04
BarBnp Arbit DP (G)	0.42	0.04
BarBnp Arbit DP (I-Mont)	0.42	0.04
BarBnp Arbit DP (I-Quar)	0.42	0.04
Tata Arbitrage (G)	4.71	0.04
Tata Arbitrage (I-Mont)	4.71	0.04
Tata Arbitrage (M)	4.71	0.04
Tata Arbitrage DP (G)	4.71	0.04
Tata Arbitrage DP (I-Mont)	4.71	0.04
Tata Arbitrage DP (M)	4.71	0.04
SBI Eq SavingsFund (G)	1.97	0.03
SBI Eq SavingsFund (I-Mont)	1.97	0.03
SBI Eq SavingsFund (I-Quar)	1.97	0.03
SBI Eq SavingsFund (MIDCWR)	1.97	0.03
SBI Eq SavingsFund (QIDCWR)	1.97	0.03
SBI Eq SavingsFundDP (G)	1.97	0.03
SBI Eq SavingsFundDP (I-Mont)	1.97	0.03
SBI Eq SavingsFundDP (I-Quar)	1.97	0.03
SBI Eq SavingsFundDP (MIDCWR)	1.97	0.03
SBI Eq SavingsFundDP (QIDCWR)	1.97	0.03
Edelw MultiAssetAl (G)	0.33	0.02
Edelw MultiAssetAl (I)	0.33	0.02
Edelw MultiAssetAlDP (G)	0.33	0.02
Edelw MultiAssetAlDP (I)	0.33	0.02
InvescIndEqSavings (G)	0.09	0.02
InvescIndEqSavings (I)	0.09	0.02
InvescoIndEqSavingDP (G)	0.09	0.02
InvescoIndEqSavingDP (I)	0.09	0.02
Kotak MulAssetAllo (G)	0.47	0.01
Kotak MulAssetAllo (I)	0.47	0.01
Kotak MulAssetAlloDP (G)	0.47	0.01
Kotak MulAssetAlloDP (I)	0.47	0.01
NJ BalancedAdvantaDP (G)	0.38	0.01
NJ BalancedAdvantaDP (I)	0.38	0.01
NJ BalancedAdvantage (G)	0.38	0.01
NJ BalancedAdvantage (I)	0.38	0.01
UTI MultiAssetAllo (G)	0.66	0.01
UTI MultiAssetAllo (I)	0.66	0.01
UTI MultiAssetAllo (I-Rein)	0.66	0.01
UTI MultiAssetAlloDP (G)	0.66	0.01
UTI MultiAssetAlloDP (I)	0.66	0.01
MiraeAs LargeCap (G)	0.20	0.00
MiraeAs LargeCap (I)	0.20	0.00
MiraeAs LargeCap DP (G)	0.20	0.00
MiraeAs LargeCap DP (I)	0.20	0.00
Sundaram MulAstAll (G)	0.09	0.00
Sundaram MulAstAll (I)	0.09	0.00
Sundaram MulAstAll (I-Rein)	0.09	0.00
Sundaram MulAstAllDP (G)	0.09	0.00
Sundaram MulAstAllDP (I)	0.09	0.00
Sundaram MulAstAllDP (I-Rein)	0.09	0.00

Peers

Other companies within the same industry or sector that are comparable to Cipla Ltd

Company	Price	Price (% change)	pe(x)	EV/EBITDA(x)	ROE(%)	ROCE(%)
Albert David Ltd	825.75	-1.80	11.65	884.42	1321.50	1.39
Lotus Eye Hospital and Institute Ltd	81.22	-0.17	338.42	3222.70	14.01	0.62
Vaishali Pharma Ltd	13.47	-1.82	449.00	1661.10	2.76	0.00
Astec Lifesciences Ltd	685.90	-1.03	0.00	3038.73	-687.11	0.00

Company Info

1935 - The Company was Incorporated at Mumbai. 1979 - The Company acquired a plot of land from MIDC at Patalganga in Kulaba district of Maharashtra State about 55 kms. from Mumbai. - 18,773 Bonus equity shares issued in proportion 1:1. 1984 - The name of the Company was changed from The Chemical Industrial & Pharmaceutical Laboratories Ltd., to the present one with effect from 20th July. 1985 - 37,546 Bonus equity shares issued in proportion 1:1 in January 1986. 1986 - During August, the Company obtained the consent of the Controller of Capital Issues to issue 3,00,000-15% secured non-convertible redeemable debentures of Rs 100 each aggregating to Rs 300 lakhs by private placement. The entire issue was subscribed by public financial institutions. They are redeemable at a premium of 5% during 1993-94. 1987 - The Company launched several new products viz., Asthalin and Beclate Rotahalers/Rotacaps-dry powder inhalation devices for asthma, presolar capsules - the first synergistic combination of a beta blocker and a sustained release calcium channel blocker for hypertension, Restyl tablets - the first anxiolytic-cum-anti depressant, Theo-Asthalin SR tablets - the first sustained release combination of two widely used bronchodilators, bromolin dry syrup and bromolin-250 capsules - antibiotic-cum-mucolytic agents, dilgard tablets - a new calcium channel blocker for angina, ibugesic plus suspension - a non steroidal anti inflammatory and anti-pyretic analgesic for paediatric use. - 75,092 Bonus equity shares issued in proportion 1:1. 1989 - The latest drugs introduced during the year were (i) Ciplox tablets (250 & 500 mg.) and infusion (50 and 100 ml.), a broad spectrum fluoroquinolone antibacterial for severe infections, (ii) cefadur capsules (250 & 500 mg.) and syrup (30 ml.), a cephalosporin antibiotic, (iii) Ulcimax tablets (20 & 40 mg.), a long-acting H2 antogonist for peptic ulcers and (iv) theoped syrup, a paediatric bronchodilator. Sales in the Company's `PROTEC' division exceeded Rs 5.50 crores for the second year of its operations. 1990 - The Company launched several new products viz., Aerocort inhaler, an anti-inflammatory bronchodilator, Norflox eye/ear drops - a broad spectrum fluoroquinolone antibacterial, Pirox Gel - the first topical piroxicam formulation in the country, Cofenac tablets - an anti-infammatory analgesic, Kinetal 400 tablets - a multi-functional drug for vascular insufficiency, Novaclox Ped tablets - a dispensible combination antibiotics, Terfed tablets and Suspension - a new non-sedative antihistamine, Depryl tablets - a broad - spectrum antidepressant, Asthalin Respirator Solution - a bronchodilator for pressure ventilation in acute asthma. The Company spent Rs 4.22 crores on R&D and Rs 8.09 crores on modernisation and expansion of plant and machinery. 1991 - The new products launched during the year were lomac capsules - a new antiulcerant, cromal inhaler - the first optimum - dose inhalant prophylactic for asthma, ciplox eye drops - the total bactericide for ocular infections, etosid injection - the first injection of indigenously manufactured etoposide for cancer therapy, proflox tablets - a key fluoroquinolone antibiotic and vasopril tablets - an ACE inhibitor for long-term management of hypertension. The research and development win g of the Company developed during the y ar felodipine - the latest anti-hypertensive drug, selegilinje - a new bulk drug for the treatment of Parkinson's disease, cetirizine HCI - an anti-histamine drug and nimodipine - a cerebral vasodilator. Work on the anti-AIDS drug AZT reached an advance stage of development. The research and development wing also developed anthelmintics oxfendazole and oribendazole, two veterinary products for exports. - In May, 6,000 equity shares offered at par as rights to pref. shareholders in prop. 1:1. Only 5,216 shares taken up. Allotment of 5 equity shares pending. 1992 - Some of the new products introduded were Zidovir capsules an antiretroviral for HIV injection, Cipril tablets for hypertension, Optipres eyedrops for glaucoma patients, Felogard for hypertension, Nodine, a non-narcotic analgesic, etc. - In compliance with the provisions of the Companies Act, 1956, the Company redeemed its 6,000 preference shares of Rs 100 each as on 30th September. - Pref. shares redeemed on 30.9.92, 1,55,395 bonus equity shares issued in prop. 1:1. 1994 - New products introduced were - Beclate Aquanase - a major advancement in allergic rhinitis; Cytoplatin - an anticancer agent; Forcan - an antifungal; Imusporin - an immunosuppressant in organ transplantation; Kelfer - an iron chelator for thalassaemia; Lanzol - a proton pump inhibitor; Nuzac - an antidepresant; Odirox - a macrolide antibiotic and Qinarsol - for chloroquin-resistant malaria. - Equity shares subdivided 155,39,500. Equity shares allotted shares issued in prop. 1:5. - The Company's manufacturing unit at Kurkumbh, which was commissioned in April. The second phase of expansion of the location was under way and this was to provide specialised facilities for the manufacture of new chemical entites. 1995 - Effective 4th July, the Company was forced to declare a lock-out as some of the workmen at the Vikhroli Unit resorted to indiscipline. The Company initiated steps to mitigate the impact it could have on production. - New products introduced were - Acivir - antivirus herpes, Anlopres - antivirus herpes, Anlopres - Calcium channel blocker in hypertension and angina, Anlopres AT - a combination antihypertensive, Budecort 200 - a higher strength corticosterord in bronchial asthma, Budenase AQ - a corticosteroid protection in allergic rhinitis, cronal - a nast cell stabiliser in allerg ic conjunctivitis, cytonid - a antiandrogenic agent in prostate cancer, Norflox - an antidiarrhoeal in diarrhoea of mixed origin, optipes S - betaxocol eye drops, profenac - anti-inflammatory eye drops, Terfed D - a combination antihistamine and decongestant, Trivedon 20 - used in ischaemic heart disease. - A new chemical entity, candocuronium iodide - a neuromuscular blocking agent was manufactured, other new bulk drugs manufactured include: Acyelovir - antiviral, Amlodipine besylate - antihypertensive and antianginal, Febantel - veterinary anthelmintic, Flutamide - antiandrogen, Flutivcasone dipropionate - a corticosteriod, zenprolide acetate - GMRH analogue. - 13,43,383 rights equity shares issued (Prem. Rs. 60/-). However, the Rights issue was underwritten. 1996 - The products launched during the year were Azee (azithromycin capsules) - a new macrolide antibiotic; Budecort (budesonide rotacaps) - dry powder inhaled corticosteriod therapy for asthama; Cipril H (lisionopril hydrochlorothiazide tablets) - a combination antihypertensive; Ciplox TZ (ciprofloxacin tinidazole tablets) - the combination bactericide for aerobic/anaerobic infections; Entosec (secnidazole tablets) - single dose therapy for amoebiasis/trichomoniasis; Fincar (fin asterid tablets) - for beign prostatic hyperphasia; Metolar (metaprolol injection) - beta-blocker protection for post myocardial infarction & Zoflut (fluticasone propionate cream) - a new topical corticosteroid. 1997 - The products introduced during the year were; Alerid-D - an antihistamine and decongestant for cold and congestion, Amlopres L - a tablet for hypertension, Apuatears - an eye drop, Azee 1000 - a single dose for STDs, Budecort Respules - neubulised corticosteroid therapy for asthma, Dilgard XL - a diltiazem, Glumet - tablet for obese diabetics, Glygard - tablet for abese diabetics, Glygard - tablet for diabetics, Ipranase AQ (ipratropium nasal spray) - an anticholinergic therapy for rhinorrhoea, Ocutim (an eye drop) - a glaucoma therapy in acquafilm formulation, Osteifos 10 - tablet for osteoporosis, Prolyte Fizz - a rehydration effervescent tablet, Pylokit - an advanced H pylori kit, Risnia - an a typical antipsychotic, Stavir - an antiretroviral for AIDS, Synclar 250 - an advanced macrolide antibiotic, Theoday - a tablet for asthma, Zoflut Lotion - a topical corticosteroid. - The bulk division of the Company had taken up, the development and manufacture of some new drugs viz., budesonide - antiasthmatic corticosteroid, carvedilol - alpha/beta blocker, ebastine - antihistamine, formoterol fumarate - antiasthmatic, meloxicam - for osteroarthritis and rheumatoid arthritis, moclobemide - antidepressant, mometasome furoate - antiflammatory corticosteroid, pantorazole sodium sesquihydrate - antiulcerant, sildenafil citrate - erectile dysfuncion. - The Company has developed a form-fill-seal equipment for the first time in India, for the manufacture of sterile formulations. This was commissioned at Vikhroli factory and is working to its full capacity. Additional capacities were set up at Kurkumbh for manufacture of effervescent tablets, soft gel capsules and injectable formulations. The Company has incurred a capital expenditure of Rs 22.73 crores during the year. - The Rs. 3.69 billion Cipla has finalised a marketing joint venture with Australia-based Genpharm, as part of its strategy to consolidate its global presence. - Pharmaceutical major Cipla Ltd grabbed the attention of traders at the Mumbai Stock Exchange (BSE) on December 26 after a large block of about 75,000 shares of the company valued at little over Rs 5 crore changed hands. - The Rs.369-crore Cipla Ltd has entered into a souring arrangement with US-based Geneva Pharmaceuticals, a wholly-owned subsidiary of Swiss multinational Ciba, for a range of generic drugs. 1998 - Pharmaceutical companies, Cipla and Wockhardt, will be seeking shareholders' approval for a proposed share buyback at their forthcoming annual general meetings. - In a notice to shareholders, Cipla has proposed introduction of a new article, Article 64 A, in the Articles of Association of the company to enable the company to purchase and re-issue any of its shares. The existing Article 64 prohibits the company from buying its own shares and applying any of its funds for the purchase of any shares of the company. - The share price of Cipla Ltd, the leading pharmaceutical company scaled a new peak of Rs 920 on the Mumbai Stock Exchange on Sept 29 following fresh bull charge. The scrip opened at Rs 900 and shot up to Rs 920 during mid-session and closed at Rs 884 following hectic trading activities. 1999 - Ranbaxy and Cipla, have entered into a strategic partnership to jointly market a select basket of drugs. The alliance will bring forth their strengths in the strongly emerging cardiovascular and perennial anti-infectives market. - As a first step, the two molecules being jointly launched are Carvedilol, a new generation anti-hypertensive and Cefpodoxime Proxetil, an advanced third generation oral cephalosporin. - The Rs 541-crore Cipla has forged a strategic alliance with the UK-based Neolab for marketing a range of generic drugs. The alliance, while improving the Indian company's access to the multi-billion dollar European market for off-patent drugs, will also see Cipla rake in royalties on sales of products covered under the deal. - Cipla's latest tie-up in the international market comes close on the heels of the company's strategic partnership with the Delhi-based Ranbaxy Laboratories for a select basket of drugs. - The Mumbai-based Cipla is working on abbreviated new drug applications (ANDAs) in collaboration with international generics firms for a range of products like flutamide (for advanced prostatic cancer) and felodipine, for hypertension. 2000 - Cipla and Ranbaxy Laboratories have expanded an existing partnership by adding one more new drug in their co-marketing arrangement. 2001 - Cipla has tied up with the US-based Zenith Goldline and United Research Labs for marketing Flutamide, an oncology drug, and Felodipine, a cardiovascular drug, in the US and European markets. - Domestic pharma giant, Cipla, has despatched its first free consignment of anti-AIDS drug, `Nevirapine', to the Indian Government for distribution under the public health system. 2002 -Reduces the price of its anti-HIV medicines such as Stavir, Lamivir, Nevimune, Dinex, Indivan, Triomune, Efavir and Duovir -Revokes interim dividend of Rs 5 per share on face value of Rs 10 per share for FY 2001-02 -Company included in the World Health Organisation's (WHO's) list of HIV-related products -Chairman and Managing Director YK Hamied was presented with the lifetime contribution award for excellence in the pharmaceutical industry by Union chemicals & fertilisers minister SS Dhindsa -Resigns from Indian Pharmaceutical Alliance (IPA) over Patents Bill 2003 -Applies its requisiton for Abbreviated New Drug Application (ANDA) with US regulators for a post-menopausal drug -National Pharmaceutical Pricing Authority (NPPA) issues notices to Cipla along with Ranbaxy for overcharging the products -Completes research studies on three Anti-HIV Drugs -Registers Stavudine, Nevirapine, other anti-AIDS products in South Africa 2004 -Signs long-term agreement with Morton Grove Pharmaceuticals Inc (MGP) of Illinois, US, for product launch in the US market -Avesthagen forges alliance with Cipla -Cipla has joined a global initiative taken up by the Vatican in collaboration with global generic pharmaceutical manufacturers and the International Federation of Catholic Pharmacies and Academics to float CUMVIVIUM -Cipla join hands with Pentech Pharma -Indian pharma major Cipla, a pioneer in supplying cheap generic AIDS drugs in Africa, has patented its three-in-one combination tablet Triomune in South Africa -Cipla introduces 'Duova' to fight chronic obstructive pulmonary disease - Launches a new treatment for arthritis in technical collaboration with California-based Cymbiotics Inc. 2005 -Set-up state-of-the-art facility for manufacture of formulations at Baddi, Himachal Pradesh. -Cipla introduces new drug for arthritis -Cipla to sign deal with Akorn Inc for anti-infective drug -Cipla to produce generic versin of bird-flu drug -Cipla to join hands with Roche - Cipla introduces new drug for arthritis 2006 - Cipla receives Scrip Award for Best Company in an Emerging Market -Safe & steady strategy gives Cipla lead over Ranbaxy -Cipla sets up subsidiary in Dubai -Cipla ties up with Ivax for US market -Cipla receives tentative US FDA approval for AIDS drugs -Cipla receives Pharma Excellence Award for 'Sustained Growth' -Cipla has given the Bonus in the Ratio of 3:2 2007 - Cipla unveils anti-malaria global initiative. -Set-up state-of-the-art facility for manufacture of formulations at Sikkim. -Award for the Forbes Asia's Best Under A Billion List! -Cipla's drug included in US anti-AIDS initiative -Anti-AIDS blitz sees pharma firms locked in ugly battle -Cipla launches emergency contraception tablet -Cipla launches estradiol transdermal spray in India -Cipla launches cut-price zanamivir in India -Cipla receives International Trade Awards 2006 for outstanding exporter of the year (Pharmaceuticals, Healthcare and Life Sciences category) 2008 -Cipla Ltd has appointed Mr. Pankaj Patel as a Director in casual vacancy with effect from March 05, 2008. -Cipla launched Roche's generic version of anti-infection drug 2009 -Cipla wins Erlotinib case against Roche -Pharmaceuticals Export Promotion Council Awards -Cipla launches drug to treat Swine flu virus -Cipla wins patent fight against Gilead Sciences 2010 -Cipla Ltd acquired Meditab Specialities Pvt. Ltd. ("Meditab") for an aggregate consideration of Rs. 133.35 crores. -Cipla Medpro has signed a deal with Biomab, a division of Chinese company Desano Pharma. -Cipla sold the marketing rights of i-Pill to Piramal Healthcare for Rs 95 crore in cash. -Cipla has tied up with the Manipal Group-promoted 'Stempeutics Research'. - Drug Maker Cipla has launched the generic Version of Pirfenidone, used to treat Idiopathic Pulmonary Fibrosis, a progressive Lung disease.India is the 2nd market to have this drug after Japan. 2011 -Cipla Cancer Palliative Care Centre launched 24 hour helpline to offer counselling to ensure more people use of the free services available. 2012 -Cipla India's second largest drug firm, has agreed to acquire South African Drugmaker Cipla Medpro with 51% stake amounts to $220 Million. -Cipla bags tentative approval for HIV treatment tablets -Drug giant Cipla Ltd has announced price reduction on 3 major anti-cancer drugs including Erlotinib (ERLOCIP), Docetaxel (DOCETAX) and Capecitabine (CAPEGARD). -Cipla bags award in the Field of Export of Pharmaceuticals during the year conferred the Highest Award 'Platinum'. 2013 -Cipla announces an offer to the shareholders of Medpro for 100% acquisition -Cipla launches the first Biosimilar of Etanercept in India 2014 -Cipla wins USD 188.95 million of Global Fund ARV Tender -MMV announces collaborations with Cipla and Strides -Cipla licenses rights for innovative product - Cipla, S&D Pharma collaborate to enter Czech Republic and Slovakia -Cipla collaborates with Hetero to launch its second biosimilar drug `Darbepoetin alfa' -Cipla invests in Chase Pharmaceuticals to support Alzheimer's disease drug development -The Registered Office of the Company has been shifted from Mumbai Central, Mumbai - 400008 to Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400 013, Tel: 022-24826000 / 022-2482695,1Fax: 022-24826893. 2015 -Cipla Ltd has entered into an agreement with partner, Biopharm SPA, to form a joint venture (JV) company in Algeria. -Cipla Ltd has launched the generic drug Sofosbuvir in brand name Hepcvir -Cipla Ltd has inked an agreement with Serum Institute of India Ltd. (SII) to market flu vaccine Nasovac-S. -Cipla Ltd has entered into a definitive agreement with Biopharma SPA for establishing a joint venture company in Algeria. -Cipla Ltd has launched a anti-ageing skin care product Cutisera&trade. developed by Stempeutics. -Cipla has launched generic tablets used for treating of hepatitis C under the brand name Hepcvir-L 2016 -Cipla gets CCI approval for investment by FIL Capital -Cipla completes acquisition of generic businesses in US -Cipla gets USFDA nod for generic anti-depressant drug -Cipla gets EIR from US FDA for Indore facility -Cipla gets USFDA final nod for Hepatitis B treatment drug -Cipla receives final approval for generic Baracluder tablets 2017 - Cipla Ltd "Authorised Key Managerial Personnel to determine materiality of events/information". - Cipla launches Hepatitis B vaccine in India - Cipla receives approval for Lamivudine Tablets - Cipla USA signs licensing agreement with MEDRx - Cipla gets WHO nod to sell TB preventing drug in HIV patients - Cipla launches Q-TIB globally - Cipla launches Rectal Artesunate Suppositories for severe malaria in young children - Cipla Receives Final Approval for Generic Epzicomr Tablets - Cipla launches Hepatitis B vaccine in India 2018 -Cipla teams up with Roche Pharma to sell cancer therapy drugs in India. -Cipla partners with Eli Lilly to market diabetes drug Basaglar in India. -Cipla receives final approval for generic version of Valganciclovir Tablets 450mg from the United States Food and Drug Administration (USFDA). -Cipla bags DMA Asia Echo Award (Silver) for Best Digital Destination and Leader Certificate in Pharma & Healthcare category. 2019 -Cipla to launch cinacalcet hydrochloride tablets in US market. -Cipla introduces Niveoli, India's first HFA inhaler for airway diseases. -Cipla receives the 18th ICSI (Institute of Company Secretaries of India) National Award for Excellence in Corporate Governance in January 2019. 2020 -Cipla completes successful phase-3 clinical study of generic asthma drug. -Cipla inks licensing pact with Gilead Sciences for potential COVID-19 treatment drug. -Cipla launches generic remdesivir for coronavirus patients. -Cipla, Stempeutics collaborate to launch Stempeucel for CLI treatment in India. -Cipla launches antibody detection kit for COVID-19 in India. -Cipla has been conferred with the 'Golden Peacock Global Award for Excellence in Coporate Governance for the year 2020. 2021 -Cipla sets up 30 MW solar plant in Maharashtra. -Cipla partners with Alvotech to market biosimilars medicines in Australia and New Zealand. -Cipla bags the National Energy Conservation Award 2021 in drug & pharmaceutical sector by the Bureau of Energy Efficiency, Ministry of Power, Government of India. -Cipla wins Gold for Remdesivir in 'Covid Care Brand' Category. 2022 -Cipla announces launch of leuprolide acetate injection depot (22.5mg). -Cipla receives USFDA approval for generic version of Revlimidr (Lenalidomide Capsules). -Cipla and DNDi launch child-friendly 4-in-1 antiretroviral treatment for young children living with HIV in South Africa. -Cipla scored highest among pharma companies in CRISIL's Sustainability Rating 2022. -Cipla wins the prestigious Frost & Sullivan and TERI's Sustainability 4.0 Award. 2023 -"Acquisition of additional stake in GoApptiv Private Limited". -Cipla to acquire South Africa-based Actor Pharma. 2024 -Cipla Limited has informed the Exchange about Acquisition of additional shares in Achira Labs Private Limited. -Cipla Limited has informed the Exchange about Merger of Cipla Technologies LLC, USA with Cipla USA Inc. -Cipla announces joint venture in the United States with Kemwell Biopharma and Manipal Education & Medical Group for global development and commercialisation of innovative Cell therapy products.

1935 - The Company was Incorporated at Mumbai. 1979 - The Company acquired a plot of land from MIDC at Patalganga in Kulaba district of Maharashtra State about 55 kms. from Mumbai. - 18,773 Bonus equity shares issued in proportion 1:1. 1984 - The name of the Company was changed from The Chemical Industrial & Pharmaceutical Laboratories Ltd., to the present one with effect from 20th July. 1985 - 37,546 Bonus equity shares issued in proportion 1:1 in January 1986. 1986 - During August, the Company obtained the consent of the Controller of Capital Issues to issue 3,00,000-15% secured non-convertible redeemable debentures of Rs 100 each aggregating to Rs 300 lakhs by private placement. The entire issue was subscribed by public financial institutions. They are redeemable at a premium of 5% during 1993-94. 1987 - The Company launched several new products viz., Asthalin and Beclate Rotahalers/Rotacaps-dry powder inhalation devices for asthma, presolar capsules - the first synergistic combination of a beta blocker and a sustained release calcium channel blocker for hypertension, Restyl tablets - the first anxiolytic-cum-anti depressant, Theo-Asthalin SR tablets - the first sustained release combination of two widely used bronchodilators, bromolin dry syrup and bromolin-250 capsules - antibiotic-cum-mucolytic agents, dilgard tablets - a new calcium channel blocker for angina, ibugesic plus suspension - a non steroidal anti inflammatory and anti-pyretic analgesic for paediatric use. - 75,092 Bonus equity shares issued in proportion 1:1. 1989 - The latest drugs introduced during the year were (i) Ciplox tablets (250 & 500 mg.) and infusion (50 and 100 ml.), a broad spectrum fluoroquinolone antibacterial for severe infections, (ii) cefadur capsules (250 & 500 mg.) and syrup (30 ml.), a cephalosporin antibiotic, (iii) Ulcimax tablets (20 & 40 mg.), a long-acting H2 antogonist for peptic ulcers and (iv) theoped syrup, a paediatric bronchodilator. Sales in the Company's `PROTEC' division exceeded Rs 5.50 crores for the second year of its operations. 1990 - The Company launched several new products viz., Aerocort inhaler, an anti-inflammatory bronchodilator, Norflox eye/ear drops - a broad spectrum fluoroquinolone antibacterial, Pirox Gel - the first topical piroxicam formulation in the country, Cofenac tablets - an anti-infammatory analgesic, Kinetal 400 tablets - a multi-functional drug for vascular insufficiency, Novaclox Ped tablets - a dispensible combination antibiotics, Terfed tablets and Suspension - a new non-sedative antihistamine, Depryl tablets - a broad - spectrum antidepressant, Asthalin Respirator Solution - a bronchodilator for pressure ventilation in acute asthma. The Company spent Rs 4.22 crores on R&D and Rs 8.09 crores on modernisation and expansion of plant and machinery. 1991 - The new products launched during the year were lomac capsules - a new antiulcerant, cromal inhaler - the first optimum - dose inhalant prophylactic for asthma, ciplox eye drops - the total bactericide for ocular infections, etosid injection - the first injection of indigenously manufactured etoposide for cancer therapy, proflox tablets - a key fluoroquinolone antibiotic and vasopril tablets - an ACE inhibitor for long-term management of hypertension. The research and development win g of the Company developed during the y ar felodipine - the latest anti-hypertensive drug, selegilinje - a new bulk drug for the treatment of Parkinson's disease, cetirizine HCI - an anti-histamine drug and nimodipine - a cerebral vasodilator. Work on the anti-AIDS drug AZT reached an advance stage of development. The research and development wing also developed anthelmintics oxfendazole and oribendazole, two veterinary products for exports. - In May, 6,000 equity shares offered at par as rights to pref. shareholders in prop. 1:1. Only 5,216 shares taken up. Allotment of 5 equity shares pending. 1992 - Some of the new products introduded were Zidovir capsules an antiretroviral for HIV injection, Cipril tablets for hypertension, Optipres eyedrops for glaucoma patients, Felogard for hypertension, Nodine, a non-narcotic analgesic, etc. - In compliance with the provisions of the Companies Act, 1956, the Company redeemed its 6,000 preference shares of Rs 100 each as on 30th September. - Pref. shares redeemed on 30.9.92, 1,55,395 bonus equity shares issued in prop. 1:1. 1994 - New products introduced were - Beclate Aquanase - a major advancement in allergic rhinitis; Cytoplatin - an anticancer agent; Forcan - an antifungal; Imusporin - an immunosuppressant in organ transplantation; Kelfer - an iron chelator for thalassaemia; Lanzol - a proton pump inhibitor; Nuzac - an antidepresant; Odirox - a macrolide antibiotic and Qinarsol - for chloroquin-resistant malaria. - Equity shares subdivided 155,39,500. Equity shares allotted shares issued in prop. 1:5. - The Company's manufacturing unit at Kurkumbh, which was commissioned in April. The second phase of expansion of the location was under way and this was to provide specialised facilities for the manufacture of new chemical entites. 1995 - Effective 4th July, the Company was forced to declare a lock-out as some of the workmen at the Vikhroli Unit resorted to indiscipline. The Company initiated steps to mitigate the impact it could have on production. - New products introduced were - Acivir - antivirus herpes, Anlopres - antivirus herpes, Anlopres - Calcium channel blocker in hypertension and angina, Anlopres AT - a combination antihypertensive, Budecort 200 - a higher strength corticosterord in bronchial asthma, Budenase AQ - a corticosteroid protection in allergic rhinitis, cronal - a nast cell stabiliser in allerg ic conjunctivitis, cytonid - a antiandrogenic agent in prostate cancer, Norflox - an antidiarrhoeal in diarrhoea of mixed origin, optipes S - betaxocol eye drops, profenac - anti-inflammatory eye drops, Terfed D - a combination antihistamine and decongestant, Trivedon 20 - used in ischaemic heart disease. - A new chemical entity, candocuronium iodide - a neuromuscular blocking agent was manufactured, other new bulk drugs manufactured include: Acyelovir - antiviral, Amlodipine besylate - antihypertensive and antianginal, Febantel - veterinary anthelmintic, Flutamide - antiandrogen, Flutivcasone dipropionate - a corticosteriod, zenprolide acetate - GMRH analogue. - 13,43,383 rights equity shares issued (Prem. Rs. 60/-). However, the Rights issue was underwritten. 1996 - The products launched during the year were Azee (azithromycin capsules) - a new macrolide antibiotic; Budecort (budesonide rotacaps) - dry powder inhaled corticosteriod therapy for asthama; Cipril H (lisionopril hydrochlorothiazide tablets) - a combination antihypertensive; Ciplox TZ (ciprofloxacin tinidazole tablets) - the combination bactericide for aerobic/anaerobic infections; Entosec (secnidazole tablets) - single dose therapy for amoebiasis/trichomoniasis; Fincar (fin asterid tablets) - for beign prostatic hyperphasia; Metolar (metaprolol injection) - beta-blocker protection for post myocardial infarction & Zoflut (fluticasone propionate cream) - a new topical corticosteroid. 1997 - The products introduced during the year were; Alerid-D - an antihistamine and decongestant for cold and congestion, Amlopres L - a tablet for hypertension, Apuatears - an eye drop, Azee 1000 - a single dose for STDs, Budecort Respules - neubulised corticosteroid therapy for asthma, Dilgard XL - a diltiazem, Glumet - tablet for obese diabetics, Glygard - tablet for abese diabetics, Glygard - tablet for diabetics, Ipranase AQ (ipratropium nasal spray) - an anticholinergic therapy for rhinorrhoea, Ocutim (an eye drop) - a glaucoma therapy in acquafilm formulation, Osteifos 10 - tablet for osteoporosis, Prolyte Fizz - a rehydration effervescent tablet, Pylokit - an advanced H pylori kit, Risnia - an a typical antipsychotic, Stavir - an antiretroviral for AIDS, Synclar 250 - an advanced macrolide antibiotic, Theoday - a tablet for asthma, Zoflut Lotion - a topical corticosteroid. - The bulk division of the Company had taken up, the development and manufacture of some new drugs viz., budesonide - antiasthmatic corticosteroid, carvedilol - alpha/beta blocker, ebastine - antihistamine, formoterol fumarate - antiasthmatic, meloxicam - for osteroarthritis and rheumatoid arthritis, moclobemide - antidepressant, mometasome furoate - antiflammatory corticosteroid, pantorazole sodium sesquihydrate - antiulcerant, sildenafil citrate - erectile dysfuncion. - The Company has developed a form-fill-seal equipment for the first time in India, for the manufacture of sterile formulations. This was commissioned at Vikhroli factory and is working to its full capacity. Additional capacities were set up at Kurkumbh for manufacture of effervescent tablets, soft gel capsules and injectable formulations. The Company has incurred a capital expenditure of Rs 22.73 crores during the year. - The Rs. 3.69 billion Cipla has finalised a marketing joint venture with Australia-based Genpharm, as part of its strategy to consolidate its global presence. - Pharmaceutical major Cipla Ltd grabbed the attention of traders at the Mumbai Stock Exchange (BSE) on December 26 after a large block of about 75,000 shares of the company valued at little over Rs 5 crore changed hands. - The Rs.369-crore Cipla Ltd has entered into a souring arrangement with US-based Geneva Pharmaceuticals, a wholly-owned subsidiary of Swiss multinational Ciba, for a range of generic drugs. 1998 - Pharmaceutical companies, Cipla and Wockhardt, will be seeking shareholders' approval for a proposed share buyback at their forthcoming annual general meetings. - In a notice to shareholders, Cipla has proposed introduction of a new article, Article 64 A, in the Articles of Association of the company to enable the company to purchase and re-issue any of its shares. The existing Article 64 prohibits the company from buying its own shares and applying any of its funds for the purchase of any shares of the company. - The share price of Cipla Ltd, the leading pharmaceutical company scaled a new peak of Rs 920 on the Mumbai Stock Exchange on Sept 29 following fresh bull charge. The scrip opened at Rs 900 and shot up to Rs 920 during mid-session and closed at Rs 884 following hectic trading activities. 1999 - Ranbaxy and Cipla, have entered into a strategic partnership to jointly market a select basket of drugs. The alliance will bring forth their strengths in the strongly emerging cardiovascular and perennial anti-infectives market. - As a first step, the two molecules being jointly launched are Carvedilol, a new generation anti-hypertensive and Cefpodoxime Proxetil, an advanced third generation oral cephalosporin. - The Rs 541-crore Cipla has forged a strategic alliance with the UK-based Neolab for marketing a range of generic drugs. The alliance, while improving the Indian company's access to the multi-billion dollar European market for off-patent drugs, will also see Cipla rake in royalties on sales of products covered under the deal. - Cipla's latest tie-up in the international market comes close on the heels of the company's strategic partnership with the Delhi-based Ranbaxy Laboratories for a select basket of drugs. - The Mumbai-based Cipla is working on abbreviated new drug applications (ANDAs) in collaboration with international generics firms for a range of products like flutamide (for advanced prostatic cancer) and felodipine, for hypertension. 2000 - Cipla and Ranbaxy Laboratories have expanded an existing partnership by adding one more new drug in their co-marketing arrangement. 2001 - Cipla has tied up with the US-based Zenith Goldline and United Research Labs for marketing Flutamide, an oncology drug, and Felodipine, a cardiovascular drug, in the US and European markets. - Domestic pharma giant, Cipla, has despatched its first free consignment of anti-AIDS drug, `Nevirapine', to the Indian Government for distribution under the public health system. 2002 -Reduces the price of its anti-HIV medicines such as Stavir, Lamivir, Nevimune, Dinex, Indivan, Triomune, Efavir and Duovir -Revokes interim dividend of Rs 5 per share on face value of Rs 10 per share for FY 2001-02 -Company included in the World Health Organisation's (WHO's) list of HIV-related products -Chairman and Managing Director YK Hamied was presented with the lifetime contribution award for excellence in the pharmaceutical industry by Union chemicals & fertilisers minister SS Dhindsa -Resigns from Indian Pharmaceutical Alliance (IPA) over Patents Bill 2003 -Applies its requisiton for Abbreviated New Drug Application (ANDA) with US regulators for a post-menopausal drug -National Pharmaceutical Pricing Authority (NPPA) issues notices to Cipla along with Ranbaxy for overcharging the products -Completes research studies on three Anti-HIV Drugs -Registers Stavudine, Nevirapine, other anti-AIDS products in South Africa 2004 -Signs long-term agreement with Morton Grove Pharmaceuticals Inc (MGP) of Illinois, US, for product launch in the US market -Avesthagen forges alliance with Cipla -Cipla has joined a global initiative taken up by the Vatican in collaboration with global generic pharmaceutical manufacturers and the International Federation of Catholic Pharmacies and Academics to float CUMVIVIUM -Cipla join hands with Pentech Pharma -Indian pharma major Cipla, a pioneer in supplying cheap generic AIDS drugs in Africa, has patented its three-in-one combination tablet Triomune in South Africa -Cipla introduces 'Duova' to fight chronic obstructive pulmonary disease - Launches a new treatment for arthritis in technical collaboration with California-based Cymbiotics Inc. 2005 -Set-up state-of-the-art facility for manufacture of formulations at Baddi, Himachal Pradesh. -Cipla introduces new drug for arthritis -Cipla to sign deal with Akorn Inc for anti-infective drug -Cipla to produce generic versin of bird-flu drug -Cipla to join hands with Roche - Cipla introduces new drug for arthritis 2006 - Cipla receives Scrip Award for Best Company in an Emerging Market -Safe & steady strategy gives Cipla lead over Ranbaxy -Cipla sets up subsidiary in Dubai -Cipla ties up with Ivax for US market -Cipla receives tentative US FDA approval for AIDS drugs -Cipla receives Pharma Excellence Award for 'Sustained Growth' -Cipla has given the Bonus in the Ratio of 3:2 2007 - Cipla unveils anti-malaria global initiative. -Set-up state-of-the-art facility for manufacture of formulations at Sikkim. -Award for the Forbes Asia's Best Under A Billion List! -Cipla's drug included in US anti-AIDS initiative -Anti-AIDS blitz sees pharma firms locked in ugly battle -Cipla launches emergency contraception tablet -Cipla launches estradiol transdermal spray in India -Cipla launches cut-price zanamivir in India -Cipla receives International Trade Awards 2006 for outstanding exporter of the year (Pharmaceuticals, Healthcare and Life Sciences category) 2008 -Cipla Ltd has appointed Mr. Pankaj Patel as a Director in casual vacancy with effect from March 05, 2008. -Cipla launched Roche's generic version of anti-infection drug 2009 -Cipla wins Erlotinib case against Roche -Pharmaceuticals Export Promotion Council Awards -Cipla launches drug to treat Swine flu virus -Cipla wins patent fight against Gilead Sciences 2010 -Cipla Ltd acquired Meditab Specialities Pvt. Ltd. ("Meditab") for an aggregate consideration of Rs. 133.35 crores. -Cipla Medpro has signed a deal with Biomab, a division of Chinese company Desano Pharma. -Cipla sold the marketing rights of i-Pill to Piramal Healthcare for Rs 95 crore in cash. -Cipla has tied up with the Manipal Group-promoted 'Stempeutics Research'. - Drug Maker Cipla has launched the generic Version of Pirfenidone, used to treat Idiopathic Pulmonary Fibrosis, a progressive Lung disease.India is the 2nd market to have this drug after Japan. 2011 -Cipla Cancer Palliative Care Centre launched 24 hour helpline to offer counselling to ensure more people use of the free services available. 2012 -Cipla India's second largest drug firm, has agreed to acquire South African Drugmaker Cipla Medpro with 51% stake amounts to $220 Million. -Cipla bags tentative approval for HIV treatment tablets -Drug giant Cipla Ltd has announced price reduction on 3 major anti-cancer drugs including Erlotinib (ERLOCIP), Docetaxel (DOCETAX) and Capecitabine (CAPEGARD). -Cipla bags award in the Field of Export of Pharmaceuticals during the year conferred the Highest Award 'Platinum'. 2013 -Cipla announces an offer to the shareholders of Medpro for 100% acquisition -Cipla launches the first Biosimilar of Etanercept in India 2014 -Cipla wins USD 188.95 million of Global Fund ARV Tender -MMV announces collaborations with Cipla and Strides -Cipla licenses rights for innovative product - Cipla, S&D Pharma collaborate to enter Czech Republic and Slovakia -Cipla collaborates with Hetero to launch its second biosimilar drug `Darbepoetin alfa' -Cipla invests in Chase Pharmaceuticals to support Alzheimer's disease drug development -The Registered Office of the Company has been shifted from Mumbai Central, Mumbai - 400008 to Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400 013, Tel: 022-24826000 / 022-2482695,1Fax: 022-24826893. 2015 -Cipla Ltd has entered into an agreement with partner, Biopharm SPA, to form a joint venture (JV) company in Algeria. -Cipla Ltd has launched the generic drug Sofosbuvir in brand name Hepcvir -Cipla Ltd has inked an agreement with Serum Institute of India Ltd. (SII) to market flu vaccine Nasovac-S. -Cipla Ltd has entered into a definitive agreement with Biopharma SPA for establishing a joint venture company in Algeria. -Cipla Ltd has launched a anti-ageing skin care product Cutisera&trade. developed by Stempeutics. -Cipla has launched generic tablets used for treating of hepatitis C under the brand name Hepcvir-L 2016 -Cipla gets CCI approval for investment by FIL Capital -Cipla completes acquisition of generic businesses in US -Cipla gets USFDA nod for generic anti-depressant drug -Cipla gets EIR from US FDA for Indore facility -Cipla gets USFDA final nod for Hepatitis B treatment drug -Cipla receives final approval for generic Baracluder tablets 2017 - Cipla Ltd "Authorised Key Managerial Personnel to determine materiality of events/information". - Cipla launches Hepatitis B vaccine in India - Cipla receives approval for Lamivudine Tablets - Cipla USA signs licensing agreement with MEDRx - Cipla gets WHO nod to sell TB preventing drug in HIV patients - Cipla launches Q-TIB globally - Cipla launches Rectal Artesunate Suppositories for severe malaria in young children - Cipla Receives Final Approval for Generic Epzicomr Tablets - Cipla launches Hepatitis B vaccine in India 2018 -Cipla teams up with Roche Pharma to sell cancer therapy drugs in India. -Cipla partners with Eli Lilly to market diabetes drug Basaglar in India. -Cipla receives final approval for generic version of Valganciclovir Tablets 450mg from the United States Food and Drug Administration (USFDA). -Cipla bags DMA Asia Echo Award (Silver) for Best Digital Destination and Leader Certificate in Pharma & Healthcare category. 2019 -Cipla to launch cinacalcet hydrochloride tablets in US market. -Cipla introduces Niveoli, India's first HFA inhaler for airway diseases. -Cipla receives the 18th ICSI (Institute of Company Secretaries of India) National Award for Excellence in Corporate Governance in January 2019. 2020 -Cipla completes successful phase-3 clinical study of generic asthma drug. -Cipla inks licensing pact with Gilead Sciences for potential COVID-19 treatment drug. -Cipla launches generic remdesivir for coronavirus patients. -Cipla, Stempeutics collaborate to launch Stempeucel for CLI treatment in India. -Cipla launches antibody detection kit for COVID-19 in India. -Cipla has been conferred with the 'Golden Peacock Global Award for Excellence in Coporate Governance for the year 2020. 2021 -Cipla sets up 30 MW solar plant in Maharashtra. -Cipla partners with Alvotech to market biosimilars medicines in Australia and New Zealand. -Cipla bags the National Energy Conservation Award 2021 in drug & pharmaceutical sector by the Bureau of Energy Efficiency, Ministry of Power, Government of India. -Cipla wins Gold for Remdesivir in 'Covid Care Brand' Category. 2022 -Cipla announces launch of leuprolide acetate injection depot (22.5mg). -Cipla receives USFDA approval for generic version of Revlimidr (Lenalidomide Capsules). -Cipla and DNDi launch child-friendly 4-in-1 antiretroviral treatment for young children living with HIV in South Africa. -Cipla scored highest among pharma companies in CRISIL's Sustainability Rating 2022. -Cipla wins the prestigious Frost & Sullivan and TERI's Sustainability 4.0 Award. 2023 -"Acquisition of additional stake in GoApptiv Private Limited". -Cipla to acquire South Africa-based Actor Pharma. 2024 -Cipla Limited has informed the Exchange about Acquisition of additional shares in Achira Labs Private Limited. -Cipla Limited has informed the Exchange about Merger of Cipla Technologies LLC, USA with Cipla USA Inc. -Cipla announces joint venture in the United States with Kemwell Biopharma and Manipal Education & Medical Group for global development and commercialisation of innovative Cell therapy products.

Read More

Parent Organisation

Cipla Ltd.

Founded

17/08/1935

Managing Director

Dr.Y K Hamied

NSE Symbol

CIPLAEQ

FAQ

What is the current price of Cipla Ltd?

The current price of Cipla Ltd is ₹ 1551.00. ₹ 1550.10.

What is the 52-week high and low for Cipla Ltd?

The 52-week high for Cipla Ltd is ₹ 1570.10 and the 52-week low is ₹ 1530.05. ₹ 1570.80 and the 52-week low is ₹ 1538.00.

What is Cipla Ltd market cap?

The market capitalization of Cipla Ltd is currently ₹ 125192.34. ₹ 125192.34. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

How to Buy Cipla Ltd Shares?

To buy Cipla Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

How do you invest in Cipla Ltd?

To invest in Cipla Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Cipla Ltd shares.

Who is the CEO of Cipla Ltd ?

The CEO of Cipla Ltd is Dr.Y K Hamied, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.